<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE collection SYSTEM "BioC.dtd"><collection><source>BioC-API</source><date>20250207</date><key>collection.key</key><document><id>10001244</id><infon key="license">CC BY</infon><passage><infon key="article-id_doi">10.3390/cells12050788</infon><infon key="article-id_pmc">10001244</infon><infon key="article-id_pmid">36899924</infon><infon key="article-id_publisher-id">cells-12-00788</infon><infon key="elocation-id">788</infon><infon key="issue">5</infon><infon key="kwd">NF-kappaB signalling cancer chromatin landscape epigenetic</infon><infon key="license">Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).</infon><infon key="name_0">surname:Deka;given-names:Kamalakshi</infon><infon key="name_1">surname:Li;given-names:Yinghui</infon><infon key="name_2">surname:Carrera;given-names:Ana Clara</infon><infon key="section_type">TITLE</infon><infon key="type">front</infon><infon key="volume">12</infon><infon key="year">2023</infon><offset>0</offset><text>Transcriptional Regulation during Aberrant Activation of NF-kappaB Signalling in Cancer</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>88</offset><text>The NF-kappaB signalling pathway is a major signalling cascade involved in the regulation of inflammation and innate immunity. It is also increasingly recognised as a crucial player in many steps of cancer initiation and progression. The five members of the NF-kappaB family of transcription factors are activated through two major signalling pathways, the canonical and non-canonical pathways. The canonical NF-kappaB pathway is prevalently activated in various human malignancies as well as inflammation-related disease conditions. Meanwhile, the significance of non-canonical NF-kappaB pathway in disease pathogenesis is also increasingly recognized in recent studies. In this review, we discuss the double-edged role of the NF-kappaB pathway in inflammation and cancer, which depends on the severity and extent of the inflammatory response. We also discuss the intrinsic factors, including selected driver mutations, and extrinsic factors, such as tumour microenvironment and epigenetic modifiers, driving aberrant activation of NF-kappaB in multiple cancer types. We further provide insights into the importance of the interaction of NF-kappaB pathway components with various macromolecules to its role in transcriptional regulation in cancer. Finally, we provide a perspective on the potential role of aberrant NF-kappaB activation in altering the chromatin landscape to support oncogenic development.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>1496</offset><text>1. Introduction</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>1512</offset><text>The nuclear transcription factor NF-kappaB was discovered in 1986 as a Nuclear Factor that binds an immunoglobulin kappa light chain of activated B-cells. NF-kappaB was subsequently reported to regulate the expression of various important target genes having diverse physiological functions in multiple cell types through its specific DNA binding activity. The family of NF-kappaB transcription factors in mammals comprises five members:RelA (p65), RelB, c-Rel, NF-kappaB1 (p105/p50) and NF-kappaB2 (p100/p52). Activation of NF-kappaB occurs via two major signalling pathways:the canonical and non-canonical pathways that involve distinct regulatory mechanisms and NF-kappaB members. One of the prominent features of NF-kappaB transcription factors is their association with the member protein of IkappaB inhibitor family in the cytoplasm making them unavailable for transcriptional activation in the nucleus. The IkappaB family typically consists of five members (IkappaBalpha, IkappaBbeta, IkappaBepsilon, IkappaBzeta and BCL3), all sharing similar structures. However, unprocessed p100 and p105 proteins are also categorized as members of the IkappaB family of proteins due to the presence of typical ankyrin repeats (ANK) in their C-terminal region. An alternative transcript of p105 gene, only reported to be expressed in some murine lymphoid cells, has also been named as one of the members of the IkappaB family (IkappaBgamma). Hence, activation of both the canonical and non-canonical NF-kappaB pathway involves phosphorylation-dependent degradation of IkappaB factors by stimulus-response-activated IkappaB kinases (IKKs). The canonical NF-kappaB pathway is mediated through the activation of NF-kappaB essential modifier (NEMO)-dependent IKK (IKKgamma), whereas non-canonical NF-kappaB pathway activation requires a NEMO-independent kinase complex involving IkappaB kinase alpha (IKKalpha) and the NF-kappaB-inducing kinase (NIK). Upon activation of the canonical NF-kappaB pathway, IkappaB kinases (IKKalpha, IKKbeta and NEMO) phosphorylates inhibitory IkappaBs and target the latter for proteasomal degradation, resulting in the subsequent nuclear accumulation of NF-kappaB dimers. In the non-canonical NF-kappaB pathway, NIK phosphorylates IKKalpha on Ser 176 position, which in turn phosphorylates p100 subunit, leading to cleavage and ubiquitination mediated degradation of C-terminal half of p100 protein generating active p52 subunit. However, reports also suggest the presence of atypical nuclear-localized IkappaB proteins, referred to as the BCL3 subfamily (Bcl3, IkappaBNS, IkappaBzeta and IkappaBeta). These IkappaBs are reported to show entirely different sub-cellular localization, activation kinetics and functional diversity. They are not only capable of interacting with NF-kappaB transcription factors inside the nucleus but are also found to get induced and not degraded after NF-kappaB activation, compared to typical IkappaB members. In addition, they do not exclusively act as inhibitors of the NF-kappaB pathway, instead they can regulate the transcriptional activity of NF-kappaB transcription factors both positively and negatively. Nuclear-localized BCL3 act as transcriptional coactivators by removing suppressive p50/p50 homodimers from the promoter of its target genes, in turn allowing binding of activating p50/p65 heterodimer. Bcl3 is also reported to suppress transcription via blocking of the ubiquitination of p50 to stabilize a suppressive NF-kappaB complex in the nucleus. One interesting finding on the nuclear role of IkappaB family proteins is its direct binding to NF-kappaB target sites. Wang et al., showed that Bcl3 forms a complex with p52 homodimer to activate transcription when bound to G/C-rich kappaB sites in the DNA, whereas the same complex represses transcription when bound to A/T-centric sites in the DNA. In a recent finding, it is reported that atypical IkappaB Bcl3 enhances the generation of p52 homodimer, subsequently upregulating the expression of target genes involved in proliferation, migration and inflammation. Another BCL3 family member protein, IkappaBzeta, is reported to inhibit transactivation of p65 and its DNA-binding activity in the nucleus. In contrast, IkappaBeta have been shown to be a positive regulator of NF-kappaB-mediated expression of pro-inflammatory cytokines. Nuclear IkappaBNS is also shown to interact with several different NF-kappaB factors in the nucleus but its biological role towards the activity of NF-kappaB transcription factors is yet to be elucidated.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>6077</offset><text>In the presence of activating stimuli, the NF-kappaB-signalling cascade can be induced via either of the pathways depending on the type of stimuli, dimers formed and kinases involved in the post transcriptional modification (PTM) of IkappaBs and processing of NF-kappaB factors. In addition to innate and adaptive immune response-dependent activation of the NF-kappaB pathway, the range of stimuli activating either the canonical or non-canonical pathway varies to a large extent. The canonical pathway of NF-kappaB is highly inducible and is activated by a diverse range of stimuli, such as radiation, DNA damage, cytokines (TNF-a, IL-1, IL-6), chemokines (MCP-1, IL-8), growth factors, adhesion molecules (ICAM-1, VCAM-1, ELAM), reactive oxygen species (ROS), pattern-recognition receptors (PRRs) and pro-inflammatory receptors such as TNF receptor superfamily (TNFRs) and Toll Like receptor superfamily (TLRs). In contrast, the non-canonical NF-kappaB pathway relies on specific sets of cytokine/receptor molecules for its activation, such as tumour necrosis factor (TNF) receptor superfamily proteins, including BAFF receptor (BAFFR), CD-40, lymphotoxin beta receptor (LTbetaR), Fn14 and receptor activator of nuclear factor kappa-B (RANK), all of which signal through a MAP3K member kinase (MAP3K14) called NF-kappaB-inducing kinase (NIK), making it a master regulator of the non-canonical NF-kappaB pathway.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>7491</offset><text>Once activated, each subunit of NF-kappaB signalling cascade, p65 (RelA), RelB, c-Rel, p105/p50 (NF-kappaB1) and p100/52 (NF-kappaB2) associate with each other to form distinct transcriptionally active homo/heterodimers. Though they all possess a conserved 300-amino-acid-long amino-terminal Rel homology domain (RHD) that is important for dimerization, DNA binding and interaction with IkappaBs, as well as nuclear translocation, the role of transactivation is characterised to specific members. RelA (p65), RelB and c-Rel contain the carboxy-terminal transactivation domains (TAD), which form transcriptionally active heterodimers only with p50 and p52 subunits, in turn assisting in DNA-binding activity and activated target gene expression.. Reports also suggest formation of homodimers within Rel proteins as well as p50 and p52 subunits. Gourisankar and his group have solved the crystal structures of homodimers of several NF-kappaB pathway factors such as p65 (RelA) homodimer in complex with a DNA target (2.4 A resolution) and p50 homodimer bound to a palindromic kappaB site (2.3 A resolution). Interestingly, p50/p50 homodimer has been described to exert inhibitory effects on NF-kB regulated gene expression. c-Rel homodimer is also reported to have the ability to bind IkappaBalpha, which in turn inhibits its DNA binding but not cytoplasmic retention. A recent report also showed atypical IkB protein, Bcl3-mediated enhanced generation of p52 homodimer, in turn enhancing transcription of genes involved in cancer-associated biological processes. There are also many other combinations of dimers reported but the most prominent dimers are the RelA-p50 and RelB-p52 dimers, which are activated by the respective canonical and non-canonical pathways. The complexity of the NF-kappaB-signalling mechanisms is further illustrated by the specificity of NF-kappaB dimers in the transcriptional activation of different target genes.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>9432</offset><text>In addition, NF-kappaB member proteins also undergo various post-translational modifications (PTMs), like phosphorylation and acetylation, regulating their interaction and crosstalk with components of other signalling pathways. As mentioned earlier, the phosphorylation status of the IkappaBs determines the activation state of the NF-kappaB pathway. The availability and activity of NIK, one of the major activating components of the non-canonical pathway also depends on the PTM state of members of its degradation complex containing TRAF3/TRAF2/cIAP1/cIAP2 proteins, which keeps the level of NIK low under constitutive conditions. Upon activation, the degradation complex is recruited to the active receptor complex. This leads to the degradation of cIAP1-cIAP2, thus allowing NIK to dissociate from the complex and subsequently activate the non-canonical NF-kappaB pathway. However, in an interesting finding in both normal B cells and B cell-derived tumors, it has been shown that CD40 or BAFF receptor activation results in the complete degradation of TRAF3 and partial degradation of TRAF2 but not cIAP1-cIAP2. These findings demonstrate a ubiquitination cascade in which TRAF2 ubiquitinates and activates cIAP1-cIAP2, which then ubiquitinates TRAF3, leading to its degradation and enhanced NIK stabilization as well as processing of NF-kappaB2/p100. Low levels of TRAF proteins lead to the higher accumulation of NIK, which then phosphorylates p100 and IKKalpha, thereby activating the kinase activity important for multiple site phosphorylation of p100 at its C-terminal. Phosphorylated p100 is ubiquitinated by beta-TrCP, leading to cleavage-dependent ubiquitination-mediated degradation of C-terminal part of p100, generating active p52 subunit. The processing of p100 is important in context to various steps of regulation in the activation of NF-kappaB pathway. Unprocessed p100 binds RelA, RelB or c-Rel subunit via its C-terminal ankyrin repeats, further inhibiting the activity of Rel subunits. Hence, in the context of activation of the non-canonical NF-kappaB pathway, stabilization of NIK and processing of p100 acts as one of the major steps involving multiple PTMs of its regulator molecules.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>11646</offset><text>Specific stimuli-dependent activation of the non-canonical NF-kappaB pathway is important in regulating various important biological functions such as lymphoid organogenesis, B-cell survival and maturation, dendritic cell activation and bone metabolism. In spite of being tightly regulated by various activators and inhibitory factors, the aberrant activation of the NF-kappaB pathway has been observed in many lymphoid malignancies. Besides its role in immune regulation, NF-kappaB members have been documented to regulate transcriptional activities that promote the malignant transformation and survival of cancer cells. Several studies demonstrate the presence of promiscuous mutations responsible for inhibiting TRAF2, TRAF3 and cIAP1/2 complex or enhancing the expression/stability of NIK and other receptor molecules like CD-40 and LTbetaR. Such mutations are associated with the abnormal activation of the non-canonical NF-kappaB pathway. Additionally, recent studies suggest the interdependency of NF-kappaB-driven expression of target genes with epigenetic changes in the genome. In this review, we will discuss the activation and regulation of NF-kappaB signalling in inflammation and cancer in context to its interaction with transcription factors (TFs), kinases, epigenetic modifiers and non-coding RNAs. We focus on discussing the interdependent role of NF-kappaB-signalling components with transcription factors and chromatin modifiers in the aberrant activation of the NF-kappaB pathway, as well as in the active transcriptional activation of its target genes (summarized in Figure 1).</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>13247</offset><text>2. NF-kappaB: One of the Key Factors Linking Inflammation in Cancer </text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>13316</offset><text>Even before Vichow's hypothesis on the origin of cancer from the site of inflammation, several inflammation-associated viral and bacterial infections (Hepatitis B, Helicobacter pyroli) were found to be associated with increased risk of malignancies of the liver, colon and stomach. Additionally, statistical reports estimate that inflammatory viral infections contribute to &gt;15% of all cancers. It has been postulated that cancer cells can hijack the normal inflammatory mechanism to boost their growth and survival. In general, the normal function of immune cells is to trigger the innate and adaptive immune response to differentiate between self/non-self and destroy/engulf the foreign invaders. However, in the tumour microenvironment, cancer cells can alter the protective functions of immune cells and convert them to act as tumour-promoting cells. They are reprogrammed to secrete pro-survival inflammatory cytokines, allowing better proliferation, survival, migration, invasion and inhibition of apoptosis in cancer cells. Hence, tumour-promoting inflammation acts as one of the major hallmarks of cancer. But what remains unanswered are the regulatory molecules that link inflammation to cancer progression. One of the major pathways reported to be involved in manipulating the immune response machinery in the tumour microenvironment is the NF-kappaB pathway. </text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>14687</offset><text>Several studies have converged on the role of the NF-kappaB pathway as one of the critical missing links between inflammation and cancer. The first evidence comes from various studies reporting extensive sequence similarity between c-Rel and viral oncoprotein v-Rel in their N-terminal domain, a region referred to as the Rel Homology Region (RHR), and identification of oncogene Bcl3 as a member of the IkappaB family. In addition, many cancer cell types show elevated levels of NF-kappaB expression and activation. Endogenous activation of NF-kappaB is reported in Hs294T melanoma cells due to altered equilibrium between IkappaBalpha degradation and resynthesis, leading to overall decrease in the level of IkappaBalpha expression. Moreover, human colorectal cancer (CRC) epithelial cells have been observed to express enhanced NF-kappaB and IkappaBalpha, which is accompanied by the increased expression of cox-2 gene. Similar selective activation of the NF-kappaB pathway is also reported in breast cancer. The RelA subunit of NF-kappaB is reported to be activated in breast cancer cell lines, whereas breast tumours are shown to exhibit an absence or low level of nuclear RelA, in contrast to activated c-Rel, NF-kappaB1 and NF-kappaB2 along with bcl2 expression, as compared to nontumorigenic adjacent tissue. Most interestingly, the NF-kappaB family of transcription factors have been shown to contribute to the function and maintenance of tumour-initiating cells (TICs) in breast cancer. Experimental data indicates the activation of both the canonical and non-canonical NF-kappaB pathway to be important in the function of TICs by stimulating epithelial-to-mesenchymal transition (EMT) and upregulating the expression of the inflammatory cytokines IL-1beta and IL-6. In a recent finding, Monica et al. reported the involvement of the NF-kappaB pathway towards resistance to endocrine and chemotherapies in breast cancer. Furthermore, BRCA1 signalling, which is one of the prominent pathways activated in various cancer types including breast cancer and ovarian cancer, additionally possesses the capability to induce the NF-kappaB pathway. </text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>16838</offset><text>Additionally, in lung carcinoma, the enhanced expression of IKKbeta and NF-kappaB is reported as an important factor for tumour initiation and progression. Another NF-kappaB activity dependent type of cancer is melanoma. Studies using mice models have shown that initiation of such tumours is HRas-mediated and involves the regulation by IKKbeta in the activation of NF-kappaB. In the cell line model of Diffuse large B-cell lymphoma (DLBCL), constitutive activity of IKK and high NF-kappaB DNA-binding activity is reported in the ABC-DLBCL subtype but not in the GC-DLBCL subtype. Recently, Eluard et al. reported the presence of a new subset of Diffuse large B-cell lymphoma (DLBCL) patients showing enhanced RelB activation with aberrant gene expression and mutation profiles. Based on these studies, it can be postulated that abnormal activation of the NF-kappaB pathway in various cancer types is critical for the survival of transformed cells, particularly in the suppression of apoptosis and senescence. Apart from endogenous elevated levels of NF-kappaB expression and activation in cancers (summarized in Table 1), there are also reports on aberrant activation of NF-kappaB pathway in cancer cells. Hence, there appears to be various extrinsic and intrinsic factors regulating the malignancy-associated enhanced activation of the NF-kappaB pathway in cancers. </text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>18208</offset><text>3. Factors Contributing to the Hyperactivation of NF-kappaB Pathway in Cancers</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>18287</offset><text>3.1. Cancer Associated Immune Signalling Molecules</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>18338</offset><text>In addition to the role of elevated NF-kappaB activity in the survival of transformed cells, NF-kappaB is found to be activated in cancer stem cells (CSCs). In CSCs, it promotes the release of pro-inflammatory cytokines that exert anti-apoptotic and pro-proliferative activities. One of the prominent factors involved in the activation of the canonical NF-kappaB pathway in both solid and hematologic malignancies is the tumour microenvironment (TME). A large number of immune cells (macrophages, dendritic cells, neutrophils, mast cells, T cells and B cells) are recruited to the TME, leading to the enhanced production of cytokines, growth and angiogenic factors and proteases that degrade the extracellular matrix to support cancer development and progression. In solid tumours, the sustained activation of the NF-kappaB pathway is predominantly achieved through the continuous release of cytokines by tumour-associated macrophages (TAM) in the TME. One of the predominant properties of TAM is the ability to switch from M1- to M2-phenotype with enhanced release of anti-inflammatory cytokines, suggesting a crosstalk between cancer cells and neighboring macrophages. Interestingly, IKKbeta and NF-kappaB are also reported to assist in the polarization of macrophages towards the M2 type, which fosters and protects the tumour cells instead of attacking them. Hence, this permits malignant cells to bypass tumour immunosurveillance activity via NF-kappaB-mediated polarization of macrophages from the M1 to M2 phenotype. </text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>19863</offset><text>Activation of either of the canonical or non-canonical pathways in both solid and hematologic malignancies also depends on different sets of inflammation-associated cytokines and receptors activated in tumour cells. Induction of the canonical NF-kappaB pathway is initiated by pattern recognition receptors and diverse tumour-promoting cytokines, such as TNF, IL-1, and IL-17. On the contrary, activation of the non-canonical NF-kappaB pathway is triggered by signalling via a specific subset of TNFR superfamily members such as B-cell-activating factor belonging to TNF family receptor (BAFFR), CD-40, lymphotoxin beta-receptor (LTbetaR), receptor activator for nuclear factor kappaB (RANKL), TNFR2, Fn14, etc.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>20575</offset><text>In addition to the involvement of immune regulatory molecules in activation of both the canonical and non-canonical NF-kappaB pathways towards cancer-promoting mechanisms rather than their classical immunosurveillance roles, the important observation is their expression in non-immune cells. Enhanced expression of CD-40 is reported in many non-immune cells, such as the intestinal epithelial cells (IECs) of patients with colon cancer. This, in turn, leads to the aberrant activation of non-canonical NF-kappaB pathway, suggesting the important link between immunosurveillance and tumorigenicity. LTbetaR is expressed in lymphoid stromal and epithelial cells. BAFFR is predominantly expressed in B cells, whereas RANK, which is best known for its role in osteoclastogenesis, is also reported to be highly expressed in various cancer types like breast and prostate cancer cells, mediating the migration and skeletal metastasis of cancer cells. </text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>21520</offset><text>3.2. Intrinsic Mutations and Post Translational Modifications (PTMs)</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>21589</offset><text>In addition to the receptor dependent aberrant activation of NF-kappaB pathways in cancer, activating mutations in other signalling components of the non-canonical NF-kappaB pathway have been documented particularly in lymphoid malignancies. Such activation is driven by the presence of selected mutations inactivating the genes encoding negative regulators of the pathway (TRAF2, TRAF3, TNFAIP3, BIRC3, MAP3K14, CYLD, cIAP1/cIAP2) and activating the regulator molecules (NF-kappaB1, NF-kappaB2, CD40, LTbetaR, TACI, and NIK) in various cancer types like multiple myeloma (MM), splenic marginal zone lymphoma (SMZL), MALT lymphoma and B-cell lymphoma (Table 2). Mutations leading to constitutive activation of the kinase NIK in multiple myeloma have been found in NIK itself, that disrupts its binding with TRAF3, in turn causing dissociation of NIK from the inhibitory complex having TRAF2 and the ubiquitin ligases cIAP1 and cIAP2. This, in turn, results in NIK stabilization, leading to aberrant activation of the non-canonical NF-kappaB pathway. The genetic selection of these driver mutations by cancer cells highlights the critical importance of the NF-kappaB pathway towards cancer progression and enhanced malignancy. In the case of multiple myeloma, mutations are also reported in many other signalling subunits of non-canonical NF-kappaB pathway:NF-kappaB2, TRAF2, TRAF3, BTRC encoding beta-TrCP, which alters the inhibitory degradative pathway of NIK kinase by TRAF2/TRAF3 complex, leading to malignancy-associated activation of non-canonical NF-kappaB signalling. Overexpression of NIK due to t(17;22) chromosomal translocation is also associated with the occurrence of multiple myeloma. Oncogenic mutations in the TP53 protein are reported to be associated with higher RelA expression, in turn activating the canonical NF-kappaB pathway in human B-cell lymphomas such as Hodgkin lymphoma and, to a lesser extent in T-cell lymphoma cell lines as well. Chromosomal translocation t(10;14)(q24;q32) of the NF-kappaB2 gene is observed to be associated with a variety of hematological malignancies, such as MALT lymphomas. The translocation moves the IgG promoter to a region upstream of the bcl-10 gene, resulting in expression of a truncated bcl-10 protein, leading to activation of NF-kappaB. Another reported translocation is t(11;18), which results in the generation of a chimeric protein, AP12-MALT1, which leads to NF-kappaB activation in B-cell lymphomas. The modified NF-kappaB2 gene codes for the protein that lacks the ankyrin regulatory domain but still binds the kappa B sequence in vitro. Such rearrangement of NF-kappaB2 has been reported in both B-cell and T-cell lymphoma patients suggesting that translocation dependent truncation of the ankyrin domain may be a common mechanism in the abnormal activation of NFKB2 gene and its relevant role in lymphomagenesis. Another genomic rearrangement event reported in DLBCL is on chromosome 10q24, which results in increased NFKB2 mRNA expression, causing constitutive expression of NF-kappaB2. Chromosomal translocation of the c-Rel gene to chromosome 2p 13-15 causing its enhanced amplification has been reported in DLBCLs with a large cell component, constituting approximately 50% of B-cell non-Hodgkin's lymphomas. This chromosomal aberration of c-Rel has also been found in primary mediastinal (thymic) B-cell lymphomas and follicular large cell lymphomas, and is reported to be associated with extra nodal presentation. Another member of the NF-kappaB family, RelA, is mapped to be translocated to 11q13, a site where a number of genes involved in neoplastic development have already been mapped, suggesting a link between chromosomal translocation and the tumour-inducing role of RelA. Activating mutations (translocation t(14;19)(q32;q13.1)) in another member of the NF-kappaB pathway, Bcl3, which is a proto-oncogene, have also been observed in B-cell leukaemia. The chromosomal translocation of Bcl3 results in its enhanced expression in leukemic cells as compared to normal blood cells. In addition to biallelic deletion and chromosomal translocation, several other mutations, including missense mutation, frameshift mutation and in frame deletion are also reported to inactivate the TRAF3 gene, in turn inducing the activation of NF-kappaB pathway.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>25918</offset><text>Besides the reported genomic abnormalities, there are several other factors that can influence the transcriptional activity of NF-kappaB pathway. Reports suggest that crosstalk with certain activating and inhibitory kinases such as Glycogen Synthase Kinase (GSK-3beta), p38 and PI3K can either modulate the transcriptional activity of NF-kappaB or its upstream signalling pathways. Kinases are reported to modulate the activity of NF-kappaB in glioma cell lines and pancreatic cancer cells through post-translational modification (PTM) of the NF-kappaB subunits (p65/p50). Further studies indicate that GSK-3beta has no role in the nuclear accumulation of NF-kappaB, but instead alters the DNA-binding activity of NF-kappaB subunits by inducing hypermethylation of the target DNA. Other kinases documented to regulate the NF-kappaB pathway include the Jun- N-terminal kinase (JNK) and p38. Though both the kinases can be induced by the same stimuli (TNFalpha) that activate NF-kappaB pathway, they have been found to display differential functions on NF-kappaB activity. p38 acts as a co-factor to modulate the transactivation machinery of NF-kappaB to regulate TNF-induced IL-6 gene expression, whereas a counteracting relationship occurs between JNK and NF-kappaB. NF-kappaB complexes downregulate the c-Jun amino-terminal kinase (JNK) cascade via upregulation of gadd45beta/myd118 gene expression. Gadd45beta, in turn, targets MKK7/JNKK2, a specific and essential activator of JNK. Mechanistically, binding of gadd45beta with MKK7 blocks the catalytic activity of the latter, causing inhibition of the JNK pathway. Hence, the aberrant activation of NF-kappaB pathway depends on multiple factors including cell type, micro-environment, PTMs, enzymatic activity of regulatory molecules and chromosomal abnormalities.</text></passage><passage><infon key="file">cells-12-00788-t002.xml</infon><infon key="id">cells-12-00788-t002</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>27736</offset><text>Summarized table of various mutations/chromosomal alterations in components of NF-kappaB pathway affecting its expression and activity in different cancer types.</text></passage><passage><infon key="file">cells-12-00788-t002.xml</infon><infon key="id">cells-12-00788-t002</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-top:solid thin;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Factors/Regulators of NF-kappaB Pathway&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-top:solid thin;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Type of Mutation/Chromosomal Translocation&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-top:solid thin;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Cancer Type&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-top:solid thin;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Response&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-top:solid thin;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;References&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;italic toggle=&quot;yes&quot;&gt;TRAF3&lt;/italic&gt;
&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Bi-allelic deletion at 14q32&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;MM&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Increased p52/p100 ratios&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;xref rid=&quot;B91-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;91&lt;/xref&gt;&lt;xref rid=&quot;B177-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;177&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;italic toggle=&quot;yes&quot;&gt;TRAF2&lt;/italic&gt;
&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Bi-allelic deletion at 9q34&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;MM&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Increased p52/p100 ratios&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;xref rid=&quot;B91-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;91&lt;/xref&gt;&lt;xref rid=&quot;B177-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;177&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;italic toggle=&quot;yes&quot;&gt;CYLD&lt;/italic&gt;
&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Bi-allelic deletion at 16q12&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;MM&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Increased p52/p100 ratios&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;xref rid=&quot;B91-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;91&lt;/xref&gt;&lt;xref rid=&quot;B177-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;177&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;italic toggle=&quot;yes&quot;&gt;cIAP1/cIAP2&lt;/italic&gt;
&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Bi-allelic deletion at 11q22&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;MM&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Increased p52/p100 ratios&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;xref rid=&quot;B91-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;91&lt;/xref&gt;&lt;xref rid=&quot;B177-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;177&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;italic toggle=&quot;yes&quot;&gt;NIK&lt;/italic&gt;
&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;t(17;22) translocation, IgH translocation or amplification&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;MM&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Overexpression of &lt;italic toggle=&quot;yes&quot;&gt;NIK&lt;/italic&gt;&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;xref rid=&quot;B93-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;93&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;italic toggle=&quot;yes&quot;&gt;LTBR&lt;/italic&gt;
&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;amplification of the entire 12p chromosome arm&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;MM&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Activatory&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;xref rid=&quot;B91-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;91&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;italic toggle=&quot;yes&quot;&gt;NF-kappaB2&lt;/italic&gt;
&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;t(10;14)(q24;q32)&lt;break/&gt;t(10q24)&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;MALT Lymphoma,&lt;break/&gt;DLBCL&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Activatory,&lt;break/&gt;Enhanced expression of &lt;italic toggle=&quot;yes&quot;&gt;NF-kappaB2&lt;/italic&gt; gene and protein&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;xref rid=&quot;B15-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;15&lt;/xref&gt;&lt;xref rid=&quot;B91-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;91&lt;/xref&gt;&lt;xref rid=&quot;B153-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;153&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;italic toggle=&quot;yes&quot;&gt;AP12-MALT1&lt;/italic&gt;
&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;t(11;18)(q21;q21)&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;B-cell Lymphoma, MALT lymphoma&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Activatory&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;xref rid=&quot;B154-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;154&lt;/xref&gt;&lt;xref rid=&quot;B155-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;155&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;italic toggle=&quot;yes&quot;&gt;c-Rel&lt;/italic&gt;
&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;t(2p 13-15)&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;DLBCL, B-cell lymphoma, Follicular large cell lymphoma&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Enhanced amplification of &lt;italic toggle=&quot;yes&quot;&gt;c-Rel&lt;/italic&gt; gene&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;xref rid=&quot;B120-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;120&lt;/xref&gt;&lt;xref rid=&quot;B121-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;121&lt;/xref&gt;&lt;xref rid=&quot;B149-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;149&lt;/xref&gt;&lt;xref rid=&quot;B159-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;159&lt;/xref&gt;&lt;xref rid=&quot;B161-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;161&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;italic toggle=&quot;yes&quot;&gt;RelA&lt;/italic&gt;
&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;(11q13) site with t(11;14)(q13;q32)&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NHL, Diffuse large cell lymphoma, Squamous carcinoma of head and neck, Breast cancer &lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Activatory&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;xref rid=&quot;B159-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;159&lt;/xref&gt;&lt;xref rid=&quot;B162-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;162&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;italic toggle=&quot;yes&quot;&gt;Bcl3&lt;/italic&gt;
&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;t(14;19)(q32;q13.1)&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;B-cell leukaemia&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Activatory&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;xref rid=&quot;B163-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;163&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>27898</offset><text>Factors/Regulators of NF-kappaB Pathway	Type of Mutation/Chromosomal Translocation	Cancer Type	Response	References	 	TRAF3	Bi-allelic deletion at 14q32	MM	Increased p52/p100 ratios		 	TRAF2	Bi-allelic deletion at 9q34	MM	Increased p52/p100 ratios		 	CYLD	Bi-allelic deletion at 16q12	MM	Increased p52/p100 ratios		 	cIAP1/cIAP2	Bi-allelic deletion at 11q22	MM	Increased p52/p100 ratios		 	NIK	t(17;22) translocation, IgH translocation or amplification	MM	Overexpression of NIK		 	LTBR	amplification of the entire 12p chromosome arm	MM	Activatory		 	NF-kappaB2	t(10;14)(q24;q32)t(10q24)	MALT Lymphoma,DLBCL	Activatory,Enhanced expression of NF-kappaB2 gene and protein		 	AP12-MALT1	t(11;18)(q21;q21)	B-cell Lymphoma, MALT lymphoma	Activatory		 	c-Rel	t(2p 13-15)	DLBCL, B-cell lymphoma, Follicular large cell lymphoma	Enhanced amplification of c-Rel gene		 	RelA	(11q13) site with t(11;14)(q13;q32)	NHL, Diffuse large cell lymphoma, Squamous carcinoma of head and neck, Breast cancer 	Activatory		 	Bcl3	t(14;19)(q32;q13.1)	B-cell leukaemia	Activatory		 	</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>28954</offset><text>3.3. Epigenetic Modification in the Component(s) of NF-kappaB Pathway</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>29024</offset><text>Reports suggest the dependency of NF-kappaB components on various epigenetic factors for its activation in cancer cells. Reduced expression of histone methyltransferase EZH2 stimulates the expression of TRAF2/5 via the de-repression of their expression due to H3K27 hypermethylation by EZH2. The elevated TRAF2/5 expression, in turn, enhances TNFalpha-induced activation of NF-kappaB signalling, leading to an uncontrolled inflammatory reaction which ultimately contributes to tumorigenesis. The enhanced activation and expression of NF-kappaB-signalling component proteins in various cancer types also depends on the epigenetically modified state of its own component genes and its target genes. Triple negative breast cancer cells display a high level of NF-kappaB activation due to the enhanced expression of NIK that is caused by the epigenetic alteration (histone H3 acetylation) of the NIK gene. Hence, these studies suggest the plausible de-regulation of the NF-kappaB pathway due to epigenetic alterations.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>30039</offset><text>4. Double Edged Role of NF-kappaB from Immunosurveillance to Pro-Tumorigenic Functions</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>30126</offset><text>As discussed, the aberrant activation of the NF-kappaB pathway in cancer is a multifactorial event. Depending on the prevalent tumour microenvironment, malignancy-promoting mutations in the components of the NF-kappaB-signalling cascade, and the inflammatory molecules released by the tumour immune cells, the biological importance of the NF-kappaB pathway is diverted from the immunosurveillance mechanism towards tumour-promoting functions.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>30569</offset><text>NF-kappaB signalling has been shown to activate the expression of various inflammatory mediators, such as IL1beta, TNF and IL6, which promote cancer development. However, the question remains as:what factor(s) drives the variation in inflammatory response by the NF-kappaB pathway from a protective role towards a tumour-promoting role. The answer to this oncogenic shift is related to the severity of inflammation response which mostly occurs during chronic inflammatory conditions. During acute inflammatory conditions, NF-kappaB activation acts as a tumour immunosurveillance mechanism to assist in the targeting and elimination of transformed cells. For example, protein kinase D1-mediated activation of NF-kappaB signalling can induce the expression of antioxidant proteins such as MnSOD and anti-apoptotic proteins including A20 and cIAPs to prevent the accumulation of pro-tumorigenic ROS that can cause oncogenic mutations. NF-kappaB-mediated inhibition of ROS accumulation can also repress the activity of pro-tumorigenic transcription factors such as STAT3 and AP1. In contrast, under chronic inflammatory conditions, the continuous presence of NF-kappaB stimuli seem to outperform the inhibitory role of the negative NF-kappaB regulators, leading to constitutive activation of NF-kappaB signalling. Such constitutive activity of NF-kappaB can exert pro-tumorigenic effects ranging from cell proliferation and cell survival to malignant cell invasion and metastasis. Many cancers arise from sites of chronic infection or inflammation due to elevated ROS production by neutrophils in response to invading pathogens. This innate immune response in turn causes DNA damage and genetic mutations, thereby triggering tumour initiation. </text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>32310</offset><text>Though both the canonical and non-canonical NF-kappaB pathways are reported to be activated in various invasive and malignant cancers, the functional mechanism for downstream substrates involved in activation of the non-canonical NF-kappaB pathway are well characterized compared to the canonical pathway. The invasive nature of Glioblastoma Multiforme (GBM) cells has been reported to be associated with high RelB expression. Work on mouse tumour xenograft models also showed activation of the non-canonical NF-kappaB pathway leading to regulation of the expression of its own regulator protein NIK, which, in turn, is reported to induce dramatic cell shape changes, increase tumour cell invasion and promote aggressive orthotopic tumour growth. Point mutations at the promoter region of the telomerase reverse transcriptase (TERT) gene is one of the most frequent non-coding mutations in cancer. TERT promoter mutations (TPMs) are cancer type-specific and among the first few mutations reported in melanomas, glioblastomas and hepatocellular carcinomas. In an interesting finding, non-canonical NF-kappaB signalling is reported to drive the expression of the TERT gene carrying -146 C &gt; T mutation in its promoter region, causing telomerase reactivation, which is otherwise not activated via binding of ETS transcription factor. This data specifically highlights a novel role of the non-canonical NF-kappaB pathway in the reactivation of telomerase in cancers. Hence, the level of inflammatory response and genetic changes in the cancer cells can act as some of the major factor(s) deciding the difference between acute inflammatory response versus aberrant activator response of the NF-kappaB-signalling pathway in cancer. </text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>34037</offset><text>5. Aberrant NF-kappaB Activation Driven Expression of Tumour Promoting Genes</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>34114</offset><text>Apart from activating the expression of its immune response target genes, aberrantly activated NF-kappaB signalling in cancer cells contribute to cancer progression by acting as a transcriptional activator of various other pro-tumorigenic genes involved in cell proliferation, inhibition of apoptosis, invasion, metastasis and angiogenesis. </text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>34456</offset><text>In-depth studies also show that NF-kappaB controlled genes regulating oncogenic properties are significantly different. NF-kappaB-dependent cancer-relevant genes mostly encode for cytokines, cell cycle genes like cyclin D1, matrix metalloproteinases (MMPs) and anti-apoptotic proteins. Numerous NF-kappaB target genes such as cIAP1/2, TRAF1/2, Bcl-xL, XIAP, MnSOD and IEX-1L confer antiapoptotic properties. Specifically, the NF-kappaB target gene cIAP1/2 functions as an inhibitory factor of cancer cell apoptosis through directly binding and suppressing the effector caspases. NF-kappaB signalling controls the epithelial to mesenchymal transition and metastasis, often via upregulation of matrix metalloproteinases (MMPs). In breast cancer, NF-kappaB is also reported to induce the expression of EMT-related genes such as Twist, intercellular adhesion molecule-1 (ICAM-1), endothelial leukocyte adhesion molecule 1 (ELAM-1), vascular cell adhesion molecule 1 (VCAM-1), MMPs and serine protease urokinase-type plasminogen activator (uPA), along with the expression of one of the major tumour promoting genes Bcl2. Interestingly, one study revealed a role for NIK in the phosphorylation, enzymatic activity and pseudopodal localization of membrane type 1 MMP in highly invasive tumours like glioblastoma that is distinct from its established kinase function in the non-canonical NF-kappaB pathway. </text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>35856</offset><text>NF-kappaB signalling also contributes to tumour progression and invasion by controlling pro-angiogenic genes such as vascular endothelial growth factor (VEGF) and its receptors, macrophage inflammatory protein-1 (MCP-1) and CXC-chemokine ligand 8, also known as IL-8 (CXCL8). Activated NF-kappaB signalling in cancer transactivates the expression of cyclin D1 and c-myc that promote cancer cell proliferation. Angiogenesis, the phenomenon of new blood vessel formation is one of the hallmark phenotypes of cancer cells. Tumour angiogenesis is dependent on proinflammatory cytokines, chemokines and growth factors such as MCP-1, IL-8, TNF-alpha and VEGF, secreted by tumour-associated macrophages (TAMs) via the activated NF-kappaB pathway. Furthermore, the recruitment of bone marrow-derived cells (BMDCs) to tumours for vasculogenesis is essential for tumour angiogenesis, which is found to involve NF-kappaB-mediated enhanced expression of IL-8 and angiogenin. Subsequently, the expression and activation level of different NF-kappaB subunits can induce varying severity in different cancer types. In the case of ER-positive breast carcinoma, higher expression of RelB is associated with decreased relapse-free survival (RFS) and overall survival (OS) rate, whereas in other tumours, such as lung carcinoma, enhanced expression of NIK and RelB is associated with enhanced metastasis and shorter OS. Poor RFS outcome is reported to be associated with higher expression of non-canonical NF-kappaB target gene myoglobin. Elevated RelB activity reported in a new subset of DLBCL patients is found to confer resistance to DNA damage-induced apoptosis along with increased cIAP2 expression. In a more recent finding, sustained activation of the non-canonical NF-kappaB signalling is also shown to drive doxorubicin resistance in DLBCL via enhanced glycolysis. Hence, these studies indicate the existence of a high degree of NF-kappaB dysregulation in cancer. </text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>37812</offset><text>6. Different Modes of Deregulated NF-kappaB Signalling in Cancer</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>37877</offset><text>While we discussed the multifaceted roles of the NF-kappaB pathway linking inflammation and cancer, it is also important to understand the interacting map of the components of this pathway with other macromolecules, which, in turn, regulate the transcription of pro-oncogenic transcripts (Figure 2).</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>38177</offset><text>6.1. Interaction with Transcription Factors</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>38221</offset><text>While NF-kappaB regulates the expression and activity of various regulatory factors, its own activity can also be regulated via direct association with several other transcription factors. The most prominent ones are proto-oncogenic transcription factors such as STAT3, p53, AP1 and ETS-related genes ERG, implicating their plausible cooperative function with NF-kappaB factors in inflammation and cancer. Hence, depending on the promoter sequence and structure of the target genes, the functional link between NF-kappaB and other transcription factors might vary. One of the well-characterized factors known to co-associate with NF-kappaB is the STAT family members. NF-kappaB, in association with STAT3, regulates the expression of various cell cycle genes, anti-apoptotic genes and genes encoding cytokines and chemokines. Studies suggest that the direct interaction of RelA and NF-kappaB1 members with STAT3 facilitates both the recruitment of NF-kappaB and STAT3 onto each other's promoter sites. In another context of regulation, STAT3 modifies the RelA subunit by recruiting acetyltransferase p300, resulting in the acetylation-dependent retention of NF-kappaB in the nucleus. Such regulation leads to the enhanced activity of NF-kappaB (a tumour-promoting phenomenon) and hence, chronic stimulation of cytokines in the tumour microenvironment. Cross talk of NF-kappaB with transcription factor p53 also occurs. Enhanced secretion of the pro-inflammatory cytokine TNFalpha triggers the formation of an active complex containing nuclear RelA and p53 on kappaB binding motifs, suggesting the importance of p53 in NF-kappaB-mediated gene expression induced by canonical stimuli. In addition, some reports suggest that the RelA subunit and transcription factor p53 can regulate their respective transcriptional activities. p53 has been shown to inhibit NF-kappaB transcriptional activity, while the RelA subunit can also inhibit p53-dependent transactivation of target genes. This constitutive activation of NF-kappaB, evoked by a p53 hot-spot mutant protein frequently found in tumours, provides an explanation for the fact that p53 mutations arise more than p53 deletions in tumours of various origin. More recently, another transcription factor, the ETS family member ERG, has been identified to cross talk with NF-kappaB. As reported by various groups, the functional role of ERG is validated in various leukemia, Ewing sarcoma and prostate cancer. Interestingly, NF-kappaB activation is elevated in ERG fusion-positive prostate cancer patients and cancer cell lines. ERG is also reported to regulate expression of the NF-kappaB target gene, ICAM-1 in endothelial cells. Another interesting study also revealed the cooperative function of p52 with transcription factor ETS1 in the reactivation of telomerase in cancers via a hotspot -146 C &gt; T TERT promoter mutation. On a similar line, a recent finding has shown the involvement of the non-canonical NF-kappaB pathway in altering the genomic binding landscape of transcription factor ETS1 that supports glioma progression. Hence, a cross talk is predicted between NF-kappaB and other TFs at the level of activation and transcriptional regulation of NF-kappaB target genes, which requires further studies for in depth understanding of the mechanisms involved. </text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>41539</offset><text>6.2. Effect of Pro Tumorigenic Non-Coding RNAs</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>41586</offset><text>Considering the challenge with highly evolving cancer cells which are resistant to many available therapies either through selected genetic mutations or positive adaptation to the cancer microenvironment, it is critical to understand new alternative modes of regulations adopted by cancer cells. In recent times, one such regulatory molecule showing relevance in context to its crosstalk with the components of NF-kappaB pathway is non-coding RNAs (ncRNAs). Altered regulation at the level of epigenome mediated by non-coding RNAs (microRNAs:miRNAs and long noncoding RNAs:lncRNAs) has been found to be a prevailing factor impacting various types of malignancies. Several miRNAs are transcriptional targets of NF-kappaB, such as miR-9, miR-21, miR-143, miR-146 and miR-224, which, in turn, act as a feedback mechanism for modulating the activity of NF-kappaB. Out of these, miR-21 and miR-143 are reported to be involved in regulating the malignant phenotypes like invasion and metastasis in cancer types including breast cancer and HCC. On the other hand, NF-kappaB can also induce the expression of proteins important for the transcriptional regulation of miRNAs. One such example is the NF-kappaB driven expression of Lin28 protein, which inhibits the processing and maturation of let-7 miRNAs:a family of tumour suppressor miRNAs whose expression is downregulated in many cancer types. Let7 miRNA also targets IL6. Thus, Lin28-mediated downregulation of Let7 miRNA leads to the higher expression of IL6 and further enhances NF-kappaB signalling in a positive feedback loop mechanism. </text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>43175</offset><text>Subsequently, NF-kappaB activity is also regulated by the presence of several miRNAs mostly via repressive mechanisms. One such miRNA is miR-502e, which is reported to act as a tumour suppressor factor by altering cell proliferation in hepatoma cell lines and hepatocellular carcinoma by targeting NIK, thereby modulating the activity of non-canonical NF-kappaB signalling. Many highly expressed long non-coding RNAs (lncRNAs) are also reported to regulate the activity of NF-kappaB. The lncRNA NKILA, was reported to mask the phosphorylation motifs of IkappaB, further inhibiting the activation of NF-kappaB. Along with the aberrant activation of the NF-kappaB-signalling pathway, the expression of long non-coding RNAs (ncRNAs) is also dysregulated in different types of cancer cells, further regulating the degree of malignancy. The upregulated expression of lncRNA H19 in melanoma cells and Helicobacter pylori-induced expression of H19 in gastric cancer cells have been reported to be associated with enhanced cancer cell invasion and migration via activation of the NF-kappaB- and PI3K/Akt-signalling pathways. Another NF-kappaB-associated lncRNA reported to be upregulated in cancer cells is lncRNA NEAT1. Its overexpression promotes proliferation, migration and invasion, influences the expression of EMT markers, and activates the NF-kappaB pathway in HeLa and SiHa cells. H19 and NEAT1 are also reported to be associated with the resistance of cancer cells to chemotherapeutic drugs including bortezomib and dexamethasone respectively. Hence, it can be speculated that subunits of NF-kappaB function in association with ncRNAs to impart their pro-tumorigenic roles along with chemoresistance functions in tumour cells whose mechanism remains elusive and requires further clarification.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>44971</offset><text>7. Role of NF-kappaB Signalling in Shaping the Cancer Cell Chromatin Landscape </text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>45051</offset><text>Though the NF-kappaB family of proteins lack endogenous chromatin modifying enzymatic activity, they can exert changes in the chromatin landscape either by acting as a mediator to recruit and position chromatin modifiers onto target genes in a specific sequence dependent manner or by regulating the expression and activity of those modifiers. One noteworthy feature of NF-kappaB family members is their ability to form multimeric complexes. Apart from forming multimeric complexes with its own family proteins, NF-kappaB subunits are reported to form complexes with other proteins, which includes chromatin modifiers as well. Upon lymphotoxin treatment, non-canonical NF-kappaB signalling is activated and RelB/p52 dimer gets associated with the SWI/SNF chromatin remodeling complex via an adapter protein, requiem, to induce the expression of the BLC gene (CXCL13). Such interaction suggests an indirect role of activated NF-kappaB signalling in the epigenetic regulation of oncogene expression. Additionally, the NF-kappaB pathway also acts as a key regulator in the enhanced expression of chromatin modifiers and its subunits/interacting proteins, such as Enhancer of Zeste Homologue 2 (EZH2), a histone-lysine N-methyltransferase enzyme involved in the epigenetic modification of histone protein (H3K27), thus conferring the hypermethylation-mediated repressive gene expression of anti-oncogenic genes. In colorectal cancers, NF-kappaB activation in response to TNFalpha has been reported to induce the expression of EZH2, leading to the inhibitory promoter hyper-methylation of pro-apoptotic protein kinase cdelta binding protein (PRKCDBP) and resultant increased growth of cancer cells. Subunits of the NF-kappaB pathway can also act in a de-repression mechanism to remove the repressive chromatin marks and complexes. Some inducible gene promoters harbor high levels of the H3K9 dimethyl modification, associated with transcriptional silencing. However, upon stimulation, these marks are removed by the Aof1 histone demethylase, whose recruitment requires initially bound c-Rel dimers within the promoter region. The NF-kappaB pathway is also reported to regulate RNA Polymerase II elongation by changing the chromatin landscape via recruitment of General Control Non-Derepressible 5 (GCN5) acetyltransferase complexes that primarily modify H4K5/K8/K12 lysine residues. The accumulation of acetylated H4 histone proteins leads to the association with BRD4, which then positively regulates transcription by recruiting the elongation factor P-TEFb. Hence, the ability of the components of the NF-kappaB pathway to alter the chromatin landscape is not only limited to its signature DNA binding property but also extended to the recruitment of various chromatin modifiers assisting in transcriptional regulation. </text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_1</infon><offset>47869</offset><text>8. Concluding Remarks</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>47891</offset><text>Since the discovery of NF-kappaB nearly four decades ago, the multi-faceted roles of NF-kappaB members and their new transcription-binding partners in cancer have been gaining more clinical relevance in recent years. Although inflammation was previously implicated to promote the malignancy of human cancers, the causal mechanisms underscoring the link between inflammation and cancer have not been adequately characterized. Recent studies showing the aberrant activation of the NF-kappaB pathway in various cancer types and the regulation of NF-kappaB members in various tumorigenic events support the role of NF-kappaB as a hub linking inflammation and cancer. Although the occurrence of activating mutations in the NF-kappaB pathway is predominantly observed in hematological malignancies, the activation of NF-kappaB in solid tumours is also not negligible. The functional shift of the NF-kappaB pathway from inflammation to oncogenesis is mostly driven by the onset of chronic inflammatory conditions. NF-kappaB members can exert pro-oncogenic functions during cancer development through the activation of target gene transcription by their heterodimers. In addition, NF-kappaB components have also been demonstrated to interact with other factors, including transcription factors, kinases, epigenetic modifiers and other biological molecules like ROS and ncRNAs, to drive multiple oncogenic activities. Despite substantial progress in the understanding of various aspects of NF-kappaB signalling in cancer, the approaches for the targeted inhibition of specific components in the signalling pathway are limited due to various challenges. These challenges arise from the complex nature of its activity in different cancer types. Recent genomics studies have revealed the active selection of a wide range of driver mutations in cancer cells, some of which are important to facilitate the activation of the NF-kappaB pathway. In addition, epigenetic alterations have been documented to contribute to the aberrant activation of the NF-kappaB pathway. Conversely, the activated NF-kappaB pathway is also reported to confer changes in the chromatin landscape of cancer cells towards enhanced malignant phenotypes. Hence, these findings can potentially pave new ways for the development of precision medicine to improve the efficiency of existing cancer therapies and overcome the phenomenon of multidrug resistance in most of the cancer types.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">footnote</infon><offset>50335</offset><text>Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</text></passage><passage><infon key="section_type">AUTH_CONT</infon><infon key="type">title</infon><offset>50707</offset><text>Author Contributions</text></passage><passage><infon key="section_type">AUTH_CONT</infon><infon key="type">paragraph</infon><offset>50728</offset><text>Conceptualization, K.D. and Y.L.; writing:original draft preparation, K.D.; writing:review and editing, K.D. and Y.L.; supervision, Y.L.; project administration, Y.L.; funding acquisition, Y.L. All authors have read and agreed to the published version of the manuscript.</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">title</infon><offset>51003</offset><text>Conflicts of Interest</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">paragraph</infon><offset>51025</offset><text>The authors declare no conflict of interest.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">title</infon><offset>51070</offset><text>References</text></passage><passage><infon key="fpage">921</infon><infon key="lpage">928</infon><infon key="name_0">surname:Sen;given-names:R.</infon><infon key="name_1">surname:Baltimore;given-names:D.</infon><infon key="pub-id_doi">10.1016/0092-8674(86)90807-X</infon><infon key="pub-id_pmid">3096580</infon><infon key="section_type">REF</infon><infon key="source">Cell</infon><infon key="type">ref</infon><infon key="volume">47</infon><infon key="year">1986</infon><offset>51081</offset><text>Inducibility of kappa immunoglobulin enhancer-binding protein NF-kappaB by a posttranslational mechanism</text></passage><passage><infon key="fpage">80</infon><infon key="lpage">88</infon><infon key="name_0">surname:May;given-names:M.J.</infon><infon key="name_1">surname:Ghosh;given-names:S.</infon><infon key="pub-id_doi">10.1016/S0167-5699(97)01197-3</infon><infon key="pub-id_pmid">9509763</infon><infon key="section_type">REF</infon><infon key="source">Immunol. Today</infon><infon key="type">ref</infon><infon key="volume">19</infon><infon key="year">1998</infon><offset>51186</offset><text>Signal transduction through NF-kappaB</text></passage><passage><infon key="fpage">225</infon><infon key="lpage">260</infon><infon key="name_0">surname:Ghosh;given-names:S.</infon><infon key="name_1">surname:May;given-names:M.J.</infon><infon key="name_2">surname:Kopp;given-names:E.B.</infon><infon key="pub-id_doi">10.1146/annurev.immunol.16.1.225</infon><infon key="pub-id_pmid">9597130</infon><infon key="section_type">REF</infon><infon key="source">Annu. Rev. Immunol.</infon><infon key="type">ref</infon><infon key="volume">16</infon><infon key="year">1998</infon><offset>51224</offset><text>NF-kappaB and Rel proteins: Evolutionarily conserved mediators of immune responses</text></passage><passage><infon key="fpage">S81</infon><infon key="lpage">S96</infon><infon key="name_0">surname:Ghosh;given-names:S.</infon><infon key="name_1">surname:Karin;given-names:M.</infon><infon key="pub-id_doi">10.1016/S0092-8674(02)00703-1</infon><infon key="pub-id_pmid">11983155</infon><infon key="section_type">REF</infon><infon key="source">Cell</infon><infon key="type">ref</infon><infon key="volume">109</infon><infon key="year">2002</infon><offset>51307</offset><text>Missing pieces in the NF-kappaB puzzle</text></passage><passage><infon key="fpage">819</infon><infon key="lpage">828</infon><infon key="name_0">surname:Lin;given-names:L.</infon><infon key="name_1">surname:DeMartino;given-names:G.N.</infon><infon key="name_2">surname:Greene;given-names:W.C.</infon><infon key="pub-id_doi">10.1016/S0092-8674(00)81409-9</infon><infon key="pub-id_pmid">9529257</infon><infon key="section_type">REF</infon><infon key="source">Cell</infon><infon key="type">ref</infon><infon key="volume">92</infon><infon key="year">1998</infon><offset>51346</offset><text>Cotranslational biogenesis of NF-kappaB p50 by the 26S proteasome</text></passage><passage><infon key="fpage">414</infon><infon key="lpage">429</infon><infon key="name_0">surname:Caamano;given-names:J.</infon><infon key="name_1">surname:Hunter;given-names:C.A.</infon><infon key="pub-id_doi">10.1128/CMR.15.3.414-429.2002</infon><infon key="pub-id_pmid">12097249</infon><infon key="section_type">REF</infon><infon key="source">Clin. Microbiol. Rev.</infon><infon key="type">ref</infon><infon key="volume">15</infon><infon key="year">2002</infon><offset>51412</offset><text>NF-kappaB family of transcription factors: Central regulators of innate and adaptive immune functions</text></passage><passage><infon key="fpage">7612</infon><infon key="lpage">7617</infon><infon key="name_0">surname:Sif;given-names:S.</infon><infon key="name_1">surname:Gilmore;given-names:T.D.</infon><infon key="pub-id_doi">10.1128/jvi.67.12.7612-7617.1993</infon><infon key="pub-id_pmid">8230480</infon><infon key="section_type">REF</infon><infon key="source">J. Virol.</infon><infon key="type">ref</infon><infon key="volume">67</infon><infon key="year">1993</infon><offset>51514</offset><text>NF-kappa B p100 is one of the high-molecular-weight proteins complexed with the v-Rel oncoprotein in transformed chicken spleen cells</text></passage><passage><infon key="fpage">674</infon><infon key="lpage">684</infon><infon key="name_0">surname:Ryseck;given-names:R.-P.</infon><infon key="name_1">surname:Bull;given-names:P.</infon><infon key="name_2">surname:Takamiya;given-names:M.</infon><infon key="name_3">surname:Bours;given-names:V.</infon><infon key="name_4">surname:Siebenlist;given-names:U.</infon><infon key="name_5">surname:Dobrzanski;given-names:P.</infon><infon key="name_6">surname:Bravo;given-names:R.</infon><infon key="pub-id_pmid">1732739</infon><infon key="section_type">REF</infon><infon key="source">Mol. Cell. Biol.</infon><infon key="type">ref</infon><infon key="volume">12</infon><infon key="year">1992</infon><offset>51648</offset><text>RelB, a new Rel family transcription activator that can interact with p50-NF-kappa B</text></passage><passage><infon key="fpage">104</infon><infon key="lpage">113</infon><infon key="name_0">surname:Chen;given-names:I.</infon><infon key="name_1">surname:Wilhelmsen;given-names:K.</infon><infon key="name_2">surname:Temin;given-names:H.M.</infon><infon key="pub-id_doi">10.1128/jvi.45.1.104-113.1983</infon><infon key="pub-id_pmid">6296425</infon><infon key="section_type">REF</infon><infon key="source">J. Virol.</infon><infon key="type">ref</infon><infon key="volume">45</infon><infon key="year">1983</infon><offset>51733</offset><text>Structure and expression of c-rel, the cellular homolog to the oncogene of reticuloendotheliosis virus strain T</text></passage><passage><infon key="fpage">172</infon><infon key="lpage">182</infon><infon key="name_0">surname:Wilhelmsen;given-names:K.C.</infon><infon key="name_1">surname:Eggleton;given-names:K.</infon><infon key="name_2">surname:Temin;given-names:H.M.</infon><infon key="pub-id_doi">10.1128/jvi.52.1.172-182.1984</infon><infon key="pub-id_pmid">6090694</infon><infon key="section_type">REF</infon><infon key="source">J. Virol.</infon><infon key="type">ref</infon><infon key="volume">52</infon><infon key="year">1984</infon><offset>51845</offset><text>Nucleic acid sequences of the oncogene v-rel in reticuloendotheliosis virus strain T and its cellular homolog, the proto-oncogene c-rel</text></passage><passage><infon key="fpage">1019</infon><infon key="lpage">1029</infon><infon key="name_0">surname:Ghosh;given-names:S.</infon><infon key="name_1">surname:Gifford;given-names:A.M.</infon><infon key="name_2">surname:Riviere;given-names:L.R.</infon><infon key="name_3">surname:Tempst;given-names:P.</infon><infon key="name_4">surname:Nolan;given-names:G.P.</infon><infon key="name_5">surname:Baltimore;given-names:D.</infon><infon key="pub-id_doi">10.1016/0092-8674(90)90276-K</infon><infon key="pub-id_pmid">2203532</infon><infon key="section_type">REF</infon><infon key="source">Cell</infon><infon key="type">ref</infon><infon key="volume">62</infon><infon key="year">1990</infon><offset>51981</offset><text>Cloning of the p50 DNA binding subunit of NF-kappaB: Homology to rel and dorsal</text></passage><passage><infon key="fpage">303</infon><infon key="lpage">310</infon><infon key="name_0">surname:Ghosh;given-names:G.</infon><infon key="name_1">surname:Duyne;given-names:G.V.</infon><infon key="name_2">surname:Ghosh;given-names:S.</infon><infon key="name_3">surname:Sigler;given-names:P.B.</infon><infon key="pub-id_doi">10.1038/373303a0</infon><infon key="pub-id_pmid">7530332</infon><infon key="section_type">REF</infon><infon key="source">Nature</infon><infon key="type">ref</infon><infon key="volume">373</infon><infon key="year">1995</infon><offset>52061</offset><text>Structure of NF-kappaB p50 homodimer bound to a kappaB site</text></passage><passage><infon key="fpage">76</infon><infon key="lpage">80</infon><infon key="name_0">surname:Bours;given-names:V.</infon><infon key="name_1">surname:Villalobos;given-names:J.</infon><infon key="name_2">surname:Burd;given-names:P.R.</infon><infon key="name_3">surname:Kelly;given-names:K.</infon><infon key="name_4">surname:Siebenlist;given-names:U.</infon><infon key="pub-id_doi">10.1038/348076a0</infon><infon key="pub-id_pmid">2234062</infon><infon key="section_type">REF</infon><infon key="source">Nature</infon><infon key="type">ref</infon><infon key="volume">348</infon><infon key="year">1990</infon><offset>52121</offset><text>Cloning of a mitogen-inducible gene encoding a kappaB DNA-binding protein with homology to the rel oncogene and to cell-cycle motifs</text></passage><passage><infon key="fpage">966</infon><infon key="lpage">970</infon><infon key="name_0">surname:Meyer;given-names:R.</infon><infon key="name_1">surname:Hatada;given-names:E.N.</infon><infon key="name_2">surname:Hohmann;given-names:H.-P.</infon><infon key="name_3">surname:Haiker;given-names:M.</infon><infon key="name_4">surname:Bartsch;given-names:C.</infon><infon key="name_5">surname:Rothlisberger;given-names:U.</infon><infon key="name_6">surname:Lahm;given-names:H.-W.</infon><infon key="name_7">surname:Schlaeger;given-names:E.J.</infon><infon key="name_8">surname:Van Loon;given-names:A.</infon><infon key="name_9">surname:Scheidereit;given-names:C.</infon><infon key="pub-id_doi">10.1073/pnas.88.3.966</infon><infon key="pub-id_pmid">1992489</infon><infon key="section_type">REF</infon><infon key="source">Proc. Natl. Acad. Sci. USA</infon><infon key="type">ref</infon><infon key="volume">88</infon><infon key="year">1991</infon><offset>52254</offset><text>Cloning of the DNA-binding subunit of human nuclear factor kappa B: The level of its mRNA is strongly regulated by phorbol ester or tumor necrosis factor alpha</text></passage><passage><infon key="fpage">1075</infon><infon key="lpage">1087</infon><infon key="name_0">surname:Neri;given-names:A.</infon><infon key="name_1">surname:Chang;given-names:C.-C.</infon><infon key="name_2">surname:Lombardi;given-names:L.</infon><infon key="name_3">surname:Salina;given-names:M.</infon><infon key="name_4">surname:Corradini;given-names:P.</infon><infon key="name_5">surname:Maiolo;given-names:A.T.</infon><infon key="name_6">surname:Chaganti;given-names:R.</infon><infon key="name_7">surname:Dalla-Favera;given-names:R.</infon><infon key="pub-id_doi">10.1016/0092-8674(91)90285-7</infon><infon key="pub-id_pmid">1760839</infon><infon key="section_type">REF</infon><infon key="source">Cell</infon><infon key="type">ref</infon><infon key="volume">67</infon><infon key="year">1991</infon><offset>52414</offset><text>B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-kappaB p50</text></passage><passage><infon key="fpage">32162</infon><infon key="lpage">32167</infon><infon key="name_0">surname:Schmid;given-names:R.M.</infon><infon key="name_1">surname:Liptay;given-names:S.</infon><infon key="name_2">surname:Betts;given-names:J.C.</infon><infon key="name_3">surname:Nabel;given-names:G.J.</infon><infon key="pub-id_doi">10.1016/S0021-9258(18)31615-6</infon><infon key="pub-id_pmid">7798213</infon><infon key="section_type">REF</infon><infon key="source">J. Biol. Chem.</infon><infon key="type">ref</infon><infon key="volume">269</infon><infon key="year">1994</infon><offset>52531</offset><text>Structural and functional analysis of NF-kappa B. Determinants of DNA binding specificity and protein interaction</text></passage><passage><infon key="fpage">523</infon><infon key="lpage">537</infon><infon key="name_0">surname:MERCURIO;given-names:F.</infon><infon key="name_1">surname:DIDONATO;given-names:J.</infon><infon key="name_2">surname:ROSETTE;given-names:C.</infon><infon key="name_3">surname:Karin;given-names:M.</infon><infon key="pub-id_doi">10.1089/dna.1992.11.523</infon><infon key="pub-id_pmid">1388725</infon><infon key="section_type">REF</infon><infon key="source">DNA Cell Biol.</infon><infon key="type">ref</infon><infon key="volume">11</infon><infon key="year">1992</infon><offset>52645</offset><text>Molecular cloning and characterization of a novel rel/NF-chiB family member displaying structural and functional homology to NF-chiB p50/p105</text></passage><passage><infon key="fpage">685</infon><infon key="lpage">695</infon><infon key="name_0">surname:Bours;given-names:V.</infon><infon key="name_1">surname:Burd;given-names:P.</infon><infon key="name_2">surname:Brown;given-names:K.</infon><infon key="name_3">surname:Villalobos;given-names:J.</infon><infon key="name_4">surname:Park;given-names:S.</infon><infon key="name_5">surname:Ryseck;given-names:R.P.</infon><infon key="name_6">surname:Bravo;given-names:R.</infon><infon key="name_7">surname:Kelly;given-names:K.</infon><infon key="name_8">surname:Siebenlist;given-names:U.</infon><infon key="pub-id_pmid">1531086</infon><infon key="section_type">REF</infon><infon key="source">Mol. Cell. Biol.</infon><infon key="type">ref</infon><infon key="volume">12</infon><infon key="year">1992</infon><offset>52787</offset><text>A novel mitogen-inducible gene product related to p50/p105-NF-kappa B participates in transactivation through a kappa B site</text></passage><passage><infon key="fpage">1490</infon><infon key="lpage">1493</infon><infon key="name_0">surname:Ruben;given-names:S.M.</infon><infon key="name_1">surname:Dillon;given-names:P.J.</infon><infon key="name_2">surname:Schreck;given-names:R.</infon><infon key="name_3">surname:Henkel;given-names:T.</infon><infon key="name_4">surname:Chen;given-names:C.-H.</infon><infon key="name_5">surname:Maher;given-names:M.</infon><infon key="name_6">surname:Baeuerle;given-names:P.A.</infon><infon key="name_7">surname:Rosen;given-names:C.A.</infon><infon key="pub-id_doi">10.1126/science.2006423</infon><infon key="pub-id_pmid">2006423</infon><infon key="section_type">REF</infon><infon key="source">Science</infon><infon key="type">ref</infon><infon key="volume">251</infon><infon key="year">1991</infon><offset>52912</offset><text>Isolation of a rel-related Human cDNAThat Potentially Encodes the 65-kD Subunit of NF-kappaB</text></passage><passage><infon key="fpage">3100</infon><infon key="lpage">3109</infon><infon key="name_0">surname:Ryseck;given-names:R.-P.</infon><infon key="name_1">surname:Novotny;given-names:J.</infon><infon key="name_2">surname:Bravo;given-names:R.</infon><infon key="pub-id_doi">10.1128/MCB.15.6.3100</infon><infon key="pub-id_pmid">7760806</infon><infon key="section_type">REF</infon><infon key="source">Mol. Cell. Biol.</infon><infon key="type">ref</infon><infon key="volume">15</infon><infon key="year">1995</infon><offset>53005</offset><text>Characterization of elements determining the dimerization properties of RelB and p50</text></passage><passage><infon key="fpage">1699</infon><infon key="lpage">1702</infon><infon key="name_0">surname:Bours;given-names:V.</infon><infon key="name_1">surname:Azarenko;given-names:V.</infon><infon key="name_2">surname:Dejardin;given-names:E.</infon><infon key="name_3">surname:Siebenlist;given-names:U.</infon><infon key="pub-id_pmid">8183565</infon><infon key="section_type">REF</infon><infon key="source">Oncogene</infon><infon key="type">ref</infon><infon key="volume">9</infon><infon key="year">1994</infon><offset>53090</offset><text>Human RelB (I-Rel) functions as a kappa B site-dependent transactivating member of the family of Rel-related proteins</text></passage><passage><infon key="fpage">1109</infon><infon key="lpage">1120</infon><infon key="name_0">surname:Inoue;given-names:J.-I.</infon><infon key="name_1">surname:Kerr;given-names:L.D.</infon><infon key="name_2">surname:Kakizuka;given-names:A.</infon><infon key="name_3">surname:Verma;given-names:I.M.</infon><infon key="pub-id_doi">10.1016/0092-8674(92)90082-N</infon><infon key="pub-id_pmid">1339305</infon><infon key="section_type">REF</infon><infon key="source">Cell</infon><infon key="type">ref</infon><infon key="volume">68</infon><infon key="year">1992</infon><offset>53208</offset><text>IkappaBgamma, a 70 kd protein identical to the C-terminal half of p110 NF-kappaB: A new member of the IkappaB family</text></passage><passage><infon key="fpage">617</infon><infon key="lpage">627</infon><infon key="name_0">surname:Gerondakis;given-names:S.</infon><infon key="name_1">surname:Morrice;given-names:N.</infon><infon key="name_2">surname:Richardson;given-names:I.</infon><infon key="name_3">surname:Wettenhall;given-names:R.</infon><infon key="name_4">surname:Fecondo;given-names:J.</infon><infon key="name_5">surname:Grumont;given-names:R.</infon><infon key="section_type">REF</infon><infon key="source">Cell Growth Differ. Mol. Biol. J. Am. Assoc. Cancer Res.</infon><infon key="type">ref</infon><infon key="volume">4</infon><infon key="year">1993</infon><offset>53325</offset><text>The activity of a 70 kilodalton I kappa B molecule identical to the carboxyl terminus of the p105 NF-kappa B precursor is modulated by protein kinase A</text></passage><passage><infon key="fpage">4367</infon><infon key="lpage">4371</infon><infon key="name_0">surname:Grumont;given-names:R.J.</infon><infon key="name_1">surname:Gerondakis;given-names:S.</infon><infon key="pub-id_doi">10.1073/pnas.91.10.4367</infon><infon key="pub-id_pmid">8183915</infon><infon key="section_type">REF</infon><infon key="source">Proc. Natl. Acad. Sci. USA</infon><infon key="type">ref</infon><infon key="volume">91</infon><infon key="year">1994</infon><offset>53477</offset><text>Alternative splicing of RNA transcripts encoded by the murine p105 NF-kappa B gene generates I kappa B gamma isoforms with different inhibitory activities</text></passage><passage><infon key="fpage">6685</infon><infon key="lpage">6705</infon><infon key="name_0">surname:Scheidereit;given-names:C.</infon><infon key="pub-id_doi">10.1038/sj.onc.1209934</infon><infon key="pub-id_pmid">17072322</infon><infon key="section_type">REF</infon><infon key="source">Oncogene</infon><infon key="type">ref</infon><infon key="volume">25</infon><infon key="year">2006</infon><offset>53632</offset><text>IkappaB kinase complexes: Gateways to NF-kappaB activation and transcription</text></passage><passage><infon key="fpage">243</infon><infon key="lpage">252</infon><infon key="name_0">surname:Zandi;given-names:E.</infon><infon key="name_1">surname:Rothwarf;given-names:D.M.</infon><infon key="name_2">surname:Delhase;given-names:M.</infon><infon key="name_3">surname:Hayakawa;given-names:M.</infon><infon key="name_4">surname:Karin;given-names:M.</infon><infon key="pub-id_doi">10.1016/S0092-8674(00)80406-7</infon><infon key="pub-id_pmid">9346241</infon><infon key="section_type">REF</infon><infon key="source">Cell</infon><infon key="type">ref</infon><infon key="volume">91</infon><infon key="year">1997</infon><offset>53709</offset><text>The IkB kinase complex (IKK) contains two kinase subunits, IKKa and IKKb, necessary for IkB phosphorylation and NF-kB activation</text></passage><passage><infon key="fpage">297</infon><infon key="lpage">300</infon><infon key="name_0">surname:Rothwarf;given-names:D.M.</infon><infon key="name_1">surname:Zandi;given-names:E.</infon><infon key="name_2">surname:Natoli;given-names:G.</infon><infon key="name_3">surname:Karin;given-names:M.</infon><infon key="pub-id_doi">10.1038/26261</infon><infon key="pub-id_pmid">9751060</infon><infon key="section_type">REF</infon><infon key="source">Nature</infon><infon key="type">ref</infon><infon key="volume">395</infon><infon key="year">1998</infon><offset>53838</offset><text>IKK-gamma is an essential regulatory subunit of the IkappaB kinase complex</text></passage><passage><infon key="fpage">6842</infon><infon key="lpage">6844</infon><infon key="name_0">surname:Gilmore;given-names:T.D.</infon><infon key="pub-id_doi">10.1038/sj.onc.1203237</infon><infon key="pub-id_pmid">10602459</infon><infon key="section_type">REF</infon><infon key="source">Oncogene</infon><infon key="type">ref</infon><infon key="volume">18</infon><infon key="year">1999</infon><offset>53913</offset><text>The Rel/NF-kappaB signal transduction pathway: Introduction</text></passage><passage><infon key="fpage">32</infon><infon key="name_0">surname:Shindo;given-names:M.</infon><infon key="name_1">surname:Nakano;given-names:H.</infon><infon key="name_2">surname:Sakon;given-names:S.</infon><infon key="name_3">surname:Yagita;given-names:H.</infon><infon key="pub-id_doi">10.1159/000015058</infon><infon key="section_type">REF</infon><infon key="source">Cytogenet. Genome Res.</infon><infon key="type">ref</infon><infon key="volume">82</infon><infon key="year">1998</infon><offset>53973</offset><text>Assignment of (I kappa B) kinase (beta)(IKBKB) to human chromosome band 8p12--&gt; p11 by in situ hybridization</text></passage><passage><infon key="fpage">3792</infon><infon key="lpage">3797</infon><infon key="name_0">surname:Ling;given-names:L.</infon><infon key="name_1">surname:Cao;given-names:Z.</infon><infon key="name_2">surname:Goeddel;given-names:D.V.</infon><infon key="pub-id_doi">10.1073/pnas.95.7.3792</infon><infon key="pub-id_pmid">9520446</infon><infon key="section_type">REF</infon><infon key="source">Proc. Natl. Acad. Sci. USA</infon><infon key="type">ref</infon><infon key="volume">95</infon><infon key="year">1998</infon><offset>54082</offset><text>NF-kappaB-inducing kinase activates IKK-alpha by phosphorylation of Ser-176</text></passage><passage><infon key="fpage">201</infon><infon key="lpage">211</infon><infon key="name_0">surname:Zabel;given-names:U.</infon><infon key="name_1">surname:Henkel;given-names:T.</infon><infon key="name_2">surname:Silva;given-names:M.S.</infon><infon key="name_3">surname:Baeuerle;given-names:P.A.</infon><infon key="pub-id_doi">10.1002/j.1460-2075.1993.tb05646.x</infon><infon key="pub-id_pmid">7679069</infon><infon key="section_type">REF</infon><infon key="source">EMBO J.</infon><infon key="type">ref</infon><infon key="volume">12</infon><infon key="year">1993</infon><offset>54158</offset><text>Nuclear uptake control of NF-kappa B by MAD-3, an I kappa B protein present in the nucleus</text></passage><passage><infon key="fpage">255</infon><infon key="lpage">265</infon><infon key="name_0">surname:Zabel;given-names:U.</infon><infon key="name_1">surname:Baeuerle;given-names:P.A.</infon><infon key="pub-id_doi">10.1016/0092-8674(90)90806-P</infon><infon key="pub-id_pmid">2184941</infon><infon key="section_type">REF</infon><infon key="source">Cell</infon><infon key="type">ref</infon><infon key="volume">61</infon><infon key="year">1990</infon><offset>54249</offset><text>Purified human IkappaB can rapidly dissociate the complex of the NF-kappaB transcription factor with its cognate DNA</text></passage><passage><infon key="fpage">369</infon><infon key="lpage">378</infon><infon key="name_0">surname:Arenzana-Seisdedos;given-names:F.</infon><infon key="name_1">surname:Turpin;given-names:P.</infon><infon key="name_2">surname:Rodriguez;given-names:M.</infon><infon key="name_3">surname:Thomas;given-names:D.</infon><infon key="name_4">surname:Hay;given-names:R.T.</infon><infon key="name_5">surname:Virelizier;given-names:J.-L.</infon><infon key="name_6">surname:Dargemont;given-names:C.</infon><infon key="pub-id_doi">10.1242/jcs.110.3.369</infon><infon key="pub-id_pmid">9057089</infon><infon key="section_type">REF</infon><infon key="source">J. Cell Sci.</infon><infon key="type">ref</infon><infon key="volume">110</infon><infon key="year">1997</infon><offset>54366</offset><text>Nuclear localization of I kappa B alpha promotes active transport of NF-kappa B from the nucleus to the cytoplasm</text></passage><passage><infon key="fpage">3915</infon><infon key="lpage">3926</infon><infon key="name_0">surname:Zhang;given-names:Q.</infon><infon key="name_1">surname:Didonato;given-names:J.A.</infon><infon key="name_2">surname:Karin;given-names:M.</infon><infon key="name_3">surname:McKeithan;given-names:T.W.</infon><infon key="pub-id_pmid">8196632</infon><infon key="section_type">REF</infon><infon key="source">Mol. Cell. Biol.</infon><infon key="type">ref</infon><infon key="volume">14</infon><infon key="year">1994</infon><offset>54480</offset><text>BCL3 encodes a nuclear protein which can alter the subcellular location of NF-kappa B proteins</text></passage><passage><infon key="fpage">2489</infon><infon key="lpage">2493</infon><infon key="name_0">surname:Hatada;given-names:E.N.</infon><infon key="name_1">surname:Nieters;given-names:A.</infon><infon key="name_2">surname:Wulczyn;given-names:F.G.</infon><infon key="name_3">surname:Naumann;given-names:M.</infon><infon key="name_4">surname:Meyer;given-names:R.</infon><infon key="name_5">surname:Nucifora;given-names:G.</infon><infon key="name_6">surname:McKeithan;given-names:T.W.</infon><infon key="name_7">surname:Scheidereit;given-names:C.</infon><infon key="pub-id_doi">10.1073/pnas.89.6.2489</infon><infon key="pub-id_pmid">1532257</infon><infon key="section_type">REF</infon><infon key="source">Proc. Natl. Acad. Sci. USA</infon><infon key="type">ref</infon><infon key="volume">89</infon><infon key="year">1992</infon><offset>54575</offset><text>The ankyrin repeat domains of the NF-kappa B precursor p105 and the protooncogene bcl-3 act as specific inhibitors of NF-kappa B DNA binding</text></passage><passage><infon key="fpage">675</infon><infon key="lpage">678</infon><infon key="name_0">surname:Carmody;given-names:R.J.</infon><infon key="name_1">surname:Ruan;given-names:Q.</infon><infon key="name_2">surname:Palmer;given-names:S.</infon><infon key="name_3">surname:Hilliard;given-names:B.</infon><infon key="name_4">surname:Chen;given-names:Y.H.</infon><infon key="pub-id_doi">10.1126/science.1142953</infon><infon key="pub-id_pmid">17673665</infon><infon key="section_type">REF</infon><infon key="source">Science</infon><infon key="type">ref</infon><infon key="volume">317</infon><infon key="year">2007</infon><offset>54716</offset><text>Negative regulation of toll-like receptor signaling by NF-kappaB p50 ubiquitination blockade</text></passage><passage><infon key="fpage">824</infon><infon key="lpage">839</infon><infon key="name_0">surname:Wang;given-names:V.Y.-F.</infon><infon key="name_1">surname:Huang;given-names:W.</infon><infon key="name_2">surname:Asagiri;given-names:M.</infon><infon key="name_3">surname:Spann;given-names:N.</infon><infon key="name_4">surname:Hoffmann;given-names:A.</infon><infon key="name_5">surname:Glass;given-names:C.</infon><infon key="name_6">surname:Ghosh;given-names:G.</infon><infon key="pub-id_doi">10.1016/j.celrep.2012.08.042</infon><infon key="pub-id_pmid">23063365</infon><infon key="section_type">REF</infon><infon key="source">Cell Rep.</infon><infon key="type">ref</infon><infon key="volume">2</infon><infon key="year">2012</infon><offset>54809</offset><text>The transcriptional specificity of NF-kappaB dimers is coded within the kappaB DNA response elements</text></passage><passage><infon key="fpage">930619</infon><infon key="name_0">surname:Pan;given-names:W.</infon><infon key="name_1">surname:Deng;given-names:L.</infon><infon key="name_2">surname:Wang;given-names:H.</infon><infon key="name_3">surname:Wang;given-names:V.Y.-F.</infon><infon key="pub-id_doi">10.3389/fcell.2022.930619</infon><infon key="pub-id_pmid">35990614</infon><infon key="section_type">REF</infon><infon key="source">Front. Cell Dev. Biol.</infon><infon key="type">ref</infon><infon key="volume">10</infon><infon key="year">2022</infon><offset>54910</offset><text>Atypical IkappaB Bcl3 enhances the generation of the NF-kappaB p52 homodimer</text></passage><passage><infon key="fpage">12645</infon><infon key="lpage">12654</infon><infon key="name_0">surname:Totzke;given-names:G.</infon><infon key="name_1">surname:Essmann;given-names:F.</infon><infon key="name_2">surname:Pohlmann;given-names:S.</infon><infon key="name_3">surname:Lindenblatt;given-names:C.</infon><infon key="name_4">surname:Janicke;given-names:R.U.</infon><infon key="name_5">surname:Schulze-Osthoff;given-names:K.</infon><infon key="pub-id_doi">10.1074/jbc.M511956200</infon><infon key="pub-id_pmid">16513645</infon><infon key="section_type">REF</infon><infon key="source">J. Biol. Chem.</infon><infon key="type">ref</infon><infon key="volume">281</infon><infon key="year">2006</infon><offset>54987</offset><text>A novel member of the IkappaB family, human IkappaB-zeta, inhibits transactivation of p65 and its DNA binding</text></passage><passage><infon key="fpage">11924</infon><infon key="lpage">11929</infon><infon key="name_0">surname:Yamauchi;given-names:S.</infon><infon key="name_1">surname:Ito;given-names:H.</infon><infon key="name_2">surname:Miyajima;given-names:A.</infon><infon key="pub-id_doi">10.1073/pnas.0913179107</infon><infon key="pub-id_pmid">20547855</infon><infon key="section_type">REF</infon><infon key="source">Proc. Natl. Acad. Sci. USA</infon><infon key="type">ref</infon><infon key="volume">107</infon><infon key="year">2010</infon><offset>55097</offset><text>IkappaBeta, a nuclear IkappaB protein, positively regulates the NF-kappaB-mediated expression of proinflammatory cytokines</text></passage><passage><infon key="fpage">637</infon><infon key="lpage">648</infon><infon key="name_0">surname:Fiorini;given-names:E.</infon><infon key="name_1">surname:Schmitz;given-names:I.</infon><infon key="name_2">surname:Marissen;given-names:W.E.</infon><infon key="name_3">surname:Osborn;given-names:S.L.</infon><infon key="name_4">surname:Touma;given-names:M.</infon><infon key="name_5">surname:Sasada;given-names:T.</infon><infon key="name_6">surname:Reche;given-names:P.A.</infon><infon key="name_7">surname:Tibaldi;given-names:E.V.</infon><infon key="name_8">surname:Hussey;given-names:R.E.</infon><infon key="name_9">surname:Kruisbeek;given-names:A.M.</infon><infon key="pub-id_doi">10.1016/S1097-2765(02)00469-0</infon><infon key="pub-id_pmid">11931770</infon><infon key="section_type">REF</infon><infon key="source">Mol. Cell</infon><infon key="type">ref</infon><infon key="volume">9</infon><infon key="year">2002</infon><offset>55220</offset><text>Peptide-induced negative selection of thymocytes activates transcription of an NF-kappaB inhibitor</text></passage><passage><infon key="fpage">998</infon><infon key="lpage">1008</infon><infon key="name_0">surname:Schuster;given-names:M.</infon><infon key="name_1">surname:Glauben;given-names:R.</infon><infon key="name_2">surname:Plaza-Sirvent;given-names:C.</infon><infon key="name_3">surname:Schreiber;given-names:L.</infon><infon key="name_4">surname:Annemann;given-names:M.</infon><infon key="name_5">surname:Floess;given-names:S.</infon><infon key="name_6">surname:Kuhl;given-names:A.A.</infon><infon key="name_7">surname:Clayton;given-names:L.K.</infon><infon key="name_8">surname:Sparwasser;given-names:T.</infon><infon key="name_9">surname:Schulze-Osthoff;given-names:K.</infon><infon key="pub-id_doi">10.1016/j.immuni.2012.08.023</infon><infon key="pub-id_pmid">23200824</infon><infon key="section_type">REF</infon><infon key="source">Immunity</infon><infon key="type">ref</infon><infon key="volume">37</infon><infon key="year">2012</infon><offset>55319</offset><text>IkappaBNS protein mediates regulatory T cell development via induction of the Foxp3 transcription factor</text></passage><passage><infon key="fpage">6731</infon><infon key="lpage">6748</infon><infon key="name_0">surname:Bubici;given-names:C.</infon><infon key="name_1">surname:Papa;given-names:S.</infon><infon key="name_2">surname:Dean;given-names:K.</infon><infon key="name_3">surname:Franzoso;given-names:G.</infon><infon key="pub-id_doi">10.1038/sj.onc.1209936</infon><infon key="pub-id_pmid">17072325</infon><infon key="section_type">REF</infon><infon key="source">Oncogene</infon><infon key="type">ref</infon><infon key="volume">25</infon><infon key="year">2006</infon><offset>55424</offset><text>Mutual cross-talk between reactive oxygen species and nuclear factor-kappa B: Molecular basis and biological significance</text></passage><passage><infon key="fpage">4795</infon><infon key="lpage">4804</infon><infon key="name_0">surname:Barre;given-names:B.</infon><infon key="name_1">surname:Coqueret;given-names:O.</infon><infon key="name_2">surname:Perkins;given-names:N.D.</infon><infon key="pub-id_doi">10.4161/cc.9.24.14245</infon><infon key="pub-id_pmid">21131783</infon><infon key="section_type">REF</infon><infon key="source">Cell Cycle</infon><infon key="type">ref</infon><infon key="volume">9</infon><infon key="year">2010</infon><offset>55546</offset><text>Regulation of activity and function of the p52 NF-kappaB subunit following DNA damage</text></passage><passage><infon key="fpage">103</infon><infon key="lpage">115</infon><infon key="name_0">surname:Morgan;given-names:M.J.</infon><infon key="name_1">surname:Liu;given-names:Z.-g.</infon><infon key="pub-id_doi">10.1038/cr.2010.178</infon><infon key="pub-id_pmid">21187859</infon><infon key="section_type">REF</infon><infon key="source">Cell Res.</infon><infon key="type">ref</infon><infon key="volume">21</infon><infon key="year">2011</infon><offset>55632</offset><text>Crosstalk of reactive oxygen species and NF-kappaB signaling</text></passage><passage><infon key="fpage">2336</infon><infon key="lpage">2340</infon><infon key="name_0">surname:Osborn;given-names:L.</infon><infon key="name_1">surname:Kunkel;given-names:S.</infon><infon key="name_2">surname:Nabel;given-names:G.J.</infon><infon key="pub-id_doi">10.1073/pnas.86.7.2336</infon><infon key="pub-id_pmid">2494664</infon><infon key="section_type">REF</infon><infon key="source">Proc. Natl. Acad. Sci. USA</infon><infon key="type">ref</infon><infon key="volume">86</infon><infon key="year">1989</infon><offset>55693</offset><text>Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B</text></passage><passage><infon key="fpage">5974</infon><infon key="lpage">5978</infon><infon key="name_0">surname:Duh;given-names:E.J.</infon><infon key="name_1">surname:Maury;given-names:W.J.</infon><infon key="name_2">surname:Folks;given-names:T.M.</infon><infon key="name_3">surname:Fauci;given-names:A.S.</infon><infon key="name_4">surname:Rabson;given-names:A.B.</infon><infon key="pub-id_doi">10.1073/pnas.86.15.5974</infon><infon key="pub-id_pmid">2762307</infon><infon key="section_type">REF</infon><infon key="source">Proc. Natl. Acad. Sci. USA</infon><infon key="type">ref</infon><infon key="volume">86</infon><infon key="year">1989</infon><offset>55835</offset><text>Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat</text></passage><passage><infon key="fpage">2331</infon><infon key="lpage">2335</infon><infon key="name_0">surname:Lowenthal;given-names:J.W.</infon><infon key="name_1">surname:Ballard;given-names:D.W.</infon><infon key="name_2">surname:Bohnlein;given-names:E.</infon><infon key="name_3">surname:Greene;given-names:W.C.</infon><infon key="pub-id_doi">10.1073/pnas.86.7.2331</infon><infon key="pub-id_pmid">2494663</infon><infon key="section_type">REF</infon><infon key="source">Proc. Natl. Acad. Sci. USA</infon><infon key="type">ref</infon><infon key="volume">86</infon><infon key="year">1989</infon><offset>56005</offset><text>Tumor necrosis factor alpha induces proteins that bind specifically to kappa B-like enhancer elements and regulate interleukin 2 receptor alpha-chain gene expression in primary human T lymphocytes</text></passage><passage><infon key="fpage">5337</infon><infon key="lpage">5344</infon><infon key="name_0">surname:Awane;given-names:M.</infon><infon key="name_1">surname:Andres;given-names:P.G.</infon><infon key="name_2">surname:Li;given-names:D.J.</infon><infon key="name_3">surname:Reinecker;given-names:H.-C.</infon><infon key="pub-id_doi">10.4049/jimmunol.162.9.5337</infon><infon key="pub-id_pmid">10228009</infon><infon key="section_type">REF</infon><infon key="source">J. Immunol.</infon><infon key="type">ref</infon><infon key="volume">162</infon><infon key="year">1999</infon><offset>56202</offset><text>NF-kappaB-inducing kinase is a common mediator of IL-17-, TNF-alpha-, and IL-1beta-induced chemokine promoter activation in intestinal epithelial cells</text></passage><passage><infon key="fpage">1457</infon><infon key="lpage">1466</infon><infon key="name_0">surname:Elewaut;given-names:D.</infon><infon key="name_1">surname:DiDonato;given-names:J.A.</infon><infon key="name_2">surname:Kim;given-names:J.M.</infon><infon key="name_3">surname:Truong;given-names:F.</infon><infon key="name_4">surname:Eckmann;given-names:L.</infon><infon key="name_5">surname:Kagnoff;given-names:M.F.</infon><infon key="pub-id_doi">10.4049/jimmunol.163.3.1457</infon><infon key="pub-id_pmid">10415047</infon><infon key="section_type">REF</infon><infon key="source">J. Immunol.</infon><infon key="type">ref</infon><infon key="volume">163</infon><infon key="year">1999</infon><offset>56354</offset><text>NF-kappaB is a central regulator of the intestinal epithelial cell innate immune response induced by infection with enteroinvasive bacteria</text></passage><passage><infon key="fpage">2195</infon><infon key="lpage">2224</infon><infon key="name_0">surname:Hayden;given-names:M.S.</infon><infon key="name_1">surname:Ghosh;given-names:S.</infon><infon key="pub-id_doi">10.1101/gad.1228704</infon><infon key="pub-id_pmid">15371334</infon><infon key="section_type">REF</infon><infon key="source">Genes Dev. Biol.</infon><infon key="type">ref</infon><infon key="volume">18</infon><infon key="year">2004</infon><offset>56494</offset><text>Signaling to NF-kappaB</text></passage><passage><infon key="fpage">958</infon><infon key="lpage">965</infon><infon key="name_0">surname:Claudio;given-names:E.</infon><infon key="name_1">surname:Brown;given-names:K.</infon><infon key="name_2">surname:Park;given-names:S.</infon><infon key="name_3">surname:Wang;given-names:H.</infon><infon key="name_4">surname:Siebenlist;given-names:U.</infon><infon key="pub-id_doi">10.1038/ni842</infon><infon key="pub-id_pmid">12352969</infon><infon key="section_type">REF</infon><infon key="source">Nat. Immunol.</infon><infon key="type">ref</infon><infon key="volume">3</infon><infon key="year">2002</infon><offset>56517</offset><text>BAFF-induced NEMO-independent processing of NF-kappaB2 in maturing B cells</text></passage><passage><infon key="fpage">5375</infon><infon key="lpage">5385</infon><infon key="name_0">surname:Coope;given-names:H.</infon><infon key="name_1">surname:Atkinson;given-names:P.</infon><infon key="name_2">surname:Huhse;given-names:B.</infon><infon key="name_3">surname:Belich;given-names:M.</infon><infon key="name_4">surname:Janzen;given-names:J.</infon><infon key="name_5">surname:Holman;given-names:M.</infon><infon key="name_6">surname:Klaus;given-names:G.</infon><infon key="name_7">surname:Johnston;given-names:L.</infon><infon key="name_8">surname:Ley;given-names:S.</infon><infon key="pub-id_doi">10.1093/emboj/cdf542</infon><infon key="pub-id_pmid">12374738</infon><infon key="section_type">REF</infon><infon key="source">EMBO J.</infon><infon key="type">ref</infon><infon key="volume">21</infon><infon key="year">2002</infon><offset>56592</offset><text>CD40 regulates the processing of NF-kappaB2 p100 to p52</text></passage><passage><infon key="fpage">525</infon><infon key="lpage">535</infon><infon key="name_0">surname:Dejardin;given-names:E.</infon><infon key="name_1">surname:Droin;given-names:N.M.</infon><infon key="name_2">surname:Delhase;given-names:M.</infon><infon key="name_3">surname:Haas;given-names:E.</infon><infon key="name_4">surname:Cao;given-names:Y.</infon><infon key="name_5">surname:Makris;given-names:C.</infon><infon key="name_6">surname:Li;given-names:Z.-W.</infon><infon key="name_7">surname:Karin;given-names:M.</infon><infon key="name_8">surname:Ware;given-names:C.F.</infon><infon key="name_9">surname:Green;given-names:D.R.</infon><infon key="pub-id_doi">10.1016/S1074-7613(02)00423-5</infon><infon key="pub-id_pmid">12387745</infon><infon key="section_type">REF</infon><infon key="source">Immunity</infon><infon key="type">ref</infon><infon key="volume">17</infon><infon key="year">2002</infon><offset>56648</offset><text>The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways</text></passage><passage><infon key="fpage">515</infon><infon key="lpage">524</infon><infon key="name_0">surname:Kayagaki;given-names:N.</infon><infon key="name_1">surname:Yan;given-names:M.</infon><infon key="name_2">surname:Seshasayee;given-names:D.</infon><infon key="name_3">surname:Wang;given-names:H.</infon><infon key="name_4">surname:Lee;given-names:W.</infon><infon key="name_5">surname:French;given-names:D.M.</infon><infon key="name_6">surname:Grewal;given-names:I.S.</infon><infon key="name_7">surname:Cochran;given-names:A.G.</infon><infon key="name_8">surname:Gordon;given-names:N.C.</infon><infon key="name_9">surname:Yin;given-names:J.</infon><infon key="pub-id_doi">10.1016/S1074-7613(02)00425-9</infon><infon key="pub-id_pmid">12387744</infon><infon key="section_type">REF</infon><infon key="source">Immunity</infon><infon key="type">ref</infon><infon key="volume">17</infon><infon key="year">2002</infon><offset>56751</offset><text>BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2</text></passage><passage><infon key="fpage">1495</infon><infon key="lpage">1499</infon><infon key="name_0">surname:Senftleben;given-names:U.</infon><infon key="name_1">surname:Cao;given-names:Y.</infon><infon key="name_2">surname:Xiao;given-names:G.</infon><infon key="name_3">surname:Greten;given-names:F.R.</infon><infon key="name_4">surname:Krahn;given-names:G.</infon><infon key="name_5">surname:Bonizzi;given-names:G.</infon><infon key="name_6">surname:Chen;given-names:Y.</infon><infon key="name_7">surname:Hu;given-names:Y.</infon><infon key="name_8">surname:Fong;given-names:A.</infon><infon key="name_9">surname:Sun;given-names:S.-C.J.S.</infon><infon key="pub-id_doi">10.1126/science.1062677</infon><infon key="pub-id_pmid">11520989</infon><infon key="section_type">REF</infon><infon key="source">Science</infon><infon key="type">ref</infon><infon key="volume">293</infon><infon key="year">2001</infon><offset>56887</offset><text>Activation by IKKalpha of a second, evolutionary conserved, NF-kappaB signaling pathway</text></passage><passage><infon key="fpage">401</infon><infon key="lpage">409</infon><infon key="name_0">surname:Xiao;given-names:G.</infon><infon key="name_1">surname:Harhaj;given-names:E.W.</infon><infon key="name_2">surname:Sun;given-names:S.-C.</infon><infon key="pub-id_doi">10.1016/S1097-2765(01)00187-3</infon><infon key="pub-id_pmid">11239468</infon><infon key="section_type">REF</infon><infon key="source">Mol. Cell</infon><infon key="type">ref</infon><infon key="volume">7</infon><infon key="year">2001</infon><offset>56975</offset><text>NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100</text></passage><passage><infon key="fpage">30099</infon><infon key="lpage">30105</infon><infon key="name_0">surname:Xiao;given-names:G.</infon><infon key="name_1">surname:Fong;given-names:A.</infon><infon key="name_2">surname:Sun;given-names:S.-C.</infon><infon key="pub-id_doi">10.1074/jbc.M401428200</infon><infon key="pub-id_pmid">15140882</infon><infon key="section_type">REF</infon><infon key="source">J. Biol. Chem.</infon><infon key="type">ref</infon><infon key="volume">279</infon><infon key="year">2004</infon><offset>57045</offset><text>Induction of p100 processing by NF-kappaB-inducing kinase involves docking IkappaB kinase alpha (IKKalpha) to p100 and IKKalpha-mediated phosphorylation</text></passage><passage><infon key="fpage">6805</infon><infon key="lpage">6815</infon><infon key="name_0">surname:Xiao;given-names:G.</infon><infon key="name_1">surname:Cvijic;given-names:M.E.</infon><infon key="name_2">surname:Fong;given-names:A.</infon><infon key="name_3">surname:Harhaj;given-names:E.W.</infon><infon key="name_4">surname:Uhlik;given-names:M.T.</infon><infon key="name_5">surname:Waterfield;given-names:M.</infon><infon key="name_6">surname:Sun;given-names:S.C.</infon><infon key="pub-id_doi">10.1093/emboj/20.23.6805</infon><infon key="pub-id_pmid">11726516</infon><infon key="section_type">REF</infon><infon key="source">EMBO J.</infon><infon key="type">ref</infon><infon key="volume">20</infon><infon key="year">2001</infon><offset>57198</offset><text>Retroviral oncoprotein Tax induces processing of NF-kappaB2/p100 in T cells: Evidence for the involvement of IKKalpha</text></passage><passage><infon key="fpage">3338</infon><infon key="name_0">surname:Ghosh;given-names:G.</infon><infon key="name_1">surname:Wang;given-names:V.Y.-F.</infon><infon key="pub-id_doi">10.3389/fcell.2021.764164</infon><infon key="section_type">REF</infon><infon key="source">Front. Cell Dev. Biol.</infon><infon key="type">ref</infon><infon key="volume">9</infon><infon key="year">2021</infon><offset>57316</offset><text>Origin of the functional distinctiveness of NF-kappaB/p52</text></passage><passage><infon key="fpage">5056</infon><infon key="lpage">5060</infon><infon key="name_0">surname:Miyamoto;given-names:S.</infon><infon key="name_1">surname:Schmitt;given-names:M.J.</infon><infon key="name_2">surname:Verma;given-names:I.M.</infon><infon key="pub-id_doi">10.1073/pnas.91.11.5056</infon><infon key="pub-id_pmid">8197184</infon><infon key="section_type">REF</infon><infon key="source">Proc. Natl. Acad. Sci. USA</infon><infon key="type">ref</infon><infon key="volume">91</infon><infon key="year">1994</infon><offset>57374</offset><text>Qualitative changes in the subunit composition of kappa B-binding complexes during murine B-cell differentiation</text></passage><passage><infon key="fpage">767</infon><infon key="lpage">770</infon><infon key="name_0">surname:Lernbecher;given-names:T.</infon><infon key="name_1">surname:Muller;given-names:U.</infon><infon key="name_2">surname:Wirth;given-names:T.</infon><infon key="pub-id_doi">10.1038/365767a0</infon><infon key="pub-id_pmid">7692309</infon><infon key="section_type">REF</infon><infon key="source">Nature</infon><infon key="type">ref</infon><infon key="volume">365</infon><infon key="year">1993</infon><offset>57487</offset><text>Distinct NF-kappaB/Rel transcription factors are responsible for tissue-specific and inducible gene activation</text></passage><passage><infon key="fpage">311</infon><infon key="lpage">317</infon><infon key="name_0">surname:Muller;given-names:C.W.</infon><infon key="name_1">surname:Rey;given-names:F.A.</infon><infon key="name_2">surname:Sodeoka;given-names:M.</infon><infon key="name_3">surname:Verdine;given-names:G.L.</infon><infon key="name_4">surname:Harrison;given-names:S.C.</infon><infon key="pub-id_doi">10.1038/373311a0</infon><infon key="pub-id_pmid">7830764</infon><infon key="section_type">REF</infon><infon key="source">Nature</infon><infon key="type">ref</infon><infon key="volume">373</infon><infon key="year">1995</infon><offset>57598</offset><text>Structure of the NF-kappaB p50 homodimer bound to DNA</text></passage><passage><infon key="fpage">7078</infon><infon key="lpage">7090</infon><infon key="name_0">surname:Cramer;given-names:P.</infon><infon key="name_1">surname:Larson;given-names:C.J.</infon><infon key="name_2">surname:Verdine;given-names:G.L.</infon><infon key="name_3">surname:Muller;given-names:C.W.</infon><infon key="pub-id_doi">10.1093/emboj/16.23.7078</infon><infon key="pub-id_pmid">9384586</infon><infon key="section_type">REF</infon><infon key="source">EMBO J.</infon><infon key="type">ref</infon><infon key="volume">16</infon><infon key="year">1997</infon><offset>57652</offset><text>Structure of the human NF-kappaB p52 homodimer-DNA complex at 2.1 A resolution</text></passage><passage><infon key="fpage">67</infon><infon key="lpage">73</infon><infon key="name_0">surname:Chen;given-names:Y.-Q.</infon><infon key="name_1">surname:Ghosh;given-names:S.</infon><infon key="name_2">surname:Ghosh;given-names:G.</infon><infon key="pub-id_doi">10.1038/nsb0198-67</infon><infon key="pub-id_pmid">9437432</infon><infon key="section_type">REF</infon><infon key="source">Nat. Struct. Biol.</infon><infon key="type">ref</infon><infon key="volume">5</infon><infon key="year">1998</infon><offset>57731</offset><text>A novel DNA recognition mode by the NF-kappaB p65 homodimer</text></passage><passage><infon key="fpage">1365</infon><infon key="lpage">1373</infon><infon key="name_0">surname:Huang;given-names:D.-B.</infon><infon key="name_1">surname:Vu;given-names:D.</infon><infon key="name_2">surname:Ghosh;given-names:G.</infon><infon key="pub-id_doi">10.1016/j.str.2005.06.018</infon><infon key="pub-id_pmid">16154093</infon><infon key="section_type">REF</infon><infon key="source">Structure</infon><infon key="type">ref</infon><infon key="volume">13</infon><infon key="year">2005</infon><offset>57791</offset><text>NF-kappaB RelB forms an intertwined homodimer</text></passage><passage><infon key="fpage">64</infon><infon key="lpage">73</infon><infon key="name_0">surname:Driessler;given-names:F.</infon><infon key="name_1">surname:Venstrom;given-names:K.</infon><infon key="name_2">surname:Sabat;given-names:R.</infon><infon key="name_3">surname:Asadullah;given-names:K.</infon><infon key="name_4">surname:Schottelius;given-names:A.J.C.</infon><infon key="pub-id_doi">10.1111/j.1365-2249.2004.02342.x</infon><infon key="pub-id_pmid">14678266</infon><infon key="section_type">REF</infon><infon key="source">Clin. Exp. Immunol.</infon><infon key="type">ref</infon><infon key="volume">135</infon><infon key="year">2004</infon><offset>57837</offset><text>Molecular mechanisms of interleukin-10-mediated inhibition of NF-kappa B activity: A role for p50</text></passage><passage><infon key="fpage">519</infon><infon key="lpage">527</infon><infon key="name_0">surname:Elsharkawy;given-names:A.M.</infon><infon key="name_1">surname:Oakley;given-names:F.</infon><infon key="name_2">surname:Lin;given-names:F.</infon><infon key="name_3">surname:Packham;given-names:G.</infon><infon key="name_4">surname:Mann;given-names:D.A.</infon><infon key="name_5">surname:Mann;given-names:J.</infon><infon key="pub-id_doi">10.1016/j.jhep.2010.03.025</infon><infon key="pub-id_pmid">20579762</infon><infon key="section_type">REF</infon><infon key="source">J. Hepatol.</infon><infon key="type">ref</infon><infon key="volume">53</infon><infon key="year">2010</infon><offset>57935</offset><text>The NF-kappaB p50: p50: HDAC-1 repressor complex orchestrates transcriptional inhibition of multiple pro-inflammatory genes</text></passage><passage><infon key="fpage">872</infon><infon key="lpage">882</infon><infon key="name_0">surname:Ernst;given-names:M.K.</infon><infon key="name_1">surname:Dunn;given-names:L.L.</infon><infon key="name_2">surname:Rice;given-names:N.R.</infon><infon key="pub-id_doi">10.1128/MCB.15.2.872</infon><infon key="pub-id_pmid">7823953</infon><infon key="section_type">REF</infon><infon key="source">Mol. Cell. Biol.</infon><infon key="type">ref</infon><infon key="volume">15</infon><infon key="year">1995</infon><offset>58059</offset><text>The PEST-like sequence of I kappa B alpha is responsible for inhibition of DNA binding but not for cytoplasmic retention of c-Rel or RelA homodimers</text></passage><passage><infon key="fpage">2640</infon><infon key="lpage">2649</infon><infon key="name_0">surname:Latimer;given-names:M.</infon><infon key="name_1">surname:Ernst;given-names:M.K.</infon><infon key="name_2">surname:Dunn;given-names:L.L.</infon><infon key="name_3">surname:Drutskaya;given-names:M.</infon><infon key="name_4">surname:Rice;given-names:N.R.</infon><infon key="pub-id_doi">10.1128/MCB.18.5.2640</infon><infon key="pub-id_pmid">9566883</infon><infon key="section_type">REF</infon><infon key="source">Mol. Cell. Biol.</infon><infon key="type">ref</infon><infon key="volume">18</infon><infon key="year">1998</infon><offset>58208</offset><text>The N-terminal domain of IkappaBalpha masks the nuclear localization signal (s) of p50 and c-Rel homodimers</text></passage><passage><infon key="fpage">3139</infon><infon key="lpage">3150</infon><infon key="name_0">surname:Basak;given-names:S.</infon><infon key="name_1">surname:Shih;given-names:V.F.-S.</infon><infon key="name_2">surname:Hoffmann;given-names:A.</infon><infon key="pub-id_doi">10.1128/MCB.01469-07</infon><infon key="pub-id_pmid">18299388</infon><infon key="section_type">REF</infon><infon key="source">Mol. Cell. Biol.</infon><infon key="type">ref</infon><infon key="volume">28</infon><infon key="year">2008</infon><offset>58316</offset><text>Generation and activation of multiple dimeric transcription factors within the NF-kappaB signaling system</text></passage><passage><infon key="fpage">410</infon><infon key="lpage">413</infon><infon key="name_0">surname:Chen;given-names:F.E.</infon><infon key="name_1">surname:Huang;given-names:D.-B.</infon><infon key="name_2">surname:Chen;given-names:Y.-Q.</infon><infon key="name_3">surname:Ghosh;given-names:G.</infon><infon key="pub-id_doi">10.1038/34956</infon><infon key="pub-id_pmid">9450761</infon><infon key="section_type">REF</infon><infon key="source">Nature</infon><infon key="type">ref</infon><infon key="volume">391</infon><infon key="year">1998</infon><offset>58422</offset><text>Crystal structure of p50/p65 heterodimer of transcription factor NF-kappaB bound to DNA</text></passage><passage><infon key="fpage">26243</infon><infon key="lpage">26250</infon><infon key="name_0">surname:Liao;given-names:G.</infon><infon key="name_1">surname:Zhang;given-names:M.</infon><infon key="name_2">surname:Harhaj;given-names:E.W.</infon><infon key="name_3">surname:Sun;given-names:S.-C.</infon><infon key="pub-id_doi">10.1074/jbc.M403286200</infon><infon key="pub-id_pmid">15084608</infon><infon key="section_type">REF</infon><infon key="source">J. Biol. Chem.</infon><infon key="type">ref</infon><infon key="volume">279</infon><infon key="year">2004</infon><offset>58510</offset><text>Regulation of the NF-kappaB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation</text></passage><passage><infon key="fpage">ra27</infon><infon key="name_0">surname:de Jong;given-names:S.J.</infon><infon key="name_1">surname:Albrecht;given-names:J.-C.</infon><infon key="name_2">surname:Giehler;given-names:F.</infon><infon key="name_3">surname:Kieser;given-names:A.</infon><infon key="name_4">surname:Sticht;given-names:H.</infon><infon key="name_5">surname:Biesinger;given-names:B.</infon><infon key="pub-id_doi">10.1126/scisignal.2003309</infon><infon key="pub-id_pmid">23612708</infon><infon key="section_type">REF</infon><infon key="source">Sci. Signal.</infon><infon key="type">ref</infon><infon key="volume">6</infon><infon key="year">2013</infon><offset>58628</offset><text>Noncanonical NF-kappaB activation by the oncoprotein Tio occurs through a nonconserved TRAF3-binding motif</text></passage><passage><infon key="fpage">2413</infon><infon key="lpage">2418</infon><infon key="name_0">surname:He;given-names:J.Q.</infon><infon key="name_1">surname:Zarnegar;given-names:B.</infon><infon key="name_2">surname:Oganesyan;given-names:G.</infon><infon key="name_3">surname:Saha;given-names:S.K.</infon><infon key="name_4">surname:Yamazaki;given-names:S.</infon><infon key="name_5">surname:Doyle;given-names:S.E.</infon><infon key="name_6">surname:Dempsey;given-names:P.W.</infon><infon key="name_7">surname:Cheng;given-names:G.</infon><infon key="pub-id_doi">10.1084/jem.20061166</infon><infon key="pub-id_pmid">17015635</infon><infon key="section_type">REF</infon><infon key="source">J. Exp. Med.</infon><infon key="type">ref</infon><infon key="volume">203</infon><infon key="year">2006</infon><offset>58735</offset><text>Rescue of TRAF3-null mice by p100 NF-kappaB deficiency</text></passage><passage><infon key="fpage">1371</infon><infon key="lpage">1378</infon><infon key="name_0">surname:Zarnegar;given-names:B.J.</infon><infon key="name_1">surname:Wang;given-names:Y.</infon><infon key="name_2">surname:Mahoney;given-names:D.J.</infon><infon key="name_3">surname:Dempsey;given-names:P.W.</infon><infon key="name_4">surname:Cheung;given-names:H.H.</infon><infon key="name_5">surname:He;given-names:J.</infon><infon key="name_6">surname:Shiba;given-names:T.</infon><infon key="name_7">surname:Yang;given-names:X.</infon><infon key="name_8">surname:Yeh;given-names:W.-c.</infon><infon key="name_9">surname:Mak;given-names:T.W.</infon><infon key="pub-id_doi">10.1038/ni.1676</infon><infon key="pub-id_pmid">18997794</infon><infon key="section_type">REF</infon><infon key="source">Nat. Immunol.</infon><infon key="type">ref</infon><infon key="volume">9</infon><infon key="year">2008</infon><offset>58790</offset><text>Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK</text></passage><passage><infon key="fpage">682</infon><infon key="lpage">693</infon><infon key="name_0">surname:Vince;given-names:J.E.</infon><infon key="name_1">surname:Wong;given-names:W.W.-L.</infon><infon key="name_2">surname:Khan;given-names:N.</infon><infon key="name_3">surname:Feltham;given-names:R.</infon><infon key="name_4">surname:Chau;given-names:D.</infon><infon key="name_5">surname:Ahmed;given-names:A.U.</infon><infon key="name_6">surname:Benetatos;given-names:C.A.</infon><infon key="name_7">surname:Chunduru;given-names:S.K.</infon><infon key="name_8">surname:Condon;given-names:S.M.</infon><infon key="name_9">surname:McKinlay;given-names:M.</infon><infon key="pub-id_doi">10.1016/j.cell.2007.10.037</infon><infon key="pub-id_pmid">18022363</infon><infon key="section_type">REF</infon><infon key="source">Cell</infon><infon key="type">ref</infon><infon key="volume">131</infon><infon key="year">2007</infon><offset>58943</offset><text>IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis</text></passage><passage><infon key="fpage">669</infon><infon key="lpage">681</infon><infon key="name_0">surname:Varfolomeev;given-names:E.</infon><infon key="name_1">surname:Blankenship;given-names:J.W.</infon><infon key="name_2">surname:Wayson;given-names:S.M.</infon><infon key="name_3">surname:Fedorova;given-names:A.V.</infon><infon key="name_4">surname:Kayagaki;given-names:N.</infon><infon key="name_5">surname:Garg;given-names:P.</infon><infon key="name_6">surname:Zobel;given-names:K.</infon><infon key="name_7">surname:Dynek;given-names:J.N.</infon><infon key="name_8">surname:Elliott;given-names:L.O.</infon><infon key="name_9">surname:Wallweber;given-names:H.J.</infon><infon key="pub-id_doi">10.1016/j.cell.2007.10.030</infon><infon key="pub-id_pmid">18022362</infon><infon key="section_type">REF</infon><infon key="source">Cell</infon><infon key="type">ref</infon><infon key="volume">131</infon><infon key="year">2007</infon><offset>59011</offset><text>IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis</text></passage><passage><infon key="fpage">943</infon><infon key="lpage">954</infon><infon key="name_0">surname:Brown;given-names:K.D.</infon><infon key="name_1">surname:Hostager;given-names:B.S.</infon><infon key="name_2">surname:Bishop;given-names:G.A.</infon><infon key="pub-id_doi">10.1084/jem.193.8.943</infon><infon key="pub-id_pmid">11304555</infon><infon key="section_type">REF</infon><infon key="source">J. Exp. Med.</infon><infon key="type">ref</infon><infon key="volume">193</infon><infon key="year">2001</infon><offset>59119</offset><text>Differential signaling and tumor necrosis factor receptor-associated factor (Traf) degradation mediated by Cd40 and the Epstein-Barr virus oncoprotein latent membrane protein 1 (Lmp1)</text></passage><passage><infon key="fpage">1364</infon><infon key="lpage">1370</infon><infon key="name_0">surname:Vallabhapurapu;given-names:S.</infon><infon key="name_1">surname:Matsuzawa;given-names:A.</infon><infon key="name_2">surname:Zhang;given-names:W.</infon><infon key="name_3">surname:Tseng;given-names:P.-H.</infon><infon key="name_4">surname:Keats;given-names:J.J.</infon><infon key="name_5">surname:Wang;given-names:H.</infon><infon key="name_6">surname:Vignali;given-names:D.A.</infon><infon key="name_7">surname:Bergsagel;given-names:P.L.</infon><infon key="name_8">surname:Karin;given-names:M.</infon><infon key="pub-id_doi">10.1038/ni.1678</infon><infon key="pub-id_pmid">18997792</infon><infon key="section_type">REF</infon><infon key="source">Nat. Immunol.</infon><infon key="type">ref</infon><infon key="volume">9</infon><infon key="year">2008</infon><offset>59305</offset><text>Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling</text></passage><passage><infon key="fpage">1309</infon><infon key="lpage">1317</infon><infon key="name_0">surname:Liang;given-names:C.</infon><infon key="name_1">surname:Zhang;given-names:M.</infon><infon key="name_2">surname:Sun;given-names:S.-C.</infon><infon key="pub-id_doi">10.1016/j.cellsig.2005.10.011</infon><infon key="pub-id_pmid">16303288</infon><infon key="section_type">REF</infon><infon key="source">Cell. Signal.</infon><infon key="type">ref</infon><infon key="volume">18</infon><infon key="year">2006</infon><offset>59454</offset><text>beta-TrCP binding and processing of NF-kappaB2/p100 involve its phosphorylation at serines 866 and 870</text></passage><passage><infon key="fpage">591</infon><infon key="lpage">602</infon><infon key="name_0">surname:Savinova;given-names:O.V.</infon><infon key="name_1">surname:Hoffmann;given-names:A.</infon><infon key="name_2">surname:Ghosh;given-names:G.</infon><infon key="pub-id_doi">10.1016/j.molcel.2009.04.033</infon><infon key="pub-id_pmid">19524538</infon><infon key="section_type">REF</infon><infon key="source">Mol. Cell</infon><infon key="type">ref</infon><infon key="volume">34</infon><infon key="year">2009</infon><offset>59557</offset><text>The Nfkb1 and Nfkb2 proteins p105 and p100 function as the core of high-molecular-weight heterogeneous complexes</text></passage><passage><infon key="fpage">6363</infon><infon key="lpage">6371</infon><infon key="name_0">surname:Betts;given-names:J.C.</infon><infon key="name_1">surname:Nabel;given-names:G.J.</infon><infon key="pub-id_doi">10.1128/MCB.16.11.6363</infon><infon key="pub-id_pmid">8887665</infon><infon key="section_type">REF</infon><infon key="source">Mol. Cell. Biol.</infon><infon key="type">ref</infon><infon key="volume">16</infon><infon key="year">1996</infon><offset>59670</offset><text>Differential regulation of NF-kappaB2 (p100) processing and control by amino-terminal sequences</text></passage><passage><infon key="fpage">877</infon><infon key="lpage">884</infon><infon key="name_0">surname:Biswas;given-names:S.K.</infon><infon key="name_1">surname:Lewis;given-names:C.E.</infon><infon key="pub-id_doi">10.1189/jlb.0310153</infon><infon key="pub-id_pmid">20573802</infon><infon key="section_type">REF</infon><infon key="source">J. Leukoc. Biol.</infon><infon key="type">ref</infon><infon key="volume">88</infon><infon key="year">2010</infon><offset>59766</offset><text>NF-kappaB as a central regulator of macrophage function in tumors</text></passage><passage><infon key="fpage">1161</infon><infon key="lpage">1179</infon><infon key="name_0">surname:Dejardin;given-names:E.</infon><infon key="pub-id_doi">10.1016/j.bcp.2006.08.007</infon><infon key="section_type">REF</infon><infon key="source">J Biochem. Pharmacol.</infon><infon key="type">ref</infon><infon key="volume">72</infon><infon key="year">2006</infon><offset>59832</offset><text>The alternative NF-kappaB pathway from biochemistry to biology: Pitfalls and promises for future drug development</text></passage><passage><infon key="fpage">446</infon><infon key="name_0">surname:Espinosa;given-names:L.</infon><infon key="name_1">surname:Bigas;given-names:A.</infon><infon key="name_2">surname:Mulero;given-names:M.C.</infon><infon key="pub-id_pmid">21984965</infon><infon key="section_type">REF</infon><infon key="source">Am. J. Cancer Res.</infon><infon key="type">ref</infon><infon key="volume">1</infon><infon key="year">2011</infon><offset>59946</offset><text>Alternative nuclear functions for NF-kappaB family members</text></passage><passage><infon key="fpage">203</infon><infon key="lpage">234</infon><infon key="name_0">surname:Hayden;given-names:M.S.</infon><infon key="name_1">surname:Ghosh;given-names:S.</infon><infon key="pub-id_doi">10.1101/gad.183434.111</infon><infon key="section_type">REF</infon><infon key="source">Genes</infon><infon key="type">ref</infon><infon key="volume">26</infon><infon key="year">2012</infon><offset>60005</offset><text>NF-kappaB, the first quarter-century: Remarkable progress and outstanding questions</text></passage><passage><infon key="fpage">1</infon><infon key="lpage">15</infon><infon key="name_0">surname:Hoesel;given-names:B.</infon><infon key="name_1">surname:Schmid;given-names:J.A.</infon><infon key="pub-id_doi">10.1186/1476-4598-12-86</infon><infon key="pub-id_pmid">23915189</infon><infon key="section_type">REF</infon><infon key="source">Mol. Cancer Res.</infon><infon key="type">ref</infon><infon key="volume">12</infon><infon key="year">2013</infon><offset>60089</offset><text>The complexity of NF-kappaB signaling in inflammation and cancer</text></passage><passage><infon key="fpage">a000034</infon><infon key="name_0">surname:Oeckinghaus;given-names:A.</infon><infon key="name_1">surname:Ghosh;given-names:S.</infon><infon key="pub-id_doi">10.1101/cshperspect.a000034</infon><infon key="pub-id_pmid">20066092</infon><infon key="section_type">REF</infon><infon key="source">Cold Spring Harb. Perspect. Biol.</infon><infon key="type">ref</infon><infon key="volume">1</infon><infon key="year">2009</infon><offset>60154</offset><text>The NF-kappaB family of transcription factors and its regulation</text></passage><passage><infon key="fpage">71</infon><infon key="lpage">85</infon><infon key="name_0">surname:Sun;given-names:S.-C.</infon><infon key="pub-id_doi">10.1038/cr.2010.177</infon><infon key="pub-id_pmid">21173796</infon><infon key="section_type">REF</infon><infon key="source">Cell Res.</infon><infon key="type">ref</infon><infon key="volume">21</infon><infon key="year">2011</infon><offset>60219</offset><text>Non-canonical NF-kappaB signaling pathway</text></passage><passage><infon key="fpage">131</infon><infon key="lpage">144</infon><infon key="name_0">surname:Keats;given-names:J.J.</infon><infon key="name_1">surname:Fonseca;given-names:R.</infon><infon key="name_2">surname:Chesi;given-names:M.</infon><infon key="name_3">surname:Schop;given-names:R.</infon><infon key="name_4">surname:Baker;given-names:A.</infon><infon key="name_5">surname:Chng;given-names:W.-J.</infon><infon key="name_6">surname:Van Wier;given-names:S.</infon><infon key="name_7">surname:Tiedemann;given-names:R.</infon><infon key="name_8">surname:Shi;given-names:C.-X.</infon><infon key="name_9">surname:Sebag;given-names:M.</infon><infon key="pub-id_doi">10.1016/j.ccr.2007.07.003</infon><infon key="pub-id_pmid">17692805</infon><infon key="section_type">REF</infon><infon key="source">Cancer Cell</infon><infon key="type">ref</infon><infon key="volume">12</infon><infon key="year">2007</infon><offset>60261</offset><text>Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma</text></passage><passage><infon key="fpage">1756</infon><infon key="lpage">1769</infon><infon key="name_0">surname:Yilmaz;given-names:Z.B.</infon><infon key="name_1">surname:Kofahl;given-names:B.</infon><infon key="name_2">surname:Beaudette;given-names:P.</infon><infon key="name_3">surname:Baum;given-names:K.</infon><infon key="name_4">surname:Ipenberg;given-names:I.</infon><infon key="name_5">surname:Weih;given-names:F.</infon><infon key="name_6">surname:Wolf;given-names:J.</infon><infon key="name_7">surname:Dittmar;given-names:G.</infon><infon key="name_8">surname:Scheidereit;given-names:C.</infon><infon key="pub-id_doi">10.1016/j.celrep.2014.11.014</infon><infon key="pub-id_pmid">25482563</infon><infon key="section_type">REF</infon><infon key="source">Cell Rep.</infon><infon key="type">ref</infon><infon key="volume">9</infon><infon key="year">2014</infon><offset>60347</offset><text>Quantitative dissection and modeling of the NF-kappaB p100-p105 module reveals interdependent precursor proteolysis</text></passage><passage><infon key="fpage">115</infon><infon key="lpage">130</infon><infon key="name_0">surname:Annunziata;given-names:C.M.</infon><infon key="name_1">surname:Davis;given-names:R.E.</infon><infon key="name_2">surname:Demchenko;given-names:Y.</infon><infon key="name_3">surname:Bellamy;given-names:W.</infon><infon key="name_4">surname:Gabrea;given-names:A.</infon><infon key="name_5">surname:Zhan;given-names:F.</infon><infon key="name_6">surname:Lenz;given-names:G.</infon><infon key="name_7">surname:Hanamura;given-names:I.</infon><infon key="name_8">surname:Wright;given-names:G.</infon><infon key="name_9">surname:Xiao;given-names:W.</infon><infon key="pub-id_doi">10.1016/j.ccr.2007.07.004</infon><infon key="pub-id_pmid">17692804</infon><infon key="section_type">REF</infon><infon key="source">Cancer Cell</infon><infon key="type">ref</infon><infon key="volume">12</infon><infon key="year">2007</infon><offset>60463</offset><text>Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma</text></passage><passage><infon key="fpage">467</infon><infon key="lpage">472</infon><infon key="name_0">surname:Chapman;given-names:M.A.</infon><infon key="name_1">surname:Lawrence;given-names:M.S.</infon><infon key="name_2">surname:Keats;given-names:J.J.</infon><infon key="name_3">surname:Cibulskis;given-names:K.</infon><infon key="name_4">surname:Sougnez;given-names:C.</infon><infon key="name_5">surname:Schinzel;given-names:A.C.</infon><infon key="name_6">surname:Harview;given-names:C.L.</infon><infon key="name_7">surname:Brunet;given-names:J.-P.</infon><infon key="name_8">surname:Ahmann;given-names:G.J.</infon><infon key="name_9">surname:Adli;given-names:M.</infon><infon key="pub-id_doi">10.1038/nature09837</infon><infon key="pub-id_pmid">21430775</infon><infon key="section_type">REF</infon><infon key="source">Nature</infon><infon key="type">ref</infon><infon key="volume">471</infon><infon key="year">2011</infon><offset>60588</offset><text>Initial genome sequencing and analysis of multiple myeloma</text></passage><passage><infon key="fpage">715</infon><infon key="lpage">726</infon><infon key="name_0">surname:Zhang;given-names:B.</infon><infon key="name_1">surname:Calado;given-names:D.P.</infon><infon key="name_2">surname:Wang;given-names:Z.</infon><infon key="name_3">surname:Frohler;given-names:S.</infon><infon key="name_4">surname:Kochert;given-names:K.</infon><infon key="name_5">surname:Qian;given-names:Y.</infon><infon key="name_6">surname:Koralov;given-names:S.B.</infon><infon key="name_7">surname:Schmidt-Supprian;given-names:M.</infon><infon key="name_8">surname:Sasaki;given-names:Y.</infon><infon key="name_9">surname:Unitt;given-names:C.</infon><infon key="pub-id_doi">10.1016/j.celrep.2015.03.059</infon><infon key="pub-id_pmid">25921526</infon><infon key="section_type">REF</infon><infon key="source">Cell Rep.</infon><infon key="type">ref</infon><infon key="volume">11</infon><infon key="year">2015</infon><offset>60647</offset><text>An oncogenic role for alternative NF-kappaB signaling in DLBCL revealed upon deregulated BCL6 expression</text></passage><passage><infon key="fpage">666</infon><infon key="lpage">689</infon><infon key="name_0">surname:SHELDON;given-names:W.H.</infon><infon key="name_1">surname:JAMES;given-names:D.F.</infon><infon key="pub-id_doi">10.1001/archinte.1948.00220230064006</infon><infon key="section_type">REF</infon><infon key="source">Arch. Intern. Med.</infon><infon key="type">ref</infon><infon key="volume">81</infon><infon key="year">1948</infon><offset>60752</offset><text>Cirrhosis following infectious hepatitis: A report of five cases, in two of which there was superimposed primary liver cell carcinoma</text></passage><passage><infon key="fpage">1007</infon><infon key="lpage">1010</infon><infon key="name_0">surname:Walshe;given-names:J.</infon><infon key="name_1">surname:Wolff;given-names:H.</infon><infon key="pub-id_doi">10.1016/S0140-6736(52)91183-5</infon><infon key="pub-id_pmid">12991683</infon><infon key="section_type">REF</infon><infon key="source">Lancet</infon><infon key="type">ref</infon><infon key="volume">2</infon><infon key="year">1952</infon><offset>60886</offset><text>Primary Carcinoma of the Liver following Viral Hepatitis. Report of Two Cases</text></passage><passage><infon key="fpage">523</infon><infon key="name_0">surname:Steiner;given-names:P.</infon><infon key="name_1">surname:Davies;given-names:J.</infon><infon key="pub-id_doi">10.1038/bjc.1957.64</infon><infon key="pub-id_pmid">13510509</infon><infon key="section_type">REF</infon><infon key="source">Br. J. Cancer</infon><infon key="type">ref</infon><infon key="volume">11</infon><infon key="year">1957</infon><offset>60964</offset><text>Cirrhosis and primary liver carcinoma in Uganda Africans</text></passage><passage><infon key="fpage">1624</infon><infon key="lpage">1633</infon><infon key="name_0">surname:Higginson;given-names:J.</infon><infon key="pub-id_pmid">14098901</infon><infon key="section_type">REF</infon><infon key="source">Cancer Res.</infon><infon key="type">ref</infon><infon key="volume">23</infon><infon key="year">1963</infon><offset>61021</offset><text>The geographical pathology of primary liver cancer</text></passage><passage><infon key="fpage">387</infon><infon key="lpage">400</infon><infon key="name_0">surname:Pisani;given-names:P.</infon><infon key="name_1">surname:Parkin;given-names:D.M.</infon><infon key="name_2">surname:Munoz;given-names:N.</infon><infon key="name_3">surname:Ferlay;given-names:J.J.C.E.</infon><infon key="section_type">REF</infon><infon key="source">Cancer Epidemiol. Prev. Biomark.</infon><infon key="type">ref</infon><infon key="volume">6</infon><infon key="year">1997</infon><offset>61072</offset><text>Cancer and infection: Estimates of the attributable fraction in 1990</text></passage><passage><infon key="fpage">61</infon><infon key="lpage">74</infon><infon key="name_0">surname:Kuper;given-names:H.</infon><infon key="name_1">surname:Adami;given-names:H.O.</infon><infon key="name_2">surname:Trichopoulos;given-names:D.</infon><infon key="pub-id_doi">10.1046/j.1365-2796.2001.00742.x</infon><infon key="section_type">REF</infon><infon key="source">J. Intern. Med.</infon><infon key="type">ref</infon><infon key="volume">249</infon><infon key="year">2001</infon><offset>61141</offset><text>Infections as a major preventable cause of human cancer</text></passage><passage><infon key="fpage">695</infon><infon key="lpage">711</infon><infon key="name_0">surname:Gilmore;given-names:T.D.</infon><infon key="name_1">surname:Gerondakis;given-names:S.</infon><infon key="pub-id_doi">10.1177/1947601911421925</infon><infon key="section_type">REF</infon><infon key="source">Genes Cancer Cell</infon><infon key="type">ref</infon><infon key="volume">2</infon><infon key="year">2011</infon><offset>61197</offset><text>The c-Rel transcription factor in development and disease</text></passage><passage><infon key="fpage">241</infon><infon key="lpage">265</infon><infon key="name_0">surname:Gilmore;given-names:T.D.</infon><infon key="pub-id_doi">10.1007/0-306-48158-8_10</infon><infon key="section_type">REF</infon><infon key="source">Signal Transduction Cancer</infon><infon key="type">ref</infon><infon key="year">2004</infon><offset>61255</offset><text>The Rel/NF-kappaB/IkappaB signal transduction pathway and cancer</text></passage><passage><infon key="fpage">3032</infon><infon key="lpage">3039</infon><infon key="name_0">surname:Shattuck-Brandt;given-names:R.L.</infon><infon key="name_1">surname:Richmond;given-names:A.</infon><infon key="pub-id_pmid">9230219</infon><infon key="section_type">REF</infon><infon key="source">Cancer Res.</infon><infon key="type">ref</infon><infon key="volume">57</infon><infon key="year">1997</infon><offset>61320</offset><text>Enhanced degradation of I-kappaBalpha contributes to endogenous activation of NF-kappaB in Hs294T melanoma cells</text></passage><passage><infon key="fpage">106</infon><infon key="lpage">115</infon><infon key="name_0">surname:Charalambous;given-names:M.</infon><infon key="name_1">surname:Lightfoot;given-names:T.</infon><infon key="name_2">surname:Speirs;given-names:V.</infon><infon key="name_3">surname:Horgan;given-names:K.</infon><infon key="name_4">surname:Gooderham;given-names:N.</infon><infon key="pub-id_doi">10.1038/sj.bjc.6605120</infon><infon key="pub-id_pmid">19513071</infon><infon key="section_type">REF</infon><infon key="source">Br. J. Cancer</infon><infon key="type">ref</infon><infon key="volume">101</infon><infon key="year">2009</infon><offset>61433</offset><text>Expression of COX-2, NF-kappaB-p65, NF-kappaB-p50 and IKKalpha in malignant and adjacent normal human colorectal tissue</text></passage><passage><infon key="fpage">1123</infon><infon key="lpage">1131</infon><infon key="name_0">surname:Cogswell;given-names:P.C.</infon><infon key="name_1">surname:Guttridge;given-names:D.C.</infon><infon key="name_2">surname:Funkhouser;given-names:W.K.</infon><infon key="name_3">surname:Baldwin;given-names:A.S.</infon><infon key="pub-id_doi">10.1038/sj.onc.1203412</infon><infon key="pub-id_pmid">10713699</infon><infon key="section_type">REF</infon><infon key="source">Oncogene</infon><infon key="type">ref</infon><infon key="volume">19</infon><infon key="year">2000</infon><offset>61553</offset><text>Selective activation of NF-kappaB subunits in human breast cancer: Potential roles for NF-kappaB2/p52 and for Bcl-3</text></passage><passage><infon key="fpage">1297</infon><infon key="lpage">1305</infon><infon key="name_0">surname:Kendellen;given-names:M.F.</infon><infon key="name_1">surname:Bradford;given-names:J.W.</infon><infon key="name_2">surname:Lawrence;given-names:C.L.</infon><infon key="name_3">surname:Clark;given-names:K.S.</infon><infon key="name_4">surname:Baldwin;given-names:A.S.</infon><infon key="pub-id_doi">10.1038/onc.2013.64</infon><infon key="pub-id_pmid">23474754</infon><infon key="section_type">REF</infon><infon key="source">Oncogene</infon><infon key="type">ref</infon><infon key="volume">33</infon><infon key="year">2014</infon><offset>61669</offset><text>Canonical and non-canonical NF-kappaB signaling promotes breast cancer tumor-initiating cells</text></passage><passage><infon key="fpage">225</infon><infon key="lpage">231</infon><infon key="name_0">surname:Poma;given-names:P.</infon><infon key="name_1">surname:Labbozzetta;given-names:M.</infon><infon key="name_2">surname:D'Alessandro;given-names:N.</infon><infon key="name_3">surname:Notarbartolo;given-names:M.</infon><infon key="pub-id_doi">10.1089/omi.2017.0020</infon><infon key="section_type">REF</infon><infon key="source">Omics: A J. Integr. Biol.</infon><infon key="type">ref</infon><infon key="volume">21</infon><infon key="year">2017</infon><offset>61763</offset><text>NF-kappaB is a potential molecular drug target in triple-negative breast cancers</text></passage><passage><infon key="fpage">10568</infon><infon key="name_0">surname:Devanaboyina;given-names:M.</infon><infon key="name_1">surname:Kaur;given-names:J.</infon><infon key="name_2">surname:Whiteley;given-names:E.</infon><infon key="name_3">surname:Lin;given-names:L.</infon><infon key="name_4">surname:Einloth;given-names:K.</infon><infon key="name_5">surname:Morand;given-names:S.</infon><infon key="name_6">surname:Stanbery;given-names:L.</infon><infon key="name_7">surname:Hamouda;given-names:D.</infon><infon key="name_8">surname:Nemunaitis;given-names:J.</infon><infon key="pub-id_doi">10.3389/or.2022.10568</infon><infon key="pub-id_pmid">36531159</infon><infon key="section_type">REF</infon><infon key="source">Oncol. Rev.</infon><infon key="type">ref</infon><infon key="volume">16</infon><infon key="year">2022</infon><offset>61844</offset><text>NF-kappaB Signaling in Tumor Pathways Focusing on Breast and Ovarian Cancer</text></passage><passage><infon key="fpage">263</infon><infon key="lpage">270</infon><infon key="name_0">surname:Saitoh;given-names:Y.</infon><infon key="name_1">surname:Bruyn;given-names:V.J.M.</infon><infon key="name_2">surname:Uota;given-names:S.</infon><infon key="name_3">surname:Hasegawa;given-names:A.</infon><infon key="name_4">surname:Yamamoto;given-names:N.</infon><infon key="name_5">surname:Imoto;given-names:I.</infon><infon key="name_6">surname:Inazawa;given-names:J.</infon><infon key="name_7">surname:Yamaoka;given-names:S.</infon><infon key="pub-id_doi">10.1016/j.lungcan.2010.03.001</infon><infon key="pub-id_pmid">20338663</infon><infon key="section_type">REF</infon><infon key="source">Lung Cancer</infon><infon key="type">ref</infon><infon key="volume">70</infon><infon key="year">2010</infon><offset>61920</offset><text>Overexpression of NF-kappaB inducing kinase underlies constitutive NF-kappaB activation in lung cancer cells</text></passage><passage><infon key="fpage">2563</infon><infon key="lpage">2574</infon><infon key="name_0">surname:Yang;given-names:J.</infon><infon key="name_1">surname:Splittgerber;given-names:R.</infon><infon key="name_2">surname:Yull;given-names:F.E.</infon><infon key="name_3">surname:Kantrow;given-names:S.</infon><infon key="name_4">surname:Ayers;given-names:G.D.</infon><infon key="name_5">surname:Karin;given-names:M.</infon><infon key="name_6">surname:Richmond;given-names:A.</infon><infon key="pub-id_doi">10.1172/JCI42358</infon><infon key="pub-id_pmid">20530876</infon><infon key="section_type">REF</infon><infon key="source">J. Clin. Investig.</infon><infon key="type">ref</infon><infon key="volume">120</infon><infon key="year">2010</infon><offset>62029</offset><text>Conditional ablation of Ikkb inhibits melanoma tumor development in mice</text></passage><passage><infon key="fpage">1861</infon><infon key="lpage">1874</infon><infon key="name_0">surname:Davis;given-names:R.E.</infon><infon key="name_1">surname:Brown;given-names:K.D.</infon><infon key="name_2">surname:Siebenlist;given-names:U.</infon><infon key="name_3">surname:Staudt;given-names:L.M.</infon><infon key="pub-id_doi">10.1084/jem.194.12.1861</infon><infon key="pub-id_pmid">11748286</infon><infon key="section_type">REF</infon><infon key="source">J. Exp. Med.</infon><infon key="type">ref</infon><infon key="volume">194</infon><infon key="year">2001</infon><offset>62102</offset><text>Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells</text></passage><passage><infon key="fpage">384</infon><infon key="lpage">398</infon><infon key="name_0">surname:Eluard;given-names:B.</infon><infon key="name_1">surname:Nuan-Aliman;given-names:S.</infon><infon key="name_2">surname:Faumont;given-names:N.</infon><infon key="name_3">surname:Collares;given-names:D.</infon><infon key="name_4">surname:Bordereaux;given-names:D.</infon><infon key="name_5">surname:Montagne;given-names:A.</infon><infon key="name_6">surname:Martins;given-names:I.</infon><infon key="name_7">surname:Cagnard;given-names:N.</infon><infon key="name_8">surname:Caly;given-names:M.</infon><infon key="name_9">surname:Taoui;given-names:O.</infon><infon key="pub-id_doi">10.1182/blood.2020010039</infon><infon key="pub-id_pmid">34232979</infon><infon key="section_type">REF</infon><infon key="source">Blood J. Am. Soc. Hematol.</infon><infon key="type">ref</infon><infon key="volume">139</infon><infon key="year">2022</infon><offset>62232</offset><text>The alternative RelB NF-kappaB subunit is a novel critical player in diffuse large B-cell lymphoma</text></passage><passage><infon key="fpage">675</infon><infon key="lpage">682</infon><infon key="name_0">surname:Kojima;given-names:M.</infon><infon key="name_1">surname:Morisaki;given-names:T.</infon><infon key="name_2">surname:Sasaki;given-names:N.</infon><infon key="name_3">surname:Nakano;given-names:K.</infon><infon key="name_4">surname:Mibu;given-names:R.</infon><infon key="name_5">surname:Tanaka;given-names:M.</infon><infon key="name_6">surname:Katano;given-names:M.</infon><infon key="pub-id_pmid">15161011</infon><infon key="section_type">REF</infon><infon key="source">Anticancer Res.</infon><infon key="type">ref</infon><infon key="volume">24</infon><infon key="year">2004</infon><offset>62331</offset><text>Increased nuclear factor-kB activation in human colorectal carcinoma and its correlation with tumor progression</text></passage><passage><infon key="fpage">238</infon><infon key="name_0">surname:Li;given-names:W.</infon><infon key="name_1">surname:Tan;given-names:D.</infon><infon key="name_2">surname:Zenali;given-names:M.J.</infon><infon key="name_3">surname:Brown;given-names:R.E.</infon><infon key="section_type">REF</infon><infon key="source">Int. J. Clin. Exp. Pathol.</infon><infon key="type">ref</infon><infon key="volume">3</infon><infon key="year">2010</infon><offset>62443</offset><text>Constitutive activation of nuclear factor-kappa B (NF-kB) signaling pathway in fibrolamellar hepatocellular carcinoma</text></passage><passage><infon key="elocation-id">e57489</infon><infon key="name_0">surname:Lee;given-names:D.W.</infon><infon key="name_1">surname:Ramakrishnan;given-names:D.</infon><infon key="name_2">surname:Valenta;given-names:J.</infon><infon key="name_3">surname:Parney;given-names:I.F.</infon><infon key="name_4">surname:Bayless;given-names:K.J.</infon><infon key="name_5">surname:Sitcheran;given-names:R.</infon><infon key="pub-id_doi">10.1371/journal.pone.0057489</infon><infon key="pub-id_pmid">23451236</infon><infon key="section_type">REF</infon><infon key="source">PLoS ONE</infon><infon key="type">ref</infon><infon key="volume">8</infon><infon key="year">2013</infon><offset>62561</offset><text>The NF-kappaB RelB protein is an oncogenic driver of mesenchymal glioma</text></passage><passage><infon key="fpage">386</infon><infon key="lpage">394</infon><infon key="name_0">surname:Zeng;given-names:F.</infon><infon key="name_1">surname:Wang;given-names:K.</infon><infon key="name_2">surname:Huang;given-names:R.</infon><infon key="name_3">surname:Liu;given-names:Y.</infon><infon key="name_4">surname:Zhang;given-names:Y.</infon><infon key="name_5">surname:Hu;given-names:H.</infon><infon key="pub-id_doi">10.3892/ol.2019.10296</infon><infon key="pub-id_pmid">31289510</infon><infon key="section_type">REF</infon><infon key="source">Oncol. Lett.</infon><infon key="type">ref</infon><infon key="volume">18</infon><infon key="year">2019</infon><offset>62633</offset><text>RELB: A novel prognostic marker for glioblastoma as identified by population-based analysis</text></passage><passage><infon key="elocation-id">e59127</infon><infon key="name_0">surname:Cormier;given-names:F.</infon><infon key="name_1">surname:Monjanel;given-names:H.</infon><infon key="name_2">surname:Fabre;given-names:C.</infon><infon key="name_3">surname:Billot;given-names:K.</infon><infon key="name_4">surname:Sapharikas;given-names:E.</infon><infon key="name_5">surname:Chereau;given-names:F.</infon><infon key="name_6">surname:Bordereaux;given-names:D.</infon><infon key="name_7">surname:Molina;given-names:T.J.</infon><infon key="name_8">surname:Avet-Loiseau;given-names:H.</infon><infon key="name_9">surname:Baud;given-names:V.</infon><infon key="pub-id_doi">10.1371/journal.pone.0059127</infon><infon key="pub-id_pmid">23555623</infon><infon key="section_type">REF</infon><infon key="source">PLoS ONE</infon><infon key="type">ref</infon><infon key="volume">8</infon><infon key="year">2013</infon><offset>62725</offset><text>Frequent engagement of RelB activation is critical for cell survival in multiple myeloma</text></passage><passage><infon key="fpage">3541</infon><infon key="lpage">3552</infon><infon key="name_0">surname:Demchenko;given-names:Y.N.</infon><infon key="name_1">surname:Glebov;given-names:O.K.</infon><infon key="name_2">surname:Zingone;given-names:A.</infon><infon key="name_3">surname:Keats;given-names:J.J.</infon><infon key="name_4">surname:Bergsagel;given-names:P.L.</infon><infon key="name_5">surname:Kuehl;given-names:W.M.</infon><infon key="pub-id_doi">10.1182/blood-2009-09-243535</infon><infon key="pub-id_pmid">20053756</infon><infon key="section_type">REF</infon><infon key="source">Blood J. Am. Soc. Hematol.</infon><infon key="type">ref</infon><infon key="volume">115</infon><infon key="year">2010</infon><offset>62814</offset><text>Classical and/or alternative NF-kappaB pathway activation in multiple myeloma</text></passage><passage><infon key="fpage">1571</infon><infon key="lpage">1578</infon><infon key="name_0">surname:Joos;given-names:S.</infon><infon key="name_1">surname:Otano-Joos;given-names:M.I.</infon><infon key="name_2">surname:Ziegler;given-names:S.</infon><infon key="name_3">surname:Bruderlein;given-names:S.</infon><infon key="name_4">surname:Du Manoir;given-names:S.</infon><infon key="name_5">surname:Bentz;given-names:M.</infon><infon key="name_6">surname:Moller;given-names:P.</infon><infon key="name_7">surname:Lichter;given-names:P.</infon><infon key="pub-id_doi">10.1182/blood.V87.4.1571.bloodjournal8741571</infon><infon key="pub-id_pmid">8608249</infon><infon key="section_type">REF</infon><infon key="source">Blood</infon><infon key="type">ref</infon><infon key="volume">87</infon><infon key="year">1996</infon><offset>62892</offset><text>Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene</text></passage><passage><infon key="fpage">3681</infon><infon key="lpage">3686</infon><infon key="name_0">surname:Barth;given-names:T.F.</infon><infon key="name_1">surname:Martin-Subero;given-names:J.I.</infon><infon key="name_2">surname:Joos;given-names:S.</infon><infon key="name_3">surname:Menz;given-names:C.K.</infon><infon key="name_4">surname:Hasel;given-names:C.</infon><infon key="name_5">surname:Mechtersheimer;given-names:G.</infon><infon key="name_6">surname:Parwaresch;given-names:R.M.</infon><infon key="name_7">surname:Lichter;given-names:P.</infon><infon key="name_8">surname:Siebert;given-names:R.</infon><infon key="name_9">surname:Moller;given-names:P.</infon><infon key="pub-id_doi">10.1182/blood-2002-08-2577</infon><infon key="section_type">REF</infon><infon key="source">Blood J. Am. Soc. Hematol.</infon><infon key="type">ref</infon><infon key="volume">101</infon><infon key="year">2003</infon><offset>63034</offset><text>Gains of 2p involving the REL locus correlate with nuclear c-Rel protein accumulation in neoplastic cells of classical Hodgkin lymphoma</text></passage><passage><infon key="fpage">1937</infon><infon key="lpage">1947</infon><infon key="name_0">surname:Rosenwald;given-names:A.</infon><infon key="name_1">surname:Wright;given-names:G.</infon><infon key="name_2">surname:Chan;given-names:W.C.</infon><infon key="name_3">surname:Connors;given-names:J.M.</infon><infon key="name_4">surname:Campo;given-names:E.</infon><infon key="name_5">surname:Fisher;given-names:R.I.</infon><infon key="name_6">surname:Gascoyne;given-names:R.D.</infon><infon key="name_7">surname:Muller-Hermelink;given-names:H.K.</infon><infon key="name_8">surname:Smeland;given-names:E.B.</infon><infon key="name_9">surname:Giltnane;given-names:J.M.</infon><infon key="pub-id_doi">10.1056/NEJMoa012914</infon><infon key="pub-id_pmid">12075054</infon><infon key="section_type">REF</infon><infon key="source">N. Engl. J. Med.</infon><infon key="type">ref</infon><infon key="volume">346</infon><infon key="year">2002</infon><offset>63170</offset><text>The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma</text></passage><passage><infon key="fpage">v2</infon><infon key="name_0">surname:Cherry;given-names:E.</infon><infon key="name_1">surname:Lee;given-names:D.</infon><infon key="name_2">surname:Jung;given-names:J.</infon><infon key="name_3">surname:Sitcheran;given-names:R.</infon><infon key="pub-id_doi">10.1093/neuonc/nou238.6</infon><infon key="section_type">REF</infon><infon key="source">Neuro-Oncol.</infon><infon key="type">ref</infon><infon key="volume">16</infon><infon key="year">2014</infon><offset>63274</offset><text>AI-06NON-CANONICAL NF-kB SIGNALING DRIVES THE AGGRESSIVE INVASIVENESS OF GLIOBLASTOMA</text></passage><passage><infon key="fpage">145</infon><infon key="lpage">149</infon><infon key="name_0">surname:Bours;given-names:V.</infon><infon key="name_1">surname:Dejardin;given-names:E.</infon><infon key="name_2">surname:Goujon-Letawe;given-names:F.</infon><infon key="name_3">surname:Merville;given-names:M.-P.</infon><infon key="name_4">surname:Castronovo;given-names:V.</infon><infon key="pub-id_doi">10.1016/0006-2952(94)90448-0</infon><infon key="pub-id_pmid">8311838</infon><infon key="section_type">REF</infon><infon key="source">Biochem. Pharmacol.</infon><infon key="type">ref</infon><infon key="volume">47</infon><infon key="year">1994</infon><offset>63360</offset><text>The NF-kappaB transcription factor and cancer: High expression of NF-kappaB-and IkappaB-related proteins in tumor cell lines</text></passage><passage><infon key="fpage">729</infon><infon key="lpage">739</infon><infon key="name_0">surname:Bours;given-names:V.</infon><infon key="name_1">surname:Franzoso;given-names:G.</infon><infon key="name_2">surname:Azarenko;given-names:V.</infon><infon key="name_3">surname:Park;given-names:S.</infon><infon key="name_4">surname:Kanno;given-names:T.</infon><infon key="name_5">surname:Brown;given-names:K.</infon><infon key="name_6">surname:Siebenlist;given-names:U.</infon><infon key="pub-id_doi">10.1016/0092-8674(93)90401-B</infon><infon key="pub-id_pmid">8453667</infon><infon key="section_type">REF</infon><infon key="source">Cell</infon><infon key="type">ref</infon><infon key="volume">72</infon><infon key="year">1993</infon><offset>63485</offset><text>The oncoprotein Bcl-3 directly transactivates through kappaB motifs via association with DNA-binding p50B homodimers</text></passage><passage><infon key="fpage">943</infon><infon key="lpage">953</infon><infon key="name_0">surname:Krappmann;given-names:D.</infon><infon key="name_1">surname:Emmerich;given-names:F.</infon><infon key="name_2">surname:Kordes;given-names:U.</infon><infon key="name_3">surname:Scharschmidt;given-names:E.</infon><infon key="name_4">surname:Dorken;given-names:B.</infon><infon key="name_5">surname:Scheidereit;given-names:C.</infon><infon key="pub-id_doi">10.1038/sj.onc.1202351</infon><infon key="pub-id_pmid">10023670</infon><infon key="section_type">REF</infon><infon key="source">Oncogene</infon><infon key="type">ref</infon><infon key="volume">18</infon><infon key="year">1999</infon><offset>63602</offset><text>Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/Reed-Sternberg cells</text></passage><passage><infon key="fpage">2537</infon><infon key="lpage">2542</infon><infon key="name_0">surname:Keller;given-names:S.A.</infon><infon key="name_1">surname:Schattner;given-names:E.J.</infon><infon key="name_2">surname:Cesarman;given-names:E.</infon><infon key="section_type">REF</infon><infon key="source">Blood J. Am. Soc. Hematol.</infon><infon key="type">ref</infon><infon key="volume">96</infon><infon key="year">2000</infon><offset>63696</offset><text>Inhibition of NF-kappaB induces apoptosis of KSHV-infected primary effusion lymphoma cells</text></passage><passage><infon key="fpage">1652</infon><infon key="lpage">1655</infon><infon key="name_0">surname:Ballard;given-names:D.W.</infon><infon key="name_1">surname:Bohnlein;given-names:E.</infon><infon key="name_2">surname:Lowenthal;given-names:J.W.</infon><infon key="name_3">surname:Wano;given-names:Y.</infon><infon key="name_4">surname:Franza;given-names:B.R.</infon><infon key="name_5">surname:Greene;given-names:W.C.</infon><infon key="pub-id_doi">10.1126/science.2843985</infon><infon key="pub-id_pmid">2843985</infon><infon key="section_type">REF</infon><infon key="source">Science</infon><infon key="type">ref</infon><infon key="volume">241</infon><infon key="year">1988</infon><offset>63787</offset><text>HTLV-I tax induces cellular proteins that activate the kappaB element in the IL-2 receptor alpha gene</text></passage><passage><infon key="elocation-id">655</infon><infon key="name_0">surname:Kaltschmidt;given-names:C.</infon><infon key="name_1">surname:Banz-Jansen;given-names:C.</infon><infon key="name_2">surname:Benhidjeb;given-names:T.</infon><infon key="name_3">surname:Beshay;given-names:M.</infon><infon key="name_4">surname:Forster;given-names:C.</infon><infon key="name_5">surname:Greiner;given-names:J.</infon><infon key="name_6">surname:Hamelmann;given-names:E.</infon><infon key="name_7">surname:Jorch;given-names:N.</infon><infon key="name_8">surname:Mertzlufft;given-names:F.</infon><infon key="name_9">surname:Pfitzenmaier;given-names:J.</infon><infon key="pub-id_doi">10.3390/cancers11050655</infon><infon key="pub-id_pmid">31083587</infon><infon key="section_type">REF</infon><infon key="source">Cancers</infon><infon key="type">ref</infon><infon key="volume">11</infon><infon key="year">2019</infon><offset>63889</offset><text>A role for NF-kappaB in organ specific cancer and cancer stem cells</text></passage><passage><infon key="fpage">a006676</infon><infon key="name_0">surname:Watnick;given-names:R.S.</infon><infon key="pub-id_doi">10.1101/cshperspect.a006676</infon><infon key="pub-id_pmid">23209177</infon><infon key="section_type">REF</infon><infon key="source">Cold Spring Harb. Perspect. Med.</infon><infon key="type">ref</infon><infon key="volume">2</infon><infon key="year">2012</infon><offset>63957</offset><text>The role of the tumor microenvironment in regulating angiogenesis</text></passage><passage><infon key="fpage">651</infon><infon key="name_0">surname:Zamarron;given-names:B.F.</infon><infon key="name_1">surname:Chen;given-names:W.</infon><infon key="pub-id_doi">10.7150/ijbs.7.651</infon><infon key="pub-id_pmid">21647333</infon><infon key="section_type">REF</infon><infon key="source">Int. J. Biol. Sci.</infon><infon key="type">ref</infon><infon key="volume">7</infon><infon key="year">2011</infon><offset>64023</offset><text>Dual roles of immune cells and their factors in cancer development and progression</text></passage><passage><infon key="fpage">5728</infon><infon key="lpage">5739</infon><infon key="name_0">surname:Movahedi;given-names:K.</infon><infon key="name_1">surname:Laoui;given-names:D.</infon><infon key="name_2">surname:Gysemans;given-names:C.</infon><infon key="name_3">surname:Baeten;given-names:M.</infon><infon key="name_4">surname:Stange;given-names:G.</infon><infon key="name_5">surname:Van den Bossche;given-names:J.</infon><infon key="name_6">surname:Mack;given-names:M.</infon><infon key="name_7">surname:Pipeleers;given-names:D.</infon><infon key="name_8">surname:In't Veld;given-names:P.</infon><infon key="name_9">surname:De Baetselier;given-names:P.</infon><infon key="pub-id_doi">10.1158/0008-5472.CAN-09-4672</infon><infon key="pub-id_pmid">20570887</infon><infon key="section_type">REF</infon><infon key="source">Cancer Res.</infon><infon key="type">ref</infon><infon key="volume">70</infon><infon key="year">2010</infon><offset>64106</offset><text>Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C (high) monocytes</text></passage><passage><infon key="fpage">1261</infon><infon key="lpage">1268</infon><infon key="name_0">surname:Hagemann;given-names:T.</infon><infon key="name_1">surname:Lawrence;given-names:T.</infon><infon key="name_2">surname:McNeish;given-names:I.</infon><infon key="name_3">surname:Charles;given-names:K.A.</infon><infon key="name_4">surname:Kulbe;given-names:H.</infon><infon key="name_5">surname:Thompson;given-names:R.G.</infon><infon key="name_6">surname:Robinson;given-names:S.C.</infon><infon key="name_7">surname:Balkwill;given-names:F.R.</infon><infon key="pub-id_doi">10.1084/jem.20080108</infon><infon key="pub-id_pmid">18490490</infon><infon key="section_type">REF</infon><infon key="source">J. Exp. Med.</infon><infon key="type">ref</infon><infon key="volume">205</infon><infon key="year">2008</infon><offset>64228</offset><text>&quot;Re-educating&quot; tumor-associated macrophages by targeting NF-kappaB</text></passage><passage><infon key="fpage">2206</infon><infon key="lpage">2214</infon><infon key="name_0">surname:Chefetz;given-names:I.</infon><infon key="name_1">surname:Holmberg;given-names:J.C.</infon><infon key="name_2">surname:Alvero;given-names:A.B.</infon><infon key="name_3">surname:Visintin;given-names:I.</infon><infon key="name_4">surname:Mor;given-names:G.</infon><infon key="pub-id_doi">10.4161/cc.10.13.16348</infon><infon key="pub-id_pmid">21623171</infon><infon key="section_type">REF</infon><infon key="source">Cell Cycle</infon><infon key="type">ref</infon><infon key="volume">10</infon><infon key="year">2011</infon><offset>64296</offset><text>Inhibition of Aurora-A kinase induces cell cycle arrest in epithelial ovarian cancer stem cells by affecting NFkB pathway</text></passage><passage><infon key="fpage">24</infon><infon key="lpage">26</infon><infon key="name_0">surname:Sun;given-names:S.-C.</infon><infon key="name_1">surname:Harhaj;given-names:E.W.</infon><infon key="section_type">REF</infon><infon key="source">NF-Kb/Rel Transcription Factor Fam</infon><infon key="type">ref</infon><infon key="year">2006</infon><offset>64419</offset><text>Receptors and adaptors for NF-kB signaling</text></passage><passage><infon key="fpage">771</infon><infon key="lpage">781</infon><infon key="name_0">surname:Novack;given-names:D.V.</infon><infon key="name_1">surname:Yin;given-names:L.</infon><infon key="name_2">surname:Hagen-Stapleton;given-names:A.</infon><infon key="name_3">surname:Schreiber;given-names:R.D.</infon><infon key="name_4">surname:Goeddel;given-names:D.V.</infon><infon key="name_5">surname:Ross;given-names:F.P.</infon><infon key="name_6">surname:Teitelbaum;given-names:S.L.</infon><infon key="pub-id_doi">10.1084/jem.20030116</infon><infon key="pub-id_pmid">12939342</infon><infon key="section_type">REF</infon><infon key="source">J. Exp. Med.</infon><infon key="type">ref</infon><infon key="volume">198</infon><infon key="year">2003</infon><offset>64462</offset><text>The IkappaB function of NF-kappaB2 p100 controls stimulated osteoclastogenesis</text></passage><passage><infon key="fpage">53222</infon><infon key="lpage">53231</infon><infon key="name_0">surname:Munroe;given-names:M.E.</infon><infon key="name_1">surname:Bishop;given-names:G.A.</infon><infon key="pub-id_doi">10.1074/jbc.M410539200</infon><infon key="pub-id_pmid">15485859</infon><infon key="section_type">REF</infon><infon key="source">J. Biol. Chem.</infon><infon key="type">ref</infon><infon key="volume">279</infon><infon key="year">2004</infon><offset>64541</offset><text>Role of tumor necrosis factor (TNF) receptor-associated factor 2 (TRAF2) in distinct and overlapping CD40 and TNF receptor 2/CD120b-mediated B lymphocyte activation</text></passage><passage><infon key="fpage">7394</infon><infon key="lpage">7404</infon><infon key="name_0">surname:Rauert;given-names:H.</infon><infon key="name_1">surname:Wicovsky;given-names:A.</infon><infon key="name_2">surname:Muller;given-names:N.</infon><infon key="name_3">surname:Siegmund;given-names:D.</infon><infon key="name_4">surname:Spindler;given-names:V.</infon><infon key="name_5">surname:Waschke;given-names:J.</infon><infon key="name_6">surname:Kneitz;given-names:C.</infon><infon key="name_7">surname:Wajant;given-names:H.</infon><infon key="pub-id_doi">10.1074/jbc.M109.037341</infon><infon key="pub-id_pmid">20038584</infon><infon key="section_type">REF</infon><infon key="source">J. Biol. Chem.</infon><infon key="type">ref</infon><infon key="volume">285</infon><infon key="year">2010</infon><offset>64706</offset><text>Membrane tumor necrosis factor (TNF) induces p100 processing via TNF receptor-2 (TNFR2)</text></passage><passage><infon key="fpage">36005</infon><infon key="lpage">36012</infon><infon key="name_0">surname:Saitoh;given-names:T.</infon><infon key="name_1">surname:Nakayama;given-names:M.</infon><infon key="name_2">surname:Nakano;given-names:H.</infon><infon key="name_3">surname:Yagita;given-names:H.</infon><infon key="name_4">surname:Yamamoto;given-names:N.</infon><infon key="name_5">surname:Yamaoka;given-names:S.</infon><infon key="pub-id_doi">10.1074/jbc.M304266200</infon><infon key="pub-id_pmid">12840022</infon><infon key="section_type">REF</infon><infon key="source">J. Biol. Chem.</infon><infon key="type">ref</infon><infon key="volume">278</infon><infon key="year">2003</infon><offset>64794</offset><text>TWEAK induces NF-kappaB2 p100 processing and long lasting NF-kappaB activation</text></passage><passage><infon key="fpage">1448</infon><infon key="lpage">1456</infon><infon key="name_0">surname:Gelbmann;given-names:C.</infon><infon key="name_1">surname:Leeb;given-names:S.</infon><infon key="name_2">surname:Vogl;given-names:D.</infon><infon key="name_3">surname:Maendel;given-names:M.</infon><infon key="name_4">surname:Herfarth;given-names:H.</infon><infon key="name_5">surname:Scholmerich;given-names:J.</infon><infon key="name_6">surname:Falk;given-names:W.</infon><infon key="name_7">surname:Rogler;given-names:G.</infon><infon key="pub-id_doi">10.1136/gut.52.10.1448</infon><infon key="pub-id_pmid">12970138</infon><infon key="section_type">REF</infon><infon key="source">Gut</infon><infon key="type">ref</infon><infon key="volume">52</infon><infon key="year">2003</infon><offset>64873</offset><text>Inducible CD40 expression mediates NFkappaB activation and cytokine secretion in human colonic fibroblasts</text></passage><passage><infon key="fpage">4049</infon><infon key="lpage">4057</infon><infon key="name_0">surname:Liu;given-names:Z.</infon><infon key="name_1">surname:Colpaert;given-names:S.</infon><infon key="name_2">surname:D'Haens;given-names:G.R.</infon><infon key="name_3">surname:Kasran;given-names:A.</infon><infon key="name_4">surname:de Boer;given-names:M.</infon><infon key="name_5">surname:Rutgeerts;given-names:P.</infon><infon key="name_6">surname:Geboes;given-names:K.</infon><infon key="name_7">surname:Ceuppens;given-names:J.L.</infon><infon key="pub-id_doi">10.4049/jimmunol.163.7.4049</infon><infon key="pub-id_pmid">10491009</infon><infon key="section_type">REF</infon><infon key="source">J. Immunol.</infon><infon key="type">ref</infon><infon key="volume">163</infon><infon key="year">1999</infon><offset>64980</offset><text>Hyperexpression of CD40 ligand (CD154) in inflammatory bowel disease and its contribution to pathogenic cytokine production</text></passage><passage><infon key="fpage">1248</infon><infon key="lpage">1256</infon><infon key="name_0">surname:Danese;given-names:S.</infon><infon key="name_1">surname:Scaldaferri;given-names:F.</infon><infon key="name_2">surname:Vetrano;given-names:S.</infon><infon key="name_3">surname:Stefanelli;given-names:T.</infon><infon key="name_4">surname:Graziani;given-names:C.</infon><infon key="name_5">surname:Repici;given-names:A.</infon><infon key="name_6">surname:Ricci;given-names:R.</infon><infon key="name_7">surname:Straface;given-names:G.</infon><infon key="name_8">surname:Sgambato;given-names:A.</infon><infon key="name_9">surname:Malesci;given-names:A.</infon><infon key="pub-id_doi">10.1136/gut.2006.111989</infon><infon key="pub-id_pmid">17317789</infon><infon key="section_type">REF</infon><infon key="source">Gut</infon><infon key="type">ref</infon><infon key="volume">56</infon><infon key="year">2007</infon><offset>65104</offset><text>Critical role of the CD40-CD40-ligand pathway in regulating mucosal inflammation-driven angiogenesis in inflammatory bowel disease</text></passage><passage><infon key="fpage">233</infon><infon key="lpage">245</infon><infon key="name_0">surname:Blake;given-names:M.L.</infon><infon key="name_1">surname:Tometsko;given-names:M.</infon><infon key="name_2">surname:Miller;given-names:R.</infon><infon key="name_3">surname:Jones;given-names:J.C.</infon><infon key="name_4">surname:Dougall;given-names:W.C.</infon><infon key="pub-id_doi">10.1007/s10585-013-9624-3</infon><infon key="pub-id_pmid">24272640</infon><infon key="section_type">REF</infon><infon key="source">Clin. Exp. Metastasis</infon><infon key="type">ref</infon><infon key="volume">31</infon><infon key="year">2014</infon><offset>65237</offset><text>RANK expression on breast cancer cells promotes skeletal metastasis</text></passage><passage><infon key="fpage">92</infon><infon key="lpage">104</infon><infon key="name_0">surname:Armstrong;given-names:A.P.</infon><infon key="name_1">surname:Miller;given-names:R.E.</infon><infon key="name_2">surname:Jones;given-names:J.C.</infon><infon key="name_3">surname:Zhang;given-names:J.</infon><infon key="name_4">surname:Keller;given-names:E.T.</infon><infon key="name_5">surname:Dougall;given-names:W.C.</infon><infon key="pub-id_doi">10.1002/pros.20678</infon><infon key="pub-id_pmid">18008334</infon><infon key="section_type">REF</infon><infon key="source">Prostate</infon><infon key="type">ref</infon><infon key="volume">68</infon><infon key="year">2008</infon><offset>65305</offset><text>RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes</text></passage><passage><infon key="fpage">4930</infon><infon key="lpage">4934</infon><infon key="name_0">surname:Rossi;given-names:D.</infon><infon key="name_1">surname:Deaglio;given-names:S.</infon><infon key="name_2">surname:Dominguez-Sola;given-names:D.</infon><infon key="name_3">surname:Rasi;given-names:S.</infon><infon key="name_4">surname:Vaisitti;given-names:T.</infon><infon key="name_5">surname:Agostinelli;given-names:C.</infon><infon key="name_6">surname:Spina;given-names:V.</infon><infon key="name_7">surname:Bruscaggin;given-names:A.</infon><infon key="name_8">surname:Monti;given-names:S.</infon><infon key="name_9">surname:Cerri;given-names:M.</infon><infon key="section_type">REF</infon><infon key="source">Blood J. Am. Soc. Hematol.</infon><infon key="type">ref</infon><infon key="volume">118</infon><infon key="year">2011</infon><offset>65429</offset><text>Alteration of BIRC3 and multiple other NF-kappaB pathway genes in splenic marginal zone lymphoma</text></passage><passage><infon key="fpage">1418</infon><infon key="lpage">1428</infon><infon key="name_0">surname:Hyeon;given-names:J.</infon><infon key="name_1">surname:Lee;given-names:B.</infon><infon key="name_2">surname:Shin;given-names:S.-H.</infon><infon key="name_3">surname:Yoo;given-names:H.Y.</infon><infon key="name_4">surname:Kim;given-names:S.J.</infon><infon key="name_5">surname:Kim;given-names:W.S.</infon><infon key="name_6">surname:Park;given-names:W.-Y.</infon><infon key="name_7">surname:Ko;given-names:Y.-H.</infon><infon key="pub-id_doi">10.1038/s41379-018-0064-0</infon><infon key="pub-id_pmid">29765142</infon><infon key="section_type">REF</infon><infon key="source">Mod. Pathol.</infon><infon key="type">ref</infon><infon key="volume">31</infon><infon key="year">2018</infon><offset>65526</offset><text>Targeted deep sequencing of gastric marginal zone lymphoma identified alterations of TRAF3 and TNFAIP3 that were mutually exclusive for MALT1 rearrangement</text></passage><passage><infon key="fpage">6831</infon><infon key="lpage">6843</infon><infon key="name_0">surname:Courtois;given-names:G.</infon><infon key="name_1">surname:Gilmore;given-names:T.</infon><infon key="pub-id_doi">10.1038/sj.onc.1209939</infon><infon key="pub-id_pmid">17072331</infon><infon key="section_type">REF</infon><infon key="source">Oncogene</infon><infon key="type">ref</infon><infon key="volume">25</infon><infon key="year">2006</infon><offset>65682</offset><text>Mutations in the NF-kappa B signaling pathway: Implications for human disease</text></passage><passage><infon key="fpage">2839</infon><infon key="lpage">2845</infon><infon key="name_0">surname:Fracchiolla;given-names:N.</infon><infon key="name_1">surname:Lombardi;given-names:L.</infon><infon key="name_2">surname:Salina;given-names:M.</infon><infon key="name_3">surname:Migliazza;given-names:A.</infon><infon key="name_4">surname:Baldini;given-names:L.</infon><infon key="name_5">surname:Berti;given-names:E.</infon><infon key="name_6">surname:Cro;given-names:L.</infon><infon key="name_7">surname:Polli;given-names:E.</infon><infon key="name_8">surname:Maiolo;given-names:A.</infon><infon key="name_9">surname:Neri;given-names:A.</infon><infon key="pub-id_pmid">8378093</infon><infon key="section_type">REF</infon><infon key="source">Oncogene</infon><infon key="type">ref</infon><infon key="volume">8</infon><infon key="year">1993</infon><offset>65760</offset><text>Structural alterations of the NF-kappa B transcription factor lyt-10 in lymphoid malignancies</text></passage><passage><infon key="fpage">4321</infon><infon key="lpage">4330</infon><infon key="name_0">surname:Barth;given-names:T.F.</infon><infon key="name_1">surname:Dohner;given-names:H.</infon><infon key="name_2">surname:Werner;given-names:C.A.</infon><infon key="name_3">surname:Stilgenbauer;given-names:S.</infon><infon key="name_4">surname:Schlotter;given-names:M.</infon><infon key="name_5">surname:Pawlita;given-names:M.</infon><infon key="name_6">surname:Lichter;given-names:P.</infon><infon key="name_7">surname:Moller;given-names:P.</infon><infon key="name_8">surname:Bentz;given-names:M.</infon><infon key="section_type">REF</infon><infon key="source">Blood J. Am. Soc. Hematol.</infon><infon key="type">ref</infon><infon key="volume">91</infon><infon key="year">1998</infon><offset>65854</offset><text>Characteristic pattern of chromosomal gains and losses in primary large B-cell lymphomas of the gastrointestinal tract</text></passage><passage><infon key="fpage">1235</infon><infon key="lpage">1241</infon><infon key="name_0">surname:Lu;given-names:D.</infon><infon key="name_1">surname:Thompson;given-names:J.</infon><infon key="name_2">surname:Gorski;given-names:G.</infon><infon key="name_3">surname:Rice;given-names:N.</infon><infon key="name_4">surname:Mayer;given-names:M.</infon><infon key="name_5">surname:Yunis;given-names:J.</infon><infon key="pub-id_pmid">1650444</infon><infon key="section_type">REF</infon><infon key="source">Oncogene</infon><infon key="type">ref</infon><infon key="volume">6</infon><infon key="year">1991</infon><offset>65973</offset><text>Alterations at the rel locus in human lymphoma</text></passage><passage><infon key="fpage">129</infon><infon key="lpage">135</infon><infon key="name_0">surname:Kalaitzidis;given-names:D.</infon><infon key="name_1">surname:Gilmore;given-names:T.D.</infon><infon key="pub-id_doi">10.1002/gcc.10051</infon><infon key="pub-id_pmid">11921291</infon><infon key="section_type">REF</infon><infon key="source">Genes Chromosom. Cancer</infon><infon key="type">ref</infon><infon key="volume">34</infon><infon key="year">2002</infon><offset>66020</offset><text>Genomic organization and expression of the rearranged REL proto-oncogene in the human B-cell lymphoma cell line RC-K8</text></passage><passage><infon key="fpage">3321</infon><infon key="name_0">surname:Zhang;given-names:M.</infon><infon key="name_1">surname:Xu-Monette;given-names:Z.Y.</infon><infon key="name_2">surname:Li;given-names:L.</infon><infon key="name_3">surname:Manyam;given-names:G.C.</infon><infon key="name_4">surname:Visco;given-names:C.</infon><infon key="name_5">surname:Tzankov;given-names:A.</infon><infon key="name_6">surname:Wang;given-names:J.</infon><infon key="name_7">surname:Montes-Moreno;given-names:S.</infon><infon key="name_8">surname:Dybkaer;given-names:K.</infon><infon key="name_9">surname:Chiu;given-names:A.</infon><infon key="pub-id_doi">10.18632/aging.101121</infon><infon key="pub-id_pmid">27941215</infon><infon key="section_type">REF</infon><infon key="source">Aging</infon><infon key="type">ref</infon><infon key="volume">8</infon><infon key="year">2016</infon><offset>66138</offset><text>RelA NF-kappaB subunit activation as a therapeutic target in diffuse large B-cell lymphoma</text></passage><passage><infon key="fpage">35</infon><infon key="lpage">45</infon><infon key="name_0">surname:Willis;given-names:T.G.</infon><infon key="name_1">surname:Jadayel;given-names:D.M.</infon><infon key="name_2">surname:Du;given-names:M.-Q.</infon><infon key="name_3">surname:Peng;given-names:H.</infon><infon key="name_4">surname:Perry;given-names:A.R.</infon><infon key="name_5">surname:Abdul-Rauf;given-names:M.</infon><infon key="name_6">surname:Price;given-names:H.</infon><infon key="name_7">surname:Karran;given-names:L.</infon><infon key="name_8">surname:Majekodunmi;given-names:O.</infon><infon key="name_9">surname:Wlodarska;given-names:I.J.C.</infon><infon key="pub-id_doi">10.1016/S0092-8674(00)80957-5</infon><infon key="pub-id_pmid">9989495</infon><infon key="section_type">REF</infon><infon key="source">Cell</infon><infon key="type">ref</infon><infon key="volume">96</infon><infon key="year">1999</infon><offset>66229</offset><text>Bcl10 is involved in t (1; 14)(p22; q32) of MALT B cell lymphoma and mutated in multiple tumor types</text></passage><passage><infon key="fpage">5785</infon><infon key="lpage">5794</infon><infon key="name_0">surname:Akagi;given-names:T.</infon><infon key="name_1">surname:Motegi;given-names:M.</infon><infon key="name_2">surname:Tamura;given-names:A.</infon><infon key="name_3">surname:Suzuki;given-names:R.</infon><infon key="name_4">surname:Hosokawa;given-names:Y.</infon><infon key="name_5">surname:Suzuki;given-names:H.</infon><infon key="name_6">surname:Ota;given-names:H.</infon><infon key="name_7">surname:Nakamura;given-names:S.</infon><infon key="name_8">surname:Morishima;given-names:Y.</infon><infon key="name_9">surname:Taniwaki;given-names:M.</infon><infon key="pub-id_doi">10.1038/sj.onc.1203018</infon><infon key="pub-id_pmid">10523859</infon><infon key="section_type">REF</infon><infon key="source">Oncogene</infon><infon key="type">ref</infon><infon key="volume">18</infon><infon key="year">1999</infon><offset>66330</offset><text>A novel gene, MALT1 at 18q21, is involved in t (11; 18)(q21; q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue</text></passage><passage><infon key="fpage">19012</infon><infon key="lpage">19019</infon><infon key="name_0">surname:Lucas;given-names:P.C.</infon><infon key="name_1">surname:Yonezumi;given-names:M.</infon><infon key="name_2">surname:Inohara;given-names:N.</infon><infon key="name_3">surname:McAllister-Lucas;given-names:L.M.</infon><infon key="name_4">surname:Abazeed;given-names:M.E.</infon><infon key="name_5">surname:Chen;given-names:F.F.</infon><infon key="name_6">surname:Yamaoka;given-names:S.</infon><infon key="name_7">surname:Seto;given-names:M.</infon><infon key="name_8">surname:Nunez;given-names:G.</infon><infon key="pub-id_doi">10.1074/jbc.M009984200</infon><infon key="pub-id_pmid">11262391</infon><infon key="section_type">REF</infon><infon key="source">J. Biol. Chem.</infon><infon key="type">ref</infon><infon key="volume">276</infon><infon key="year">2001</infon><offset>66468</offset><text>Bcl10 and MALT1, independent targets of chromosomal translocation in malt lymphoma, cooperate in a novel NF-kappaB signaling pathway</text></passage><passage><infon key="fpage">961</infon><infon key="lpage">967</infon><infon key="name_0">surname:Uren;given-names:A.G.</infon><infon key="name_1">surname:O'Rourke;given-names:K.</infon><infon key="name_2">surname:Aravind;given-names:L.A.</infon><infon key="name_3">surname:Pisabarro;given-names:M.T.</infon><infon key="name_4">surname:Seshagiri;given-names:S.</infon><infon key="name_5">surname:Koonin;given-names:E.V.</infon><infon key="name_6">surname:Dixit;given-names:V.M.</infon><infon key="pub-id_doi">10.1016/S1097-2765(00)00094-0</infon><infon key="pub-id_pmid">11090634</infon><infon key="section_type">REF</infon><infon key="source">Mol. Cell</infon><infon key="type">ref</infon><infon key="volume">6</infon><infon key="year">2000</infon><offset>66601</offset><text>Identification of paracaspases and metacaspases: Two ancient families of caspase-like proteins, one of which plays a key role in MALT lymphoma</text></passage><passage><infon key="fpage">5180</infon><infon key="lpage">5187</infon><infon key="name_0">surname:Chang;given-names:C.-C.</infon><infon key="name_1">surname:Zhang;given-names:J.</infon><infon key="name_2">surname:Lombardi;given-names:L.</infon><infon key="name_3">surname:Neri;given-names:A.</infon><infon key="name_4">surname:Dalla-Favera;given-names:R.</infon><infon key="pub-id_doi">10.1128/MCB.15.9.5180</infon><infon key="pub-id_pmid">7651435</infon><infon key="section_type">REF</infon><infon key="source">Mol. Cell. Biol.</infon><infon key="type">ref</infon><infon key="volume">15</infon><infon key="year">1995</infon><offset>66744</offset><text>Rearranged NFKB-2 genes in lymphoid neoplasms code for constitutively active nuclear transactivators</text></passage><passage><infon key="fpage">999</infon><infon key="lpage">1014</infon><infon key="name_0">surname:Ishikawa;given-names:H.</infon><infon key="name_1">surname:Carrasco;given-names:D.</infon><infon key="name_2">surname:Claudio;given-names:E.</infon><infon key="name_3">surname:Ryseck;given-names:R.-P.</infon><infon key="name_4">surname:Bravo;given-names:R.</infon><infon key="pub-id_doi">10.1084/jem.186.7.999</infon><infon key="pub-id_pmid">9314550</infon><infon key="section_type">REF</infon><infon key="source">J. Exp. Med.</infon><infon key="type">ref</infon><infon key="volume">186</infon><infon key="year">1997</infon><offset>66845</offset><text>Gastric hyperplasia and increased proliferative responses of lymphocytes in mice lacking the COOH-terminal ankyrin domain of NF-kappaB2</text></passage><passage><infon key="fpage">25</infon><infon key="lpage">29</infon><infon key="name_0">surname:Houldsworth;given-names:J.</infon><infon key="name_1">surname:Mathew;given-names:S.</infon><infon key="name_2">surname:Rao;given-names:P.H.</infon><infon key="name_3">surname:Dyomina;given-names:K.</infon><infon key="name_4">surname:Louie;given-names:D.C.</infon><infon key="name_5">surname:Parsa;given-names:N.</infon><infon key="name_6">surname:Offit;given-names:K.</infon><infon key="name_7">surname:Chaganti;given-names:R.</infon><infon key="pub-id_doi">10.1182/blood.V87.1.25.25</infon><infon key="pub-id_pmid">8547649</infon><infon key="section_type">REF</infon><infon key="source">Blood</infon><infon key="type">ref</infon><infon key="volume">87</infon><infon key="year">1996</infon><offset>66981</offset><text>REL proto-oncogene is frequently amplified in extranodal diffuse large cell lymphoma</text></passage><passage><infon key="fpage">2073</infon><infon key="lpage">2083</infon><infon key="name_0">surname:Kralova;given-names:J.</infon><infon key="name_1">surname:Schatzle;given-names:J.</infon><infon key="name_2">surname:Bargmann;given-names:W.</infon><infon key="name_3">surname:Bose;given-names:H.</infon><infon key="pub-id_doi">10.1128/jvi.68.4.2073-2083.1994</infon><infon key="pub-id_pmid">8138992</infon><infon key="section_type">REF</infon><infon key="source">J. Virol.</infon><infon key="type">ref</infon><infon key="volume">68</infon><infon key="year">1994</infon><offset>67066</offset><text>Transformation of avian fibroblasts overexpressing the c-rel proto-oncogene and a variant of c-rel lacking 40 C-terminal amino acids</text></passage><passage><infon key="fpage">234</infon><infon key="lpage">240</infon><infon key="name_0">surname:Rao;given-names:P.H.</infon><infon key="name_1">surname:Houldsworth;given-names:J.</infon><infon key="name_2">surname:Dyomina;given-names:K.</infon><infon key="name_3">surname:Parsa;given-names:N.Z.</infon><infon key="name_4">surname:Cigudosa;given-names:J.C.</infon><infon key="name_5">surname:Louie;given-names:D.C.</infon><infon key="name_6">surname:Popplewell;given-names:L.</infon><infon key="name_7">surname:Offit;given-names:K.</infon><infon key="name_8">surname:Jhanwar;given-names:S.C.</infon><infon key="name_9">surname:Chaganti;given-names:R.</infon><infon key="pub-id_doi">10.1182/blood.V92.1.234.413k22_234_240</infon><infon key="section_type">REF</infon><infon key="source">J. Am. Soc. Hematol.</infon><infon key="type">ref</infon><infon key="volume">92</infon><infon key="year">1998</infon><offset>67199</offset><text>Chromosomal and gene amplification in diffuse large B-cell lymphoma</text></passage><passage><infon key="fpage">191</infon><infon key="lpage">193</infon><infon key="name_0">surname:Mathew;given-names:S.</infon><infon key="name_1">surname:Murty;given-names:V.</infon><infon key="name_2">surname:Dalla-Favera;given-names:R.</infon><infon key="name_3">surname:Chaganti;given-names:R.</infon><infon key="pub-id_pmid">8423996</infon><infon key="section_type">REF</infon><infon key="source">Oncogene</infon><infon key="type">ref</infon><infon key="volume">8</infon><infon key="year">1993</infon><offset>67267</offset><text>Chromosomal localization of genes encoding the transcription factors, c-rel, NF-kBp50, NF-cBp65, and lyt-10 by fluorescence in situ</text></passage><passage><infon key="fpage">991</infon><infon key="lpage">997</infon><infon key="name_0">surname:Ohno;given-names:H.</infon><infon key="name_1">surname:Takimoto;given-names:G.</infon><infon key="name_2">surname:McKeithan;given-names:T.W.</infon><infon key="pub-id_doi">10.1016/0092-8674(90)90347-H</infon><infon key="pub-id_pmid">2180580</infon><infon key="section_type">REF</infon><infon key="source">Cell</infon><infon key="type">ref</infon><infon key="volume">60</infon><infon key="year">1990</infon><offset>67399</offset><text>The candidate proto-oncogene bcl-3 is related to genes implicated in cell lineage determination and cell cycle control</text></passage><passage><infon key="fpage">529</infon><infon key="lpage">537</infon><infon key="name_0">surname:Rylatt;given-names:D.B.</infon><infon key="name_1">surname:Aitken;given-names:A.</infon><infon key="name_2">surname:Bilham;given-names:T.</infon><infon key="name_3">surname:Condon;given-names:G.D.</infon><infon key="name_4">surname:Embi;given-names:N.</infon><infon key="name_5">surname:Cohen;given-names:P.</infon><infon key="pub-id_doi">10.1111/j.1432-1033.1980.tb06060.x</infon><infon key="pub-id_pmid">6772446</infon><infon key="section_type">REF</infon><infon key="source">Eur. J. Biochem.</infon><infon key="type">ref</infon><infon key="volume">107</infon><infon key="year">1980</infon><offset>67518</offset><text>Glycogen synthase from rabbit skeletal muscle: Amino acid sequence at the sites phosphorylated by glycogen synthase kinase-3, and extension of the N-terminal sequence containing the site phosphorylated by phosphorylase kinase</text></passage><passage><infon key="fpage">40</infon><infon key="name_0">surname:Kaidanovich-Beilin;given-names:O.</infon><infon key="name_1">surname:Woodgett;given-names:J.R.</infon><infon key="pub-id_doi">10.3389/fnmol.2011.00040</infon><infon key="pub-id_pmid">22110425</infon><infon key="section_type">REF</infon><infon key="source">Front. Mol. Neurosci.</infon><infon key="type">ref</infon><infon key="volume">4</infon><infon key="year">2011</infon><offset>67744</offset><text>GSK-3: Functional insights from cell biology and animal models</text></passage><passage><infon key="fpage">86</infon><infon key="lpage">90</infon><infon key="name_0">surname:Hoeflich;given-names:K.P.</infon><infon key="name_1">surname:Luo;given-names:J.</infon><infon key="name_2">surname:Rubie;given-names:E.A.</infon><infon key="name_3">surname:Tsao;given-names:M.-S.</infon><infon key="name_4">surname:Jin;given-names:O.</infon><infon key="name_5">surname:Woodgett;given-names:J.R.</infon><infon key="pub-id_doi">10.1038/35017574</infon><infon key="pub-id_pmid">10894547</infon><infon key="section_type">REF</infon><infon key="source">Nature</infon><infon key="type">ref</infon><infon key="volume">406</infon><infon key="year">2000</infon><offset>67807</offset><text>Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation</text></passage><passage><infon key="fpage">2076</infon><infon key="lpage">2081</infon><infon key="name_0">surname:Ougolkov;given-names:A.V.</infon><infon key="name_1">surname:Fernandez-Zapico;given-names:M.E.</infon><infon key="name_2">surname:Savoy;given-names:D.N.</infon><infon key="name_3">surname:Urrutia;given-names:R.A.</infon><infon key="name_4">surname:Billadeau;given-names:D.D.</infon><infon key="pub-id_doi">10.1158/0008-5472.CAN-04-3642</infon><infon key="pub-id_pmid">15781615</infon><infon key="section_type">REF</infon><infon key="source">Cancer Res.</infon><infon key="type">ref</infon><infon key="volume">65</infon><infon key="year">2005</infon><offset>67896</offset><text>Glycogen synthase kinase-3beta participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells</text></passage><passage><infon key="fpage">735</infon><infon key="lpage">742</infon><infon key="name_0">surname:Ougolkov;given-names:A.V.</infon><infon key="name_1">surname:Bone;given-names:N.D.</infon><infon key="name_2">surname:Fernandez-Zapico;given-names:M.E.</infon><infon key="name_3">surname:Kay;given-names:N.E.</infon><infon key="name_4">surname:Billadeau;given-names:D.D.</infon><infon key="pub-id_doi">10.1182/blood-2006-12-060947</infon><infon key="pub-id_pmid">17463171</infon><infon key="section_type">REF</infon><infon key="source">Blood J. Am. Soc. Hematol.</infon><infon key="type">ref</infon><infon key="volume">110</infon><infon key="year">2007</infon><offset>68038</offset><text>Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor kappaB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells</text></passage><passage><infon key="fpage">6643</infon><infon key="lpage">6651</infon><infon key="name_0">surname:Kotliarova;given-names:S.</infon><infon key="name_1">surname:Pastorino;given-names:S.</infon><infon key="name_2">surname:Kovell;given-names:L.C.</infon><infon key="name_3">surname:Kotliarov;given-names:Y.</infon><infon key="name_4">surname:Song;given-names:H.</infon><infon key="name_5">surname:Zhang;given-names:W.</infon><infon key="name_6">surname:Bailey;given-names:R.</infon><infon key="name_7">surname:Maric;given-names:D.</infon><infon key="name_8">surname:Zenklusen;given-names:J.C.</infon><infon key="name_9">surname:Lee;given-names:J.</infon><infon key="pub-id_doi">10.1158/0008-5472.CAN-08-0850</infon><infon key="pub-id_pmid">18701488</infon><infon key="section_type">REF</infon><infon key="source">Cancer Res.</infon><infon key="type">ref</infon><infon key="volume">68</infon><infon key="year">2008</infon><offset>68223</offset><text>Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation</text></passage><passage><infon key="fpage">7882</infon><infon key="lpage">7892</infon><infon key="name_0">surname:Mazor;given-names:M.</infon><infon key="name_1">surname:Kawano;given-names:Y.</infon><infon key="name_2">surname:Zhu;given-names:H.</infon><infon key="name_3">surname:Waxman;given-names:J.</infon><infon key="name_4">surname:Kypta;given-names:R.M.</infon><infon key="pub-id_doi">10.1038/sj.onc.1208068</infon><infon key="pub-id_pmid">15361837</infon><infon key="section_type">REF</infon><infon key="source">Oncogene</infon><infon key="type">ref</infon><infon key="volume">23</infon><infon key="year">2004</infon><offset>68348</offset><text>Inhibition of glycogen synthase kinase-3 represses androgen receptor activity and prostate cancer cell growth</text></passage><passage><infon key="fpage">1365</infon><infon key="lpage">1373</infon><infon key="name_0">surname:Shakoori;given-names:A.</infon><infon key="name_1">surname:Ougolkov;given-names:A.</infon><infon key="name_2">surname:Yu;given-names:Z.W.</infon><infon key="name_3">surname:Zhang;given-names:B.</infon><infon key="name_4">surname:Modarressi;given-names:M.H.</infon><infon key="name_5">surname:Billadeau;given-names:D.D.</infon><infon key="name_6">surname:Mai;given-names:M.</infon><infon key="name_7">surname:Takahashi;given-names:Y.</infon><infon key="name_8">surname:Minamoto;given-names:T.</infon><infon key="pub-id_doi">10.1016/j.bbrc.2005.07.041</infon><infon key="pub-id_pmid">16043125</infon><infon key="section_type">REF</infon><infon key="source">Biochem. Biophys. Res. Commun.</infon><infon key="type">ref</infon><infon key="volume">334</infon><infon key="year">2005</infon><offset>68458</offset><text>Deregulated GSK3beta activity in colorectal cancer: Its association with tumor cell survival and proliferation</text></passage><passage><infon key="fpage">35</infon><infon key="lpage">49</infon><infon key="name_0">surname:Schulze-Osthoff;given-names:K.</infon><infon key="name_1">surname:Ferrari;given-names:D.</infon><infon key="name_2">surname:Riehemann;given-names:K.</infon><infon key="name_3">surname:Wesselborg;given-names:S.</infon><infon key="pub-id_doi">10.1016/S0171-2985(97)80025-3</infon><infon key="pub-id_pmid">9442376</infon><infon key="section_type">REF</infon><infon key="source">Immunobiology</infon><infon key="type">ref</infon><infon key="volume">198</infon><infon key="year">1997</infon><offset>68569</offset><text>Regulation of NF-kappaB activation by MAP kinase cascades</text></passage><passage><infon key="fpage">308</infon><infon key="lpage">313</infon><infon key="name_0">surname:De Smaele;given-names:E.</infon><infon key="name_1">surname:Zazzeroni;given-names:F.</infon><infon key="name_2">surname:Papa;given-names:S.</infon><infon key="name_3">surname:Nguyen;given-names:D.U.</infon><infon key="name_4">surname:Jin;given-names:R.</infon><infon key="name_5">surname:Jones;given-names:J.</infon><infon key="name_6">surname:Cong;given-names:R.</infon><infon key="name_7">surname:Franzoso;given-names:G.</infon><infon key="pub-id_doi">10.1038/35104560</infon><infon key="pub-id_pmid">11713530</infon><infon key="section_type">REF</infon><infon key="source">Nature</infon><infon key="type">ref</infon><infon key="volume">414</infon><infon key="year">2001</infon><offset>68627</offset><text>Induction of gadd45 beta by NF-kappa B downregulates pro-apoptotic JNK signalling</text></passage><passage><infon key="fpage">146</infon><infon key="lpage">153</infon><infon key="name_0">surname:Papa;given-names:S.</infon><infon key="name_1">surname:Zazzeroni;given-names:F.</infon><infon key="name_2">surname:Bubici;given-names:C.</infon><infon key="name_3">surname:Jayawardena;given-names:S.</infon><infon key="name_4">surname:Alvarez;given-names:K.</infon><infon key="name_5">surname:Matsuda;given-names:S.</infon><infon key="name_6">surname:Nguyen;given-names:D.U.</infon><infon key="name_7">surname:Pham;given-names:C.G.</infon><infon key="name_8">surname:Nelsbach;given-names:A.H.</infon><infon key="name_9">surname:Melis;given-names:T.</infon><infon key="pub-id_doi">10.1038/ncb1093</infon><infon key="pub-id_pmid">14743220</infon><infon key="section_type">REF</infon><infon key="source">Nat. Cell Biol.</infon><infon key="type">ref</infon><infon key="volume">6</infon><infon key="year">2004</infon><offset>68709</offset><text>Gadd45beta mediates the NF-kappaB suppression of JNK signalling by targeting MKK7/JNKK2</text></passage><passage><infon key="fpage">1313</infon><infon key="lpage">1324</infon><infon key="name_0">surname:Vermeulen;given-names:L.</infon><infon key="name_1">surname:De Wilde;given-names:G.</infon><infon key="name_2">surname:Van Damme;given-names:P.</infon><infon key="name_3">surname:Vanden Berghe;given-names:W.</infon><infon key="name_4">surname:Haegeman;given-names:G.</infon><infon key="pub-id_doi">10.1093/emboj/cdg139</infon><infon key="pub-id_pmid">12628924</infon><infon key="section_type">REF</infon><infon key="source">EMBO J.</infon><infon key="type">ref</infon><infon key="volume">22</infon><infon key="year">2003</infon><offset>68797</offset><text>Transcriptional activation of the NF-kappaB p65 subunit by mitogen-and stress-activated protein kinase-1 (MSK1)</text></passage><passage><infon key="fpage">3285</infon><infon key="lpage">3290</infon><infon key="name_0">surname:Berghe;given-names:W.V.</infon><infon key="name_1">surname:Plaisance;given-names:S.</infon><infon key="name_2">surname:Boone;given-names:E.</infon><infon key="name_3">surname:De Bosscher;given-names:K.</infon><infon key="name_4">surname:Schmitz;given-names:M.L.</infon><infon key="name_5">surname:Fiers;given-names:W.</infon><infon key="name_6">surname:Haegeman;given-names:G.</infon><infon key="pub-id_doi">10.1074/jbc.273.6.3285</infon><infon key="pub-id_pmid">9452444</infon><infon key="section_type">REF</infon><infon key="source">J. Biol. Chem.</infon><infon key="type">ref</infon><infon key="volume">273</infon><infon key="year">1998</infon><offset>68909</offset><text>p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways are required for nuclear factor-kappaB p65 transactivation mediated by tumor necrosis factor</text></passage><passage><infon key="fpage">109</infon><infon key="name_0">surname:Bergsagel;given-names:P.L.</infon><infon key="name_1">surname:Carpten;given-names:J.</infon><infon key="name_2">surname:Chesi;given-names:M.</infon><infon key="name_3">surname:VanWier;given-names:S.</infon><infon key="name_4">surname:Keats;given-names:J.J.</infon><infon key="name_5">surname:Sebag;given-names:M.</infon><infon key="name_6">surname:Chng;given-names:W.-J.</infon><infon key="name_7">surname:Schop;given-names:R.</infon><infon key="name_8">surname:Baker;given-names:A.</infon><infon key="name_9">surname:Chng;given-names:T.-H.</infon><infon key="pub-id_doi">10.1182/blood.V108.11.109.109</infon><infon key="section_type">REF</infon><infon key="source">Blood</infon><infon key="type">ref</infon><infon key="volume">108</infon><infon key="year">2006</infon><offset>69090</offset><text>Promiscuous Mutations Frequently Activate the Non-Canonical NFkB Pathway in Multiple Myeloma (MM)</text></passage><passage><infon key="fpage">E3796</infon><infon key="lpage">E3805</infon><infon key="name_0">surname:Liu;given-names:Y.</infon><infon key="name_1">surname:Peng;given-names:J.</infon><infon key="name_2">surname:Sun;given-names:T.</infon><infon key="name_3">surname:Li;given-names:N.</infon><infon key="name_4">surname:Zhang;given-names:L.</infon><infon key="name_5">surname:Ren;given-names:J.</infon><infon key="name_6">surname:Yuan;given-names:H.</infon><infon key="name_7">surname:Kan;given-names:S.</infon><infon key="name_8">surname:Pan;given-names:Q.</infon><infon key="name_9">surname:Li;given-names:X.</infon><infon key="pub-id_doi">10.1073/pnas.1700909114</infon><infon key="pub-id_pmid">28439030</infon><infon key="section_type">REF</infon><infon key="source">Proc. Natl. Acad. Sci. USA</infon><infon key="type">ref</infon><infon key="volume">114</infon><infon key="year">2017</infon><offset>69188</offset><text>Epithelial EZH2 serves as an epigenetic determinant in experimental colitis by inhibiting TNFalpha-mediated inflammation and apoptosis</text></passage><passage><infon key="fpage">2391</infon><infon key="lpage">2397</infon><infon key="name_0">surname:Yamamoto;given-names:M.</infon><infon key="name_1">surname:Ito;given-names:T.</infon><infon key="name_2">surname:Shimizu;given-names:T.</infon><infon key="name_3">surname:Ishida;given-names:T.</infon><infon key="name_4">surname:Semba;given-names:K.</infon><infon key="name_5">surname:Watanabe;given-names:S.</infon><infon key="name_6">surname:Yamaguchi;given-names:N.</infon><infon key="name_7">surname:Inoue;given-names:J.i.</infon><infon key="pub-id_doi">10.1111/j.1349-7006.2010.01685.x</infon><infon key="pub-id_pmid">20735436</infon><infon key="section_type">REF</infon><infon key="source">Cancer Sci.</infon><infon key="type">ref</infon><infon key="volume">101</infon><infon key="year">2010</infon><offset>69323</offset><text>Epigenetic alteration of the NF-kappaB-inducing kinase (NIK) gene is involved in enhanced NIK expression in basal-like breast cancer</text></passage><passage><infon key="fpage">176</infon><infon key="lpage">187</infon><infon key="name_0">surname:Zanotto-Filho;given-names:A.</infon><infon key="name_1">surname:Goncalves;given-names:R.M.</infon><infon key="name_2">surname:Klafke;given-names:K.</infon><infon key="name_3">surname:de Souza;given-names:P.O.</infon><infon key="name_4">surname:Dillenburg;given-names:F.C.</infon><infon key="name_5">surname:Carro;given-names:L.</infon><infon key="name_6">surname:Gelain;given-names:D.P.</infon><infon key="name_7">surname:Moreira;given-names:J.C.F.</infon><infon key="pub-id_doi">10.1016/j.canlet.2016.12.015</infon><infon key="pub-id_pmid">28007636</infon><infon key="section_type">REF</infon><infon key="source">Cancer Lett.</infon><infon key="type">ref</infon><infon key="volume">390</infon><infon key="year">2017</infon><offset>69456</offset><text>Inflammatory landscape of human brain tumors reveals an NFkappaB dependent cytokine pathway associated with mesenchymal glioblastoma</text></passage><passage><infon key="fpage">689</infon><infon key="lpage">694</infon><infon key="name_0">surname:Smale;given-names:S.T.</infon><infon key="pub-id_doi">10.1038/ni.2070</infon><infon key="pub-id_pmid">21772277</infon><infon key="section_type">REF</infon><infon key="source">Nat. Immunol.</infon><infon key="type">ref</infon><infon key="volume">12</infon><infon key="year">2011</infon><offset>69589</offset><text>Hierarchies of NF-kappaB target-gene regulation</text></passage><passage><infon key="fpage">47</infon><infon key="lpage">55</infon><infon key="name_0">surname:Storz;given-names:P.</infon><infon key="name_1">surname:Doppler;given-names:H.</infon><infon key="name_2">surname:Ferran;given-names:C.</infon><infon key="name_3">surname:Grey;given-names:S.T.</infon><infon key="name_4">surname:Toker;given-names:A.</infon><infon key="pub-id_doi">10.1042/BJ20041443</infon><infon key="pub-id_pmid">15527421</infon><infon key="section_type">REF</infon><infon key="source">Biochem. J.</infon><infon key="type">ref</infon><infon key="volume">387</infon><infon key="year">2005</infon><offset>69637</offset><text>Functional dichotomy of A20 in apoptotic and necrotic cell death</text></passage><passage><infon key="fpage">2614</infon><infon key="lpage">2626</infon><infon key="name_0">surname:Storz;given-names:P.</infon><infon key="name_1">surname:Doppler;given-names:H.</infon><infon key="name_2">surname:Toker;given-names:A.</infon><infon key="pub-id_doi">10.1128/MCB.24.7.2614-2626.2004</infon><infon key="pub-id_pmid">15024053</infon><infon key="section_type">REF</infon><infon key="source">Mol. Cell. Biol.</infon><infon key="type">ref</infon><infon key="volume">24</infon><infon key="year">2004</infon><offset>69702</offset><text>Protein kinase Cdelta selectively regulates protein kinase D-dependent activation of NF-kappaB in oxidative stress signaling</text></passage><passage><infon key="fpage">1017</infon><infon key="lpage">1029</infon><infon key="name_0">surname:Tanaka;given-names:H.</infon><infon key="name_1">surname:Matsumura;given-names:I.</infon><infon key="name_2">surname:Ezoe;given-names:S.</infon><infon key="name_3">surname:Satoh;given-names:Y.</infon><infon key="name_4">surname:Sakamaki;given-names:T.</infon><infon key="name_5">surname:Albanese;given-names:C.</infon><infon key="name_6">surname:Machii;given-names:T.</infon><infon key="name_7">surname:Pestell;given-names:R.G.</infon><infon key="name_8">surname:Kanakura;given-names:Y.</infon><infon key="pub-id_doi">10.1016/S1097-2765(02)00522-1</infon><infon key="pub-id_pmid">12049738</infon><infon key="section_type">REF</infon><infon key="source">Mol. Cell</infon><infon key="type">ref</infon><infon key="volume">9</infon><infon key="year">2002</infon><offset>69827</offset><text>E2F1 and c-Myc potentiate apoptosis through inhibition of NF-kappaB activity that facilitates MnSOD-mediated ROS elimination</text></passage><passage><infon key="fpage">9453</infon><infon key="lpage">9462</infon><infon key="name_0">surname:Ji;given-names:Z.</infon><infon key="name_1">surname:He;given-names:L.</infon><infon key="name_2">surname:Regev;given-names:A.</infon><infon key="name_3">surname:Struhl;given-names:K.</infon><infon key="pub-id_doi">10.1073/pnas.1821068116</infon><infon key="pub-id_pmid">30910960</infon><infon key="section_type">REF</infon><infon key="source">Proc. Natl. Acad. Sci. USA</infon><infon key="type">ref</infon><infon key="volume">116</infon><infon key="year">2019</infon><offset>69952</offset><text>Inflammatory regulatory network mediated by the joint action of NF-kB, STAT3, and AP-1 factors is involved in many human cancers</text></passage><passage><infon key="fpage">102673</infon><infon key="name_0">surname:Kay;given-names:J.</infon><infon key="name_1">surname:Thadhani;given-names:E.</infon><infon key="name_2">surname:Samson;given-names:L.</infon><infon key="name_3">surname:Engelward;given-names:B.</infon><infon key="pub-id_doi">10.1016/j.dnarep.2019.102673</infon><infon key="pub-id_pmid">31387777</infon><infon key="section_type">REF</infon><infon key="source">DNA Repair</infon><infon key="type">ref</infon><infon key="volume">83</infon><infon key="year">2019</infon><offset>70081</offset><text>Inflammation-induced DNA damage, mutations and cancer</text></passage><passage><infon key="fpage">479</infon><infon key="lpage">496</infon><infon key="name_0">surname:Liou;given-names:G.-Y.</infon><infon key="name_1">surname:Storz;given-names:P.</infon><infon key="pub-id_doi">10.3109/10715761003667554</infon><infon key="pub-id_pmid">20370557</infon><infon key="section_type">REF</infon><infon key="source">Free Radic. Res.</infon><infon key="type">ref</infon><infon key="volume">44</infon><infon key="year">2010</infon><offset>70135</offset><text>Reactive oxygen species in cancer</text></passage><passage><infon key="fpage">6021</infon><infon key="lpage">6026</infon><infon key="name_0">surname:Killela;given-names:P.J.</infon><infon key="name_1">surname:Reitman;given-names:Z.J.</infon><infon key="name_2">surname:Jiao;given-names:Y.</infon><infon key="name_3">surname:Bettegowda;given-names:C.</infon><infon key="name_4">surname:Agrawal;given-names:N.</infon><infon key="name_5">surname:Diaz;given-names:L.A.</infon><infon key="name_6">surname:Friedman;given-names:A.H.</infon><infon key="name_7">surname:Friedman;given-names:H.</infon><infon key="name_8">surname:Gallia;given-names:G.L.</infon><infon key="name_9">surname:Giovanella;given-names:B.C.</infon><infon key="pub-id_doi">10.1073/pnas.1303607110</infon><infon key="pub-id_pmid">23530248</infon><infon key="section_type">REF</infon><infon key="source">Proc. Natl. Acad. Sci. USA</infon><infon key="type">ref</infon><infon key="volume">110</infon><infon key="year">2013</infon><offset>70169</offset><text>TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal</text></passage><passage><infon key="fpage">957</infon><infon key="lpage">959</infon><infon key="name_0">surname:Huang;given-names:F.W.</infon><infon key="name_1">surname:Hodis;given-names:E.</infon><infon key="name_2">surname:Xu;given-names:M.J.</infon><infon key="name_3">surname:Kryukov;given-names:G.V.</infon><infon key="name_4">surname:Chin;given-names:L.</infon><infon key="name_5">surname:Garraway;given-names:L.A.</infon><infon key="pub-id_doi">10.1126/science.1229259</infon><infon key="pub-id_pmid">23348506</infon><infon key="section_type">REF</infon><infon key="source">Science</infon><infon key="type">ref</infon><infon key="volume">339</infon><infon key="year">2013</infon><offset>70294</offset><text>Highly recurrent TERT promoter mutations in human melanoma</text></passage><passage><infon key="fpage">56</infon><infon key="lpage">62</infon><infon key="name_0">surname:Lorbeer;given-names:F.K.</infon><infon key="name_1">surname:Hockemeyer;given-names:D.</infon><infon key="pub-id_doi">10.1016/j.gde.2020.02.001</infon><infon key="section_type">REF</infon><infon key="source">Curr. Opin. Genet. Dev. Biol.</infon><infon key="type">ref</infon><infon key="volume">60</infon><infon key="year">2020</infon><offset>70353</offset><text>TERT promoter mutations and telomeres during tumorigenesis</text></passage><passage><infon key="fpage">959</infon><infon key="lpage">961</infon><infon key="name_0">surname:Horn;given-names:S.</infon><infon key="name_1">surname:Figl;given-names:A.</infon><infon key="name_2">surname:Rachakonda;given-names:P.S.</infon><infon key="name_3">surname:Fischer;given-names:C.</infon><infon key="name_4">surname:Sucker;given-names:A.</infon><infon key="name_5">surname:Gast;given-names:A.</infon><infon key="name_6">surname:Kadel;given-names:S.</infon><infon key="name_7">surname:Moll;given-names:I.</infon><infon key="name_8">surname:Nagore;given-names:E.</infon><infon key="name_9">surname:Hemminki;given-names:K.</infon><infon key="pub-id_doi">10.1126/science.1230062</infon><infon key="pub-id_pmid">23348503</infon><infon key="section_type">REF</infon><infon key="source">Science</infon><infon key="type">ref</infon><infon key="volume">339</infon><infon key="year">2013</infon><offset>70412</offset><text>TERT promoter mutations in familial and sporadic melanoma</text></passage><passage><infon key="fpage">1327</infon><infon key="lpage">1338</infon><infon key="name_0">surname:Li;given-names:Y.</infon><infon key="name_1">surname:Zhou;given-names:Q.-L.</infon><infon key="name_2">surname:Sun;given-names:W.</infon><infon key="name_3">surname:Chandrasekharan;given-names:P.</infon><infon key="name_4">surname:Cheng;given-names:H.S.</infon><infon key="name_5">surname:Ying;given-names:Z.</infon><infon key="name_6">surname:Lakshmanan;given-names:M.</infon><infon key="name_7">surname:Raju;given-names:A.</infon><infon key="name_8">surname:Tenen;given-names:D.G.</infon><infon key="name_9">surname:Cheng;given-names:S.-Y.</infon><infon key="pub-id_doi">10.1038/ncb3240</infon><infon key="pub-id_pmid">26389665</infon><infon key="section_type">REF</infon><infon key="source">Nat. Cell Biol.</infon><infon key="type">ref</infon><infon key="volume">17</infon><infon key="year">2015</infon><offset>70470</offset><text>Non-canonical NF-kappaB signalling and ETS1/2 cooperatively drive C250T mutant TERT promoter activation</text></passage><passage><infon key="fpage">1</infon><infon key="lpage">10</infon><infon key="name_0">surname:Xu;given-names:X.</infon><infon key="name_1">surname:Li;given-names:Y.</infon><infon key="name_2">surname:Bharath;given-names:S.R.</infon><infon key="name_3">surname:Ozturk;given-names:M.B.</infon><infon key="name_4">surname:Bowler;given-names:M.W.</infon><infon key="name_5">surname:Loo;given-names:B.Z.L.</infon><infon key="name_6">surname:Tergaonkar;given-names:V.</infon><infon key="name_7">surname:Song;given-names:H.</infon><infon key="pub-id_doi">10.1038/s41467-018-05644-0</infon><infon key="pub-id_pmid">29317637</infon><infon key="section_type">REF</infon><infon key="source">Nat. Commun.</infon><infon key="type">ref</infon><infon key="volume">9</infon><infon key="year">2018</infon><offset>70574</offset><text>Structural basis for reactivating the mutant TERT promoter by cooperative binding of p52 and ETS1</text></passage><passage><infon key="fpage">1680</infon><infon key="lpage">1683</infon><infon key="name_0">surname:Wang;given-names:C.-Y.</infon><infon key="name_1">surname:Mayo;given-names:M.W.</infon><infon key="name_2">surname:Korneluk;given-names:R.G.</infon><infon key="name_3">surname:Goeddel;given-names:D.V.</infon><infon key="name_4">surname:Baldwin;given-names:A.S.</infon><infon key="pub-id_doi">10.1126/science.281.5383.1680</infon><infon key="pub-id_pmid">9733516</infon><infon key="section_type">REF</infon><infon key="source">Science</infon><infon key="type">ref</infon><infon key="volume">281</infon><infon key="year">1998</infon><offset>70672</offset><text>NF-kappaB antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation</text></passage><passage><infon key="fpage">2631</infon><infon key="lpage">2646</infon><infon key="name_0">surname:Chen;given-names:G.G.</infon><infon key="name_1">surname:Lee;given-names:J.F.</infon><infon key="name_2">surname:Wang;given-names:S.H.</infon><infon key="name_3">surname:Chan;given-names:U.P.</infon><infon key="name_4">surname:Ip;given-names:P.C.</infon><infon key="name_5">surname:Lau;given-names:W.Y.</infon><infon key="pub-id_doi">10.1016/S0024-3205(02)01510-2</infon><infon key="pub-id_pmid">12269390</infon><infon key="section_type">REF</infon><infon key="source">Life Sci.</infon><infon key="type">ref</infon><infon key="volume">70</infon><infon key="year">2002</infon><offset>70781</offset><text>Apoptosis induced by activation of peroxisome-proliferator activated receptor-gamma is associated with Bcl-2 and Nf-kB in human colon cancer</text></passage><passage><infon key="fpage">998</infon><infon key="lpage">1001</infon><infon key="name_0">surname:Wu;given-names:M.X.</infon><infon key="name_1">surname:Ao;given-names:Z.</infon><infon key="name_2">surname:Prasad;given-names:K.</infon><infon key="name_3">surname:Wu;given-names:R.</infon><infon key="name_4">surname:Schlossman;given-names:S.F.</infon><infon key="pub-id_doi">10.1126/science.281.5379.998</infon><infon key="pub-id_pmid">9703517</infon><infon key="section_type">REF</infon><infon key="source">Science</infon><infon key="type">ref</infon><infon key="volume">281</infon><infon key="year">1998</infon><offset>70922</offset><text>IEX-1L, an apoptosis inhibitor involved in NF-kappaB-mediated cell survival</text></passage><passage><infon key="fpage">693</infon><infon key="lpage">703</infon><infon key="name_0">surname:Wang;given-names:L.</infon><infon key="name_1">surname:Du;given-names:F.</infon><infon key="name_2">surname:Wang;given-names:X.</infon><infon key="pub-id_doi">10.1016/j.cell.2008.03.036</infon><infon key="pub-id_pmid">18485876</infon><infon key="section_type">REF</infon><infon key="source">Cell</infon><infon key="type">ref</infon><infon key="volume">133</infon><infon key="year">2008</infon><offset>70998</offset><text>TNF-alpha induces two distinct caspase-8 activation pathways</text></passage><passage><infon key="fpage">24295</infon><infon key="lpage">24299</infon><infon key="name_0">surname:Varfolomeev;given-names:E.</infon><infon key="name_1">surname:Goncharov;given-names:T.</infon><infon key="name_2">surname:Fedorova;given-names:A.V.</infon><infon key="name_3">surname:Dynek;given-names:J.N.</infon><infon key="name_4">surname:Zobel;given-names:K.</infon><infon key="name_5">surname:Deshayes;given-names:K.</infon><infon key="name_6">surname:Fairbrother;given-names:W.J.</infon><infon key="name_7">surname:Vucic;given-names:D.</infon><infon key="pub-id_doi">10.1074/jbc.C800128200</infon><infon key="pub-id_pmid">18621737</infon><infon key="section_type">REF</infon><infon key="source">J. Biol. Chem.</infon><infon key="type">ref</infon><infon key="volume">283</infon><infon key="year">2008</infon><offset>71059</offset><text>c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation</text></passage><passage><infon key="fpage">569</infon><infon key="lpage">581</infon><infon key="name_0">surname:Huber;given-names:M.A.</infon><infon key="name_1">surname:Azoitei;given-names:N.</infon><infon key="name_2">surname:Baumann;given-names:B.</infon><infon key="name_3">surname:Grunert;given-names:S.</infon><infon key="name_4">surname:Sommer;given-names:A.</infon><infon key="name_5">surname:Pehamberger;given-names:H.</infon><infon key="name_6">surname:Kraut;given-names:N.</infon><infon key="name_7">surname:Beug;given-names:H.</infon><infon key="name_8">surname:Wirth;given-names:T.</infon><infon key="pub-id_doi">10.1172/JCI200421358</infon><infon key="pub-id_pmid">15314694</infon><infon key="section_type">REF</infon><infon key="source">J. Clin. Investig.</infon><infon key="type">ref</infon><infon key="volume">114</infon><infon key="year">2004</infon><offset>71171</offset><text>NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression</text></passage><passage><infon key="fpage">927</infon><infon key="lpage">939</infon><infon key="name_0">surname:Yang;given-names:J.</infon><infon key="name_1">surname:Mani;given-names:S.A.</infon><infon key="name_2">surname:Donaher;given-names:J.L.</infon><infon key="name_3">surname:Ramaswamy;given-names:S.</infon><infon key="name_4">surname:Itzykson;given-names:R.A.</infon><infon key="name_5">surname:Come;given-names:C.</infon><infon key="name_6">surname:Savagner;given-names:P.</infon><infon key="name_7">surname:Gitelman;given-names:I.</infon><infon key="name_8">surname:Richardson;given-names:A.</infon><infon key="name_9">surname:Weinberg;given-names:R.A.</infon><infon key="pub-id_doi">10.1016/j.cell.2004.06.006</infon><infon key="pub-id_pmid">15210113</infon><infon key="section_type">REF</infon><infon key="source">Cell</infon><infon key="type">ref</infon><infon key="volume">117</infon><infon key="year">2004</infon><offset>71287</offset><text>Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis</text></passage><passage><infon key="fpage">1477</infon><infon key="lpage">1480</infon><infon key="name_0">surname:Huber;given-names:M.A.</infon><infon key="name_1">surname:Beug;given-names:H.</infon><infon key="name_2">surname:Wirth;given-names:T.</infon><infon key="pub-id_doi">10.4161/cc.3.12.1280</infon><infon key="pub-id_pmid">15539952</infon><infon key="section_type">REF</infon><infon key="source">Cell Cycle</infon><infon key="type">ref</infon><infon key="volume">3</infon><infon key="year">2004</infon><offset>71375</offset><text>Epithelial-mesenchymal transition: NF-kappaB takes center stage</text></passage><passage><infon key="fpage">e231</infon><infon key="name_0">surname:Duran;given-names:C.</infon><infon key="name_1">surname:Lee;given-names:D.</infon><infon key="name_2">surname:Jung;given-names:J.</infon><infon key="name_3">surname:Ravi;given-names:S.</infon><infon key="name_4">surname:Pogue;given-names:C.</infon><infon key="name_5">surname:Toussaint;given-names:L.</infon><infon key="name_6">surname:Bayless;given-names:K.</infon><infon key="name_7">surname:Sitcheran;given-names:R.</infon><infon key="pub-id_doi">10.1038/oncsis.2016.39</infon><infon key="pub-id_pmid">27270613</infon><infon key="section_type">REF</infon><infon key="source">Oncogenesis</infon><infon key="type">ref</infon><infon key="volume">5</infon><infon key="year">2016</infon><offset>71439</offset><text>NIK regulates MT1-MMP activity and promotes glioma cell invasion independently of the canonical NF-kappaB pathway</text></passage><passage><infon key="fpage">725</infon><infon key="lpage">732</infon><infon key="name_0">surname:Xie;given-names:T.-X.</infon><infon key="name_1">surname:Xia;given-names:Z.</infon><infon key="name_2">surname:Zhang;given-names:N.</infon><infon key="name_3">surname:Gong;given-names:W.</infon><infon key="name_4">surname:Huang;given-names:S.</infon><infon key="pub-id_pmid">20127012</infon><infon key="section_type">REF</infon><infon key="source">Oncol. Rep.</infon><infon key="type">ref</infon><infon key="volume">23</infon><infon key="year">2010</infon><offset>71553</offset><text>Constitutive NF-kappaB activity regulates the expression of VEGF and IL-8 and tumor angiogenesis of human glioblastoma</text></passage><passage><infon key="fpage">1624</infon><infon key="lpage">1629</infon><infon key="name_0">surname:Yoshida;given-names:A.</infon><infon key="name_1">surname:Yoshida;given-names:S.</infon><infon key="name_2">surname:Ishibashi;given-names:T.</infon><infon key="name_3">surname:Kuwano;given-names:M.</infon><infon key="name_4">surname:Inomata;given-names:H.</infon><infon key="pub-id_pmid">10359349</infon><infon key="section_type">REF</infon><infon key="source">Investig. Ophthalmol. Vis. Sci.</infon><infon key="type">ref</infon><infon key="volume">40</infon><infon key="year">1999</infon><offset>71672</offset><text>Suppression of retinal neovascularization by the NF-kappaB inhibitor pyrrolidine dithiocarbamate in mice</text></passage><passage><infon key="fpage">71</infon><infon key="lpage">78</infon><infon key="name_0">surname:Pollard;given-names:J.W.</infon><infon key="pub-id_doi">10.1038/nrc1256</infon><infon key="pub-id_pmid">14708027</infon><infon key="section_type">REF</infon><infon key="source">Nat. Rev. Cancer</infon><infon key="type">ref</infon><infon key="volume">4</infon><infon key="year">2004</infon><offset>71777</offset><text>Tumour-educated macrophages promote tumour progression and metastasis</text></passage><passage><infon key="fpage">447</infon><infon key="lpage">458</infon><infon key="name_0">surname:Sparmann;given-names:A.</infon><infon key="name_1">surname:Bar-Sagi;given-names:D.</infon><infon key="pub-id_doi">10.1016/j.ccr.2004.09.028</infon><infon key="pub-id_pmid">15542429</infon><infon key="section_type">REF</infon><infon key="source">Cancer Cell</infon><infon key="type">ref</infon><infon key="volume">6</infon><infon key="year">2004</infon><offset>71847</offset><text>Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis</text></passage><passage><infon key="fpage">710</infon><infon key="lpage">719</infon><infon key="name_0">surname:Schmidt;given-names:D.</infon><infon key="name_1">surname:Textor;given-names:B.</infon><infon key="name_2">surname:Pein;given-names:O.T.</infon><infon key="name_3">surname:Licht;given-names:A.H.</infon><infon key="name_4">surname:Andrecht;given-names:S.</infon><infon key="name_5">surname:Sator-Schmitt;given-names:M.</infon><infon key="name_6">surname:Fusenig;given-names:N.E.</infon><infon key="name_7">surname:Angel;given-names:P.</infon><infon key="name_8">surname:Schorpp-Kistner;given-names:M.</infon><infon key="pub-id_doi">10.1038/sj.emboj.7601539</infon><infon key="pub-id_pmid">17255940</infon><infon key="section_type">REF</infon><infon key="source">EMBO J.</infon><infon key="type">ref</infon><infon key="volume">26</infon><infon key="year">2007</infon><offset>71939</offset><text>Critical role for NF-kappaB-induced JunB in VEGF regulation and tumor angiogenesis</text></passage><passage><infon key="fpage">4727</infon><infon key="lpage">4731</infon><infon key="name_0">surname:Duyao;given-names:M.P.</infon><infon key="name_1">surname:Buckler;given-names:A.J.</infon><infon key="name_2">surname:Sonenshein;given-names:G.E.</infon><infon key="pub-id_doi">10.1073/pnas.87.12.4727</infon><infon key="pub-id_pmid">2191300</infon><infon key="section_type">REF</infon><infon key="source">Proc. Natl. Acad. Sci. USA</infon><infon key="type">ref</infon><infon key="volume">87</infon><infon key="year">1990</infon><offset>72022</offset><text>Interaction of an NF-kappa B-like factor with a site upstream of the c-myc promoter</text></passage><passage><infon key="fpage">16288</infon><infon key="lpage">16291</infon><infon key="name_0">surname:Duyao;given-names:M.</infon><infon key="name_1">surname:Kessler;given-names:D.</infon><infon key="name_2">surname:Spicer;given-names:D.</infon><infon key="name_3">surname:Bartholomew;given-names:C.</infon><infon key="name_4">surname:Cleveland;given-names:J.</infon><infon key="name_5">surname:Siekevitz;given-names:M.</infon><infon key="name_6">surname:Sonenshein;given-names:G.</infon><infon key="pub-id_doi">10.1016/S0021-9258(18)41998-9</infon><infon key="pub-id_pmid">1644814</infon><infon key="section_type">REF</infon><infon key="source">J. Biol. Chem.</infon><infon key="type">ref</infon><infon key="volume">267</infon><infon key="year">1992</infon><offset>72106</offset><text>Transactivation of the c-myc promoter by human T cell leukemia virus type 1 tax is mediated by NF kappa B</text></passage><passage><infon key="fpage">2955</infon><infon key="lpage">2963</infon><infon key="name_0">surname:Kisseleva;given-names:T.</infon><infon key="name_1">surname:Song;given-names:L.</infon><infon key="name_2">surname:Vorontchikhina;given-names:M.</infon><infon key="name_3">surname:Feirt;given-names:N.</infon><infon key="name_4">surname:Kitajewski;given-names:J.</infon><infon key="name_5">surname:Schindler;given-names:C.</infon><infon key="pub-id_doi">10.1172/JCI27392</infon><infon key="pub-id_pmid">17053836</infon><infon key="section_type">REF</infon><infon key="source">J. Clin. Investig.</infon><infon key="type">ref</infon><infon key="volume">116</infon><infon key="year">2006</infon><offset>72212</offset><text>NF-kappaB regulation of endothelial cell function during LPS-induced toxemia and cancer</text></passage><passage><infon key="fpage">527</infon><infon key="lpage">538</infon><infon key="name_0">surname:Chan;given-names:D.A.</infon><infon key="name_1">surname:Kawahara;given-names:T.L.</infon><infon key="name_2">surname:Sutphin;given-names:P.D.</infon><infon key="name_3">surname:Chang;given-names:H.Y.</infon><infon key="name_4">surname:Chi;given-names:J.-T.</infon><infon key="name_5">surname:Giaccia;given-names:A.J.</infon><infon key="pub-id_doi">10.1016/j.ccr.2009.04.010</infon><infon key="pub-id_pmid">19477431</infon><infon key="section_type">REF</infon><infon key="source">Cancer Cell</infon><infon key="type">ref</infon><infon key="volume">15</infon><infon key="year">2009</infon><offset>72300</offset><text>Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment</text></passage><passage><infon key="fpage">322</infon><infon key="lpage">331</infon><infon key="name_0">surname:Rojo;given-names:F.</infon><infon key="name_1">surname:Gonzalez-Perez;given-names:A.</infon><infon key="name_2">surname:Furriol;given-names:J.</infon><infon key="name_3">surname:Nicolau;given-names:M.J.</infon><infon key="name_4">surname:Ferrer;given-names:J.</infon><infon key="name_5">surname:Burgues;given-names:O.</infon><infon key="name_6">surname:Sabbaghi;given-names:M.</infon><infon key="name_7">surname:Gonzalez-Navarrete;given-names:I.</infon><infon key="name_8">surname:Cristobal;given-names:I.</infon><infon key="name_9">surname:Serrano;given-names:L.</infon><infon key="pub-id_doi">10.1038/bjc.2016.204</infon><infon key="pub-id_pmid">27404455</infon><infon key="section_type">REF</infon><infon key="source">Br. J. Cancer</infon><infon key="type">ref</infon><infon key="volume">115</infon><infon key="year">2016</infon><offset>72402</offset><text>Non-canonical NF-kappa B pathway activation predicts outcome in borderline oestrogen receptor positive breast carcinoma</text></passage><passage><infon key="fpage">5191</infon><infon key="name_0">surname:Espinoza-Sanchez;given-names:N.A.</infon><infon key="name_1">surname:Gyorffy;given-names:B.</infon><infon key="name_2">surname:Fuentes-Panana;given-names:E.M.</infon><infon key="name_3">surname:Gotte;given-names:M.</infon><infon key="pub-id_doi">10.7150/jca.34302</infon><infon key="pub-id_pmid">31602271</infon><infon key="section_type">REF</infon><infon key="source">J. Cancer</infon><infon key="type">ref</infon><infon key="volume">10</infon><infon key="year">2019</infon><offset>72522</offset><text>Differential impact of classical and non-canonical NF-kappaB pathway-related gene expression on the survival of breast cancer patients</text></passage><passage><infon key="fpage">415</infon><infon key="lpage">421</infon><infon key="name_0">surname:Qin;given-names:H.</infon><infon key="name_1">surname:Zhou;given-names:J.</infon><infon key="name_2">surname:Zhou;given-names:P.</infon><infon key="name_3">surname:Xu;given-names:J.</infon><infon key="name_4">surname:Tang;given-names:Z.</infon><infon key="name_5">surname:Ma;given-names:H.</infon><infon key="name_6">surname:Guo;given-names:F.</infon><infon key="pub-id_doi">10.1111/1759-7714.12345</infon><infon key="pub-id_pmid">27385983</infon><infon key="section_type">REF</infon><infon key="source">Thorac. Cancer</infon><infon key="type">ref</infon><infon key="volume">7</infon><infon key="year">2016</infon><offset>72657</offset><text>Prognostic significance of RelB overexpression in non-small cell lung cancer patients</text></passage><passage><infon key="fpage">441</infon><infon key="lpage">452</infon><infon key="name_0">surname:Lim;given-names:S.K.</infon><infon key="name_1">surname:Peng;given-names:C.C.</infon><infon key="name_2">surname:Low;given-names:S.</infon><infon key="name_3">surname:Vijay;given-names:V.</infon><infon key="name_4">surname:Budiman;given-names:A.</infon><infon key="name_5">surname:Phang;given-names:B.H.</infon><infon key="name_6">surname:Lim;given-names:J.Q.</infon><infon key="name_7">surname:Jeyasekharan;given-names:A.D.</infon><infon key="name_8">surname:Lim;given-names:S.T.</infon><infon key="name_9">surname:Ong;given-names:C.K.</infon><infon key="pub-id_doi">10.1038/s41375-022-01769-w</infon><infon key="pub-id_pmid">36446947</infon><infon key="section_type">REF</infon><infon key="source">Leukemia</infon><infon key="type">ref</infon><infon key="volume">37</infon><infon key="year">2022</infon><offset>72743</offset><text>Sustained activation of non-canonical NF-kappaB signalling drives glycolytic reprogramming in doxorubicin-resistant DLBCL</text></passage><passage><infon key="fpage">464916</infon><infon key="name_0">surname:Bohlig;given-names:L.</infon><infon key="name_1">surname:Rother;given-names:K.</infon><infon key="pub-id_doi">10.1155/2011/464916</infon><infon key="pub-id_pmid">21436991</infon><infon key="section_type">REF</infon><infon key="source">J. Biomed. Biotechnol.</infon><infon key="type">ref</infon><infon key="volume">2011</infon><infon key="year">2011</infon><offset>72865</offset><text>One function:Multiple mechanisms: The manifold activities of p53 as a transcriptional repressor</text></passage><passage><infon key="fpage">1433</infon><infon key="lpage">1448</infon><infon key="name_0">surname:Perkins;given-names:N.D.</infon><infon key="pub-id_doi">10.1016/S1357-2725(97)00088-5</infon><infon key="pub-id_pmid">9570137</infon><infon key="section_type">REF</infon><infon key="source">Int. J. Biochem. Cell Biol.</infon><infon key="type">ref</infon><infon key="volume">29</infon><infon key="year">1997</infon><offset>72963</offset><text>Achieving transcriptional specificity with NF-kappaB</text></passage><passage><infon key="fpage">327</infon><infon key="lpage">334</infon><infon key="name_0">surname:Wang;given-names:S.</infon><infon key="name_1">surname:Liu;given-names:Z.</infon><infon key="name_2">surname:Wang;given-names:L.</infon><infon key="name_3">surname:Zhang;given-names:X.</infon><infon key="pub-id_doi">10.1038/cmi.2009.43</infon><infon key="pub-id_pmid">19887045</infon><infon key="section_type">REF</infon><infon key="source">Cell. Mol. Immunol.</infon><infon key="type">ref</infon><infon key="volume">6</infon><infon key="year">2009</infon><offset>73016</offset><text>NF-kappaB signaling pathway, inflammation and colorectal cancer</text></passage><passage><infon key="fpage">285</infon><infon key="lpage">296</infon><infon key="name_0">surname:Greten;given-names:F.R.</infon><infon key="name_1">surname:Eckmann;given-names:L.</infon><infon key="name_2">surname:Greten;given-names:T.F.</infon><infon key="name_3">surname:Park;given-names:J.M.</infon><infon key="name_4">surname:Li;given-names:Z.-W.</infon><infon key="name_5">surname:Egan;given-names:L.J.</infon><infon key="name_6">surname:Kagnoff;given-names:M.F.</infon><infon key="name_7">surname:Karin;given-names:M.</infon><infon key="pub-id_doi">10.1016/j.cell.2004.07.013</infon><infon key="pub-id_pmid">15294155</infon><infon key="section_type">REF</infon><infon key="source">Cell</infon><infon key="type">ref</infon><infon key="volume">118</infon><infon key="year">2004</infon><offset>73080</offset><text>IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer</text></passage><passage><infon key="fpage">26115</infon><infon key="lpage">26125</infon><infon key="name_0">surname:Bohuslav;given-names:J.</infon><infon key="name_1">surname:Chen;given-names:L.-f.</infon><infon key="name_2">surname:Kwon;given-names:H.</infon><infon key="name_3">surname:Mu;given-names:Y.</infon><infon key="name_4">surname:Greene;given-names:W.C.</infon><infon key="pub-id_doi">10.1074/jbc.M313509200</infon><infon key="pub-id_pmid">15073170</infon><infon key="section_type">REF</infon><infon key="source">J. Biol. Chem.</infon><infon key="type">ref</infon><infon key="volume">279</infon><infon key="year">2004</infon><offset>73171</offset><text>p53 induces NF-kappaB activation by an IkappaB kinase-independent mechanism involving phosphorylation of p65 by ribosomal S6 kinase 1</text></passage><passage><infon key="fpage">3485</infon><infon key="lpage">3495</infon><infon key="name_0">surname:Webster;given-names:G.A.</infon><infon key="name_1">surname:Perkins;given-names:N.D.</infon><infon key="pub-id_doi">10.1128/MCB.19.5.3485</infon><infon key="pub-id_pmid">10207072</infon><infon key="section_type">REF</infon><infon key="source">Mol. Cell. Biol.</infon><infon key="type">ref</infon><infon key="volume">19</infon><infon key="year">1999</infon><offset>73305</offset><text>Transcriptional cross talk between NF-kappaB and p53</text></passage><passage><infon key="fpage">79</infon><infon key="lpage">88</infon><infon key="name_0">surname:Vaughan;given-names:C.A.</infon><infon key="name_1">surname:Singh;given-names:S.</infon><infon key="name_2">surname:Windle;given-names:B.</infon><infon key="name_3">surname:Sankala;given-names:H.M.</infon><infon key="name_4">surname:Graves;given-names:P.R.</infon><infon key="name_5">surname:Yeudall;given-names:W.A.</infon><infon key="name_6">surname:Deb;given-names:S.P.</infon><infon key="name_7">surname:Deb;given-names:S.</infon><infon key="pub-id_doi">10.1016/j.abb.2011.12.006</infon><infon key="pub-id_pmid">22198284</infon><infon key="section_type">REF</infon><infon key="source">Arch. Biochem. Biophys.</infon><infon key="type">ref</infon><infon key="volume">518</infon><infon key="year">2012</infon><offset>73358</offset><text>p53 mutants induce transcription of NF-kappaB2 in H1299 cells through CBP and STAT binding on the NF-kappaB2 promoter and gain of function activity</text></passage><passage><infon key="fpage">549</infon><infon key="lpage">557</infon><infon key="name_0">surname:Chen;given-names:L.-F.</infon><infon key="name_1">surname:Greene;given-names:W.C.</infon><infon key="pub-id_doi">10.1007/s00109-003-0469-0</infon><infon key="pub-id_pmid">12920522</infon><infon key="section_type">REF</infon><infon key="source">J. Mol. Med.</infon><infon key="type">ref</infon><infon key="volume">81</infon><infon key="year">2003</infon><offset>73506</offset><text>Regulation of distinct biological activities of the NF-kappaB transcription factor complex by acetylation</text></passage><passage><infon key="fpage">7780</infon><infon key="lpage">7791</infon><infon key="name_0">surname:Kim;given-names:J.-W.</infon><infon key="name_1">surname:Jang;given-names:S.-M.</infon><infon key="name_2">surname:Kim;given-names:C.-H.</infon><infon key="name_3">surname:An;given-names:J.-H.</infon><infon key="name_4">surname:Kang;given-names:E.-J.</infon><infon key="name_5">surname:Choi;given-names:K.-H.</infon><infon key="pub-id_doi">10.1074/jbc.M111.278465</infon><infon key="pub-id_pmid">22249179</infon><infon key="section_type">REF</infon><infon key="source">J. Biol. Chem.</infon><infon key="type">ref</infon><infon key="volume">287</infon><infon key="year">2012</infon><offset>73612</offset><text>New molecular bridge between RelA/p65 and NF-kappaB target genes via histone acetyltransferase TIP60 cofactor</text></passage><passage><infon key="fpage">782</infon><infon key="lpage">784</infon><infon key="name_0">surname:Beg;given-names:A.A.</infon><infon key="name_1">surname:Baltimore;given-names:D.</infon><infon key="pub-id_doi">10.1126/science.274.5288.782</infon><infon key="pub-id_pmid">8864118</infon><infon key="section_type">REF</infon><infon key="source">Science</infon><infon key="type">ref</infon><infon key="volume">274</infon><infon key="year">1996</infon><offset>73722</offset><text>An essential role for NF-kappaB in preventing TNF-alpha-induced cell death</text></passage><passage><infon key="fpage">2795</infon><infon key="lpage">2806</infon><infon key="name_0">surname:Schneider;given-names:G.</infon><infon key="name_1">surname:Henrich;given-names:A.</infon><infon key="name_2">surname:Greiner;given-names:G.</infon><infon key="name_3">surname:Wolf;given-names:V.</infon><infon key="name_4">surname:Lovas;given-names:A.</infon><infon key="name_5">surname:Wieczorek;given-names:M.</infon><infon key="name_6">surname:Wagner;given-names:T.</infon><infon key="name_7">surname:Reichardt;given-names:S.</infon><infon key="name_8">surname:Von Werder;given-names:A.</infon><infon key="name_9">surname:Schmid;given-names:R.</infon><infon key="pub-id_doi">10.1038/onc.2010.46</infon><infon key="pub-id_pmid">20190799</infon><infon key="section_type">REF</infon><infon key="source">Oncogene</infon><infon key="type">ref</infon><infon key="volume">29</infon><infon key="year">2010</infon><offset>73797</offset><text>Cross talk between stimulated NF-kappaB and the tumor suppressor p53</text></passage><passage><infon key="fpage">2865</infon><infon key="lpage">2868</infon><infon key="name_0">surname:Ichikawa;given-names:H.</infon><infon key="name_1">surname:Shimizu;given-names:K.</infon><infon key="name_2">surname:Hayashi;given-names:Y.</infon><infon key="name_3">surname:Ohki;given-names:M.</infon><infon key="pub-id_pmid">8187069</infon><infon key="section_type">REF</infon><infon key="source">Cancer Res.</infon><infon key="type">ref</infon><infon key="volume">54</infon><infon key="year">1994</infon><offset>73866</offset><text>An RNA-binding protein gene, TLS/FUS, is fused to ERG in human myeloid leukemia with t (16; 21) chromosomal translocation</text></passage><passage><infon key="fpage">3717</infon><infon key="lpage">3729</infon><infon key="name_0">surname:Prasad;given-names:D.</infon><infon key="name_1">surname:Ouchida;given-names:M.</infon><infon key="name_2">surname:Lee;given-names:L.</infon><infon key="name_3">surname:Rao;given-names:V.N.</infon><infon key="name_4">surname:Reddy;given-names:E.</infon><infon key="pub-id_pmid">7970732</infon><infon key="section_type">REF</infon><infon key="source">Oncogene</infon><infon key="type">ref</infon><infon key="volume">9</infon><infon key="year">1994</infon><offset>73988</offset><text>TLS/FUS fusion domain of TLS/FUS-erg chimeric protein resulting from the t (16; 21) chromosomal translocation in human myeloid leukemia functions as a transcriptional activation domain</text></passage><passage><infon key="fpage">146</infon><infon key="lpage">151</infon><infon key="name_0">surname:Sorensen;given-names:P.H.</infon><infon key="name_1">surname:Lessnick;given-names:S.L.</infon><infon key="name_2">surname:Lopez-Terrada;given-names:D.</infon><infon key="name_3">surname:Liu;given-names:X.F.</infon><infon key="name_4">surname:Triche;given-names:T.J.</infon><infon key="name_5">surname:Denny;given-names:C.T.</infon><infon key="pub-id_doi">10.1038/ng0294-146</infon><infon key="pub-id_pmid">8162068</infon><infon key="section_type">REF</infon><infon key="source">Nat. Genet.</infon><infon key="type">ref</infon><infon key="volume">6</infon><infon key="year">1994</infon><offset>74173</offset><text>A second Ewing's sarcoma translocation, t (21; 22), fuses the EWS gene to another ETS-family transcription factor, ERG</text></passage><passage><infon key="fpage">644</infon><infon key="lpage">648</infon><infon key="name_0">surname:Tomlins;given-names:S.A.</infon><infon key="name_1">surname:Rhodes;given-names:D.R.</infon><infon key="name_2">surname:Perner;given-names:S.</infon><infon key="name_3">surname:Dhanasekaran;given-names:S.M.</infon><infon key="name_4">surname:Mehra;given-names:R.</infon><infon key="name_5">surname:Sun;given-names:X.-W.</infon><infon key="name_6">surname:Varambally;given-names:S.</infon><infon key="name_7">surname:Cao;given-names:X.</infon><infon key="name_8">surname:Tchinda;given-names:J.</infon><infon key="name_9">surname:Kuefer;given-names:R.</infon><infon key="pub-id_doi">10.1126/science.1117679</infon><infon key="pub-id_pmid">16254181</infon><infon key="section_type">REF</infon><infon key="source">Science</infon><infon key="type">ref</infon><infon key="volume">310</infon><infon key="year">2005</infon><offset>74296</offset><text>Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer</text></passage><passage><infon key="fpage">12331</infon><infon key="lpage">12342</infon><infon key="name_0">surname:Dryden;given-names:N.H.</infon><infon key="name_1">surname:Sperone;given-names:A.</infon><infon key="name_2">surname:Martin-Almedina;given-names:S.</infon><infon key="name_3">surname:Hannah;given-names:R.L.</infon><infon key="name_4">surname:Birdsey;given-names:G.M.</infon><infon key="name_5">surname:Khan;given-names:S.T.</infon><infon key="name_6">surname:Layhadi;given-names:J.A.</infon><infon key="name_7">surname:Mason;given-names:J.C.</infon><infon key="name_8">surname:Haskard;given-names:D.O.</infon><infon key="name_9">surname:Gottgens;given-names:B.</infon><infon key="pub-id_doi">10.1074/jbc.M112.346791</infon><infon key="pub-id_pmid">22337883</infon><infon key="section_type">REF</infon><infon key="source">J. Biol. Chem.</infon><infon key="type">ref</infon><infon key="volume">287</infon><infon key="year">2012</infon><offset>74378</offset><text>The transcription factor Erg controls endothelial cell quiescence by repressing activity of nuclear factor (NF)-kappaB p65</text></passage><passage><infon key="fpage">1325</infon><infon key="lpage">1333</infon><infon key="name_0">surname:Wang;given-names:J.</infon><infon key="name_1">surname:Cai;given-names:Y.</infon><infon key="name_2">surname:Shao;given-names:L.-j.</infon><infon key="name_3">surname:Siddiqui;given-names:J.</infon><infon key="name_4">surname:Palanisamy;given-names:N.</infon><infon key="name_5">surname:Li;given-names:R.</infon><infon key="name_6">surname:Ren;given-names:C.</infon><infon key="name_7">surname:Ayala;given-names:G.</infon><infon key="name_8">surname:Ittmann;given-names:M.</infon><infon key="pub-id_doi">10.1158/0008-5472.CAN-10-2210</infon><infon key="pub-id_pmid">21169414</infon><infon key="section_type">REF</infon><infon key="source">Cancer Res.</infon><infon key="type">ref</infon><infon key="volume">71</infon><infon key="year">2011</infon><offset>74501</offset><text>Activation of NF-kappaB by TMPRSS2/ERG fusion isoforms through Toll-like receptor-4</text></passage><passage><infon key="fpage">195-IN191</infon><infon key="name_0">surname:Cai;given-names:J.</infon><infon key="name_1">surname:Kandagatla;given-names:P.</infon><infon key="name_2">surname:Singareddy;given-names:R.</infon><infon key="name_3">surname:Kropinski;given-names:A.</infon><infon key="name_4">surname:Sheng;given-names:S.</infon><infon key="name_5">surname:Cher;given-names:M.L.</infon><infon key="name_6">surname:Chinni;given-names:S.R.</infon><infon key="pub-id_doi">10.1593/tlo.09328</infon><infon key="pub-id_pmid">20563261</infon><infon key="section_type">REF</infon><infon key="source">Transl. Oncol.</infon><infon key="type">ref</infon><infon key="volume">3</infon><infon key="year">2010</infon><offset>74585</offset><text>Androgens induce functional CXCR4 through ERG factor expression in TMPRSS2-ERG fusion-positive prostate cancer cells</text></passage><passage><infon key="comment">bioRxiv 2023.2001</infon><infon key="name_0">surname:Sim;given-names:N.</infon><infon key="name_1">surname:Li;given-names:Y.</infon><infon key="pub-id_doi">10.1101/2023.01.11.523507</infon><infon key="section_type">REF</infon><infon key="source">bioRxiv</infon><infon key="type">ref</infon><infon key="year">2023</infon><offset>74702</offset><text>NF-kappaB/p52 augments ETS1 binding genome-wide to promote glioma progression</text></passage><passage><infon key="fpage">281</infon><infon key="lpage">297</infon><infon key="name_0">surname:Bartel;given-names:D.P.</infon><infon key="pub-id_doi">10.1016/S0092-8674(04)00045-5</infon><infon key="pub-id_pmid">14744438</infon><infon key="section_type">REF</infon><infon key="source">Cell</infon><infon key="type">ref</infon><infon key="volume">116</infon><infon key="year">2004</infon><offset>74780</offset><text>MicroRNAs: Genomics, biogenesis, mechanism, and function</text></passage><passage><infon key="fpage">5282</infon><infon key="lpage">5287</infon><infon key="name_0">surname:Bazzoni;given-names:F.</infon><infon key="name_1">surname:Rossato;given-names:M.</infon><infon key="name_2">surname:Fabbri;given-names:M.</infon><infon key="name_3">surname:Gaudiosi;given-names:D.</infon><infon key="name_4">surname:Mirolo;given-names:M.</infon><infon key="name_5">surname:Mori;given-names:L.</infon><infon key="name_6">surname:Tamassia;given-names:N.</infon><infon key="name_7">surname:Mantovani;given-names:A.</infon><infon key="name_8">surname:Cassatella;given-names:M.A.</infon><infon key="name_9">surname:Locati;given-names:M.</infon><infon key="pub-id_doi">10.1073/pnas.0810909106</infon><infon key="pub-id_pmid">19289835</infon><infon key="section_type">REF</infon><infon key="source">Proc. Natl. Acad. Sci. USA</infon><infon key="type">ref</infon><infon key="volume">106</infon><infon key="year">2009</infon><offset>74837</offset><text>Induction and regulatory function of miR-9 in human monocytes and neutrophils exposed to proinflammatory signals</text></passage><passage><infon key="fpage">24463</infon><infon key="name_0">surname:Fesler;given-names:A.</infon><infon key="name_1">surname:Xu;given-names:X.</infon><infon key="name_2">surname:Zheng;given-names:X.</infon><infon key="name_3">surname:Li;given-names:X.</infon><infon key="name_4">surname:Jiang;given-names:J.</infon><infon key="name_5">surname:Russo;given-names:J.J.</infon><infon key="name_6">surname:Ju;given-names:J.</infon><infon key="pub-id_doi">10.18632/oncotarget.4425</infon><infon key="pub-id_pmid">26287603</infon><infon key="section_type">REF</infon><infon key="source">Oncotarget</infon><infon key="type">ref</infon><infon key="volume">6</infon><infon key="year">2015</infon><offset>74950</offset><text>Identification of miR-215 mediated targets/pathways via translational immunoprecipitation expression analysis (TrIP-chip)</text></passage><passage><infon key="fpage">21783</infon><infon key="lpage">21795</infon><infon key="name_0">surname:Niu;given-names:J.</infon><infon key="name_1">surname:Shi;given-names:Y.</infon><infon key="name_2">surname:Tan;given-names:G.</infon><infon key="name_3">surname:Yang;given-names:C.H.</infon><infon key="name_4">surname:Fan;given-names:M.</infon><infon key="name_5">surname:Pfeffer;given-names:L.M.</infon><infon key="name_6">surname:Wu;given-names:Z.-H.</infon><infon key="pub-id_doi">10.1074/jbc.M112.355495</infon><infon key="pub-id_pmid">22547075</infon><infon key="section_type">REF</infon><infon key="source">J. Biol. Chem.</infon><infon key="type">ref</infon><infon key="volume">287</infon><infon key="year">2012</infon><offset>75072</offset><text>DNA Damage Induces NF-kappaB-Dependent microRNA-21 up-Regulation and Promotes Breast Cancer Cell Invasion</text></passage><passage><infon key="fpage">490</infon><infon key="lpage">499</infon><infon key="name_0">surname:Zhang;given-names:X.</infon><infon key="name_1">surname:Liu;given-names:S.</infon><infon key="name_2">surname:Hu;given-names:T.</infon><infon key="name_3">surname:Liu;given-names:S.</infon><infon key="name_4">surname:He;given-names:Y.</infon><infon key="name_5">surname:Sun;given-names:S.</infon><infon key="pub-id_doi">10.1002/hep.23008</infon><infon key="pub-id_pmid">19472311</infon><infon key="section_type">REF</infon><infon key="source">Hepatology</infon><infon key="type">ref</infon><infon key="volume">50</infon><infon key="year">2009</infon><offset>75178</offset><text>Up-regulated microRNA-143 transcribed by nuclear factor kappa B enhances hepatocarcinoma metastasis by repressing fibronectin expression</text></passage><passage><infon key="fpage">12481</infon><infon key="lpage">12486</infon><infon key="name_0">surname:Taganov;given-names:K.D.</infon><infon key="name_1">surname:Boldin;given-names:M.P.</infon><infon key="name_2">surname:Chang;given-names:K.-J.</infon><infon key="name_3">surname:Baltimore;given-names:D.</infon><infon key="pub-id_doi">10.1073/pnas.0605298103</infon><infon key="pub-id_pmid">16885212</infon><infon key="section_type">REF</infon><infon key="source">Proc. Natl. Acad. Sci. USA</infon><infon key="type">ref</infon><infon key="volume">103</infon><infon key="year">2006</infon><offset>75315</offset><text>NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses</text></passage><passage><infon key="fpage">855</infon><infon key="lpage">861</infon><infon key="name_0">surname:Scisciani;given-names:C.</infon><infon key="name_1">surname:Vossio;given-names:S.</infon><infon key="name_2">surname:Guerrieri;given-names:F.</infon><infon key="name_3">surname:Schinzari;given-names:V.</infon><infon key="name_4">surname:De Iaco;given-names:R.</infon><infon key="name_5">surname:de Meo;given-names:P.D.O.</infon><infon key="name_6">surname:Cervello;given-names:M.</infon><infon key="name_7">surname:Montalto;given-names:G.</infon><infon key="name_8">surname:Pollicino;given-names:T.</infon><infon key="name_9">surname:Raimondo;given-names:G.</infon><infon key="pub-id_doi">10.1016/j.jhep.2011.11.017</infon><infon key="pub-id_pmid">22178270</infon><infon key="section_type">REF</infon><infon key="source">J. Hepatol.</infon><infon key="type">ref</infon><infon key="volume">56</infon><infon key="year">2012</infon><offset>75437</offset><text>Transcriptional regulation of miR-224 upregulated in human HCCs by NFkappaB inflammatory pathways</text></passage><passage><infon key="fpage">693</infon><infon key="lpage">706</infon><infon key="name_0">surname:Iliopoulos;given-names:D.</infon><infon key="name_1">surname:Hirsch;given-names:H.A.</infon><infon key="name_2">surname:Struhl;given-names:K.</infon><infon key="pub-id_doi">10.1016/j.cell.2009.10.014</infon><infon key="pub-id_pmid">19878981</infon><infon key="section_type">REF</infon><infon key="source">Cell</infon><infon key="type">ref</infon><infon key="volume">139</infon><infon key="year">2009</infon><offset>75535</offset><text>An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation</text></passage><passage><infon key="fpage">3607</infon><infon key="lpage">3620</infon><infon key="name_0">surname:Zhang;given-names:S.</infon><infon key="name_1">surname:Shan;given-names:C.</infon><infon key="name_2">surname:Kong;given-names:G.</infon><infon key="name_3">surname:Du;given-names:Y.</infon><infon key="name_4">surname:Ye;given-names:L.</infon><infon key="name_5">surname:Zhang;given-names:X.</infon><infon key="pub-id_doi">10.1038/onc.2011.523</infon><infon key="pub-id_pmid">22105365</infon><infon key="section_type">REF</infon><infon key="source">Oncogene</infon><infon key="type">ref</infon><infon key="volume">31</infon><infon key="year">2012</infon><offset>75650</offset><text>MicroRNA-520e suppresses growth of hepatoma cells by targeting the NF-kappaB-inducing kinase (NIK)</text></passage><passage><infon key="fpage">370</infon><infon key="lpage">381</infon><infon key="name_0">surname:Liu;given-names:B.</infon><infon key="name_1">surname:Sun;given-names:L.</infon><infon key="name_2">surname:Liu;given-names:Q.</infon><infon key="name_3">surname:Gong;given-names:C.</infon><infon key="name_4">surname:Yao;given-names:Y.</infon><infon key="name_5">surname:Lv;given-names:X.</infon><infon key="name_6">surname:Lin;given-names:L.</infon><infon key="name_7">surname:Yao;given-names:H.</infon><infon key="name_8">surname:Su;given-names:F.</infon><infon key="name_9">surname:Li;given-names:D.</infon><infon key="pub-id_doi">10.1016/j.ccell.2015.02.004</infon><infon key="pub-id_pmid">25759022</infon><infon key="section_type">REF</infon><infon key="source">Cancer Cell</infon><infon key="type">ref</infon><infon key="volume">27</infon><infon key="year">2015</infon><offset>75749</offset><text>A cytoplasmic NF-kappaB interacting long noncoding RNA blocks IkappaB phosphorylation and suppresses breast cancer metastasis</text></passage><passage><infon key="fpage">7313</infon><infon key="lpage">7318</infon><infon key="name_0">surname:Liao;given-names:Z.</infon><infon key="name_1">surname:Zhao;given-names:J.</infon><infon key="name_2">surname:Yang;given-names:Y.</infon><infon key="pub-id_doi">10.3892/mmr.2018.8782</infon><infon key="pub-id_pmid">29568965</infon><infon key="section_type">REF</infon><infon key="source">Mol. Med. Rep.</infon><infon key="type">ref</infon><infon key="volume">17</infon><infon key="year">2018</infon><offset>75875</offset><text>Downregulation of lncRNA H19 inhibits the migration and invasion of melanoma cells by inactivating the NF-kappaB and PI3K/Akt signaling pathways</text></passage><passage><infon key="fpage">1</infon><infon key="lpage">8</infon><infon key="name_0">surname:Zhang;given-names:Y.</infon><infon key="name_1">surname:Yan;given-names:J.</infon><infon key="name_2">surname:Li;given-names:C.</infon><infon key="name_3">surname:Wang;given-names:X.</infon><infon key="name_4">surname:Dong;given-names:Y.</infon><infon key="name_5">surname:Shen;given-names:X.</infon><infon key="name_6">surname:Zhang;given-names:X.</infon><infon key="pub-id_doi">10.1186/s12950-019-0226-y</infon><infon key="pub-id_pmid">31787851</infon><infon key="section_type">REF</infon><infon key="source">J. Inflamm.</infon><infon key="type">ref</infon><infon key="volume">16</infon><infon key="year">2019</infon><offset>76020</offset><text>LncRNA H19 induced by helicobacter pylori infection promotes gastric cancer cell growth via enhancing NF-kappaB-induced inflammation</text></passage><passage><infon key="fpage">3265</infon><infon key="name_0">surname:Shen;given-names:X.</infon><infon key="name_1">surname:Zhao;given-names:W.</infon><infon key="name_2">surname:Zhang;given-names:Y.</infon><infon key="name_3">surname:Liang;given-names:B.</infon><infon key="pub-id_doi">10.2147/OTT.S220306</infon><infon key="section_type">REF</infon><infon key="source">OncoTargets Ther.</infon><infon key="type">ref</infon><infon key="volume">13</infon><infon key="year">2020</infon><offset>76153</offset><text>Long non-coding RNA-NEAT1 promotes cell migration and invasion via regulating miR-124/NF-kappaB pathway in cervical cancer</text></passage><passage><infon key="fpage">1</infon><infon key="lpage">14</infon><infon key="name_0">surname:Pan;given-names:Y.</infon><infon key="name_1">surname:Zhang;given-names:Y.</infon><infon key="name_2">surname:Liu;given-names:W.</infon><infon key="name_3">surname:Huang;given-names:Y.</infon><infon key="name_4">surname:Shen;given-names:X.</infon><infon key="name_5">surname:Jing;given-names:R.</infon><infon key="name_6">surname:Pu;given-names:J.</infon><infon key="name_7">surname:Wang;given-names:X.</infon><infon key="name_8">surname:Ju;given-names:S.</infon><infon key="name_9">surname:Cong;given-names:H.</infon><infon key="pub-id_doi">10.1038/s41419-018-1219-0</infon><infon key="section_type">REF</infon><infon key="source">Cell Death Dis.</infon><infon key="type">ref</infon><infon key="volume">10</infon><infon key="year">2019</infon><offset>76276</offset><text>LncRNA H19 overexpression induces bortezomib resistance in multiple myeloma by targeting MCL-1 via miR-29b-3p</text></passage><passage><infon key="fpage">e22008</infon><infon key="name_0">surname:Wu;given-names:Y.</infon><infon key="name_1">surname:Wang;given-names:H.</infon><infon key="pub-id_doi">10.1002/jbt.22008</infon><infon key="section_type">REF</infon><infon key="source">J. Biochem. Mol. Toxicol.</infon><infon key="type">ref</infon><infon key="volume">32</infon><infon key="year">2018</infon><offset>76386</offset><text>LncRNA NEAT1 promotes dexamethasone resistance in multiple myeloma by targeting miR-193a/MCL1 pathway</text></passage><passage><infon key="fpage">21951</infon><infon key="lpage">21960</infon><infon key="name_0">surname:Tando;given-names:T.</infon><infon key="name_1">surname:Ishizaka;given-names:A.</infon><infon key="name_2">surname:Watanabe;given-names:H.</infon><infon key="name_3">surname:Ito;given-names:T.</infon><infon key="name_4">surname:Iida;given-names:S.</infon><infon key="name_5">surname:Haraguchi;given-names:T.</infon><infon key="name_6">surname:Mizutani;given-names:T.</infon><infon key="name_7">surname:Izumi;given-names:T.</infon><infon key="name_8">surname:Isobe;given-names:T.</infon><infon key="name_9">surname:Akiyama;given-names:T.</infon><infon key="pub-id_doi">10.1074/jbc.M109.087783</infon><infon key="pub-id_pmid">20460684</infon><infon key="section_type">REF</infon><infon key="source">J. Biol. Chem.</infon><infon key="type">ref</infon><infon key="volume">285</infon><infon key="year">2010</infon><offset>76488</offset><text>Requiem protein links RelB/p52 and the Brm-type SWI/SNF complex in a noncanonical NF-kappaB pathway</text></passage><passage><infon key="fpage">2735</infon><infon key="lpage">2745</infon><infon key="name_0">surname:De Donatis;given-names:G.</infon><infon key="name_1">surname:Pape;given-names:E.</infon><infon key="name_2">surname:Pierron;given-names:A.</infon><infon key="name_3">surname:Cheli;given-names:Y.</infon><infon key="name_4">surname:Hofman;given-names:V.</infon><infon key="name_5">surname:Hofman;given-names:P.</infon><infon key="name_6">surname:Allegra;given-names:M.</infon><infon key="name_7">surname:Zahaf;given-names:K.</infon><infon key="name_8">surname:Bahadoran;given-names:P.</infon><infon key="name_9">surname:Rocchi;given-names:S.</infon><infon key="pub-id_doi">10.1038/onc.2015.331</infon><infon key="pub-id_pmid">26364600</infon><infon key="section_type">REF</infon><infon key="source">Oncogene</infon><infon key="type">ref</infon><infon key="volume">35</infon><infon key="year">2016</infon><offset>76588</offset><text>NF-kB2 induces senescence bypass in melanoma via a direct transcriptional activation of EZH2</text></passage><passage><infon key="fpage">7551</infon><infon key="lpage">7562</infon><infon key="name_0">surname:Lee;given-names:J.-H.</infon><infon key="name_1">surname:Kang;given-names:M.-J.</infon><infon key="name_2">surname:Han;given-names:H.-Y.</infon><infon key="name_3">surname:Lee;given-names:M.-G.</infon><infon key="name_4">surname:Jeong;given-names:S.-I.</infon><infon key="name_5">surname:Ryu;given-names:B.-K.</infon><infon key="name_6">surname:Ha;given-names:T.-K.</infon><infon key="name_7">surname:Her;given-names:N.-G.</infon><infon key="name_8">surname:Han;given-names:J.</infon><infon key="name_9">surname:Park;given-names:S.J.</infon><infon key="pub-id_doi">10.1158/1078-0432.CCR-11-1026</infon><infon key="pub-id_pmid">21980136</infon><infon key="section_type">REF</infon><infon key="source">Clin. Cancer Res.</infon><infon key="type">ref</infon><infon key="volume">17</infon><infon key="year">2011</infon><offset>76681</offset><text>Epigenetic alteration of PRKCDBP in colorectal cancers and its implication in tumor cell resistance to TNFalpha-induced apoptosis</text></passage><passage><infon key="fpage">750</infon><infon key="lpage">760</infon><infon key="name_0">surname:van Essen;given-names:D.</infon><infon key="name_1">surname:Zhu;given-names:Y.</infon><infon key="name_2">surname:Saccani;given-names:S.</infon><infon key="pub-id_doi">10.1016/j.molcel.2010.08.010</infon><infon key="pub-id_pmid">20832726</infon><infon key="section_type">REF</infon><infon key="source">Mol. Cell</infon><infon key="type">ref</infon><infon key="volume">39</infon><infon key="year">2010</infon><offset>76811</offset><text>A feed-forward circuit controlling inducible NF-kappaB target gene activation by promoter histone demethylation</text></passage><passage><infon key="fpage">2219</infon><infon key="lpage">2224</infon><infon key="name_0">surname:Saccani;given-names:S.</infon><infon key="name_1">surname:Natoli;given-names:G.</infon><infon key="pub-id_doi">10.1101/gad.232502</infon><infon key="pub-id_pmid">12208844</infon><infon key="section_type">REF</infon><infon key="source">Genes Dev. Biol.</infon><infon key="type">ref</infon><infon key="volume">16</infon><infon key="year">2002</infon><offset>76923</offset><text>Dynamic changes in histone H3 Lys 9 methylation occurring at tightly regulated inducible inflammatory genes</text></passage><passage><infon key="fpage">129</infon><infon key="lpage">145</infon><infon key="name_0">surname:Hargreaves;given-names:D.C.</infon><infon key="name_1">surname:Horng;given-names:T.</infon><infon key="name_2">surname:Medzhitov;given-names:R.</infon><infon key="pub-id_doi">10.1016/j.cell.2009.05.047</infon><infon key="pub-id_pmid">19596240</infon><infon key="section_type">REF</infon><infon key="source">Cell</infon><infon key="type">ref</infon><infon key="volume">138</infon><infon key="year">2009</infon><offset>77031</offset><text>Control of inducible gene expression by signal-dependent transcriptional elongation</text></passage><passage><infon key="file">cells-12-00788-g001.jpg</infon><infon key="id">cells-12-00788-f001</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>77115</offset><text>Aberrant activation and transcriptional regulation of NF-kappaB pathway in cancer. In addition to constitutive activator molecules of both the canonical and non-canonical NF-kappaB pathway (highlighted in grey box), activation of the NF-kappaB pathway in cancer occurs via various other factors involving cytokines like TNF-alpha, IL-1, IL-17 secreted by tumour-associated macrophages (TAMs) and oncogenic driver mutations in various regulatory factors of the pathway (highlighted in pink box). Upon such activation, the activated NF-kappaB subunits interact with pro-tumorigenic transcription factors (highlighted in red oval), causing activation of alternative target genes associated with tumour promotion phenotypes, angiogenesis and tumour-associated non-coding RNAs.</text></passage><passage><infon key="file">cells-12-00788-g002.jpg</infon><infon key="id">cells-12-00788-f002</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>77888</offset><text>Graphical summary of the mode of activation of oncogenic pathways by NF-kappaB signalling cascade via direct (bottom panel) and indirect (upper panel) interaction/regulations of various macromolecular components and factors.</text></passage><passage><infon key="file">cells-12-00788-t001.xml</infon><infon key="id">cells-12-00788-t001</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>78113</offset><text>Summarized table of alteration of different components of NF-kappaB pathway in different cancer types (HCC: Human Colorectal Carcinoma; FLHCC: Fibrolamellar Hepatocellular Carcinoma; GBM: Glioblastoma Multiforme; MM: Multiple Myeloma; DLBCL: Diffuse large B-cell lymphoma; PMBL: Primary Mediastinal B-cell Lymphoma; ABC-DLBCL: Activated B-cell-like Diffuse large B-cell Lymphoma; PEL: Primary Effusion Lymphoma; ALT: Adult T-cell Lymphoma/Leukemia).</text></passage><passage><infon key="file">cells-12-00788-t001.xml</infon><infon key="id">cells-12-00788-t001</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th align=&quot;left&quot; valign=&quot;middle&quot; style=&quot;border-top:solid thin;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Factors of NF-kappaB Pathway and Alterations&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-top:solid thin;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Cancer Type&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-top:solid thin;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;References&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;RelA (p65)&lt;list list-type=&quot;bullet&quot;&gt;&lt;list-item&gt;&lt;p&gt;Higher expression and activation of p65 in tumour tissue compared to normal tissue&lt;/p&gt;&lt;/list-item&gt;&lt;/list&gt;&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;HCC, FLHCC, Breast cancer cell lines&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;xref rid=&quot;B105-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;105&lt;/xref&gt;&lt;xref rid=&quot;B114-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;114&lt;/xref&gt;&lt;xref rid=&quot;B115-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;115&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;RelB&lt;list list-type=&quot;bullet&quot;&gt;&lt;list-item&gt;&lt;p&gt;Frequent activation of RelB leading to non-canonical NF-kappaB pathway activation&lt;/p&gt;&lt;/list-item&gt;&lt;/list&gt;&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;GBM, MM, DLBCL&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;xref rid=&quot;B113-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;113&lt;/xref&gt;&lt;xref rid=&quot;B116-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;116&lt;/xref&gt;&lt;xref rid=&quot;B117-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;117&lt;/xref&gt;&lt;xref rid=&quot;B118-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;118&lt;/xref&gt;&lt;xref rid=&quot;B119-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;119&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;c-Rel&lt;list list-type=&quot;bullet&quot;&gt;&lt;list-item&gt;&lt;p&gt;Gain of chromosomal material (9p) leading enhanced expression of &lt;italic toggle=&quot;yes&quot;&gt;c-Rel&lt;/italic&gt;&lt;/p&gt;&lt;/list-item&gt;&lt;list-item&gt;&lt;p&gt;Gain of 2p leading to nuclear accumulation of c-Rel&lt;/p&gt;&lt;/list-item&gt;&lt;/list&gt;&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Breast tumours, Hodgkin lymphoma, DLBCL, GC-DLBCL, PMBL&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;xref rid=&quot;B120-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;120&lt;/xref&gt;&lt;xref rid=&quot;B121-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;121&lt;/xref&gt;&lt;xref rid=&quot;B122-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;122&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NF-kappaB-inducing kinase (NIK)&lt;list list-type=&quot;bullet&quot;&gt;&lt;list-item&gt;&lt;p&gt;Enhanced activation/overexpression of NIK in cancer cells/tumour compared to normal&lt;/p&gt;&lt;/list-item&gt;&lt;/list&gt;&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;GBM, MM, Hodgkin lymphoma&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;xref rid=&quot;B110-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;110&lt;/xref&gt;&lt;xref rid=&quot;B119-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;119&lt;/xref&gt;&lt;xref rid=&quot;B123-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;123&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;IkappaBalpha&lt;list list-type=&quot;bullet&quot;&gt;&lt;list-item&gt;&lt;p&gt;Enhanced degradation of IkappaBalpha causing endogenous activation of NF-kappaB pathway&lt;/p&gt;&lt;/list-item&gt;&lt;list-item&gt;&lt;p&gt;High expression of IkappaBalpha transcript in certain cancer type&lt;/p&gt;&lt;/list-item&gt;&lt;list-item&gt;&lt;p&gt;Direct transactivation via interaction with kappaB motifs in the DNA inside the nucleus&lt;/p&gt;&lt;/list-item&gt;&lt;/list&gt;&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Ovarian Carcinoma cell line, HCC, Melanoma&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;xref rid=&quot;B104-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;104&lt;/xref&gt;&lt;xref rid=&quot;B105-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;105&lt;/xref&gt;&lt;xref rid=&quot;B109-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;109&lt;/xref&gt;&lt;xref rid=&quot;B124-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;124&lt;/xref&gt;&lt;xref rid=&quot;B125-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;125&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;IKK&lt;list list-type=&quot;bullet&quot;&gt;&lt;list-item&gt;&lt;p&gt;Higher expression of endogenous IKK in tumour tissue compared to normal tissue&lt;/p&gt;&lt;/list-item&gt;&lt;list-item&gt;&lt;p&gt;Constitutive IKK activity causing enhanced activation of NF-kappaB pathway&lt;/p&gt;&lt;/list-item&gt;&lt;/list&gt;&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Lung carcinoma, Melanoma, Hodgkin lymphoma, ABC-DLBCL, PEL, ALT, HCC&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;xref rid=&quot;B105-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;105&lt;/xref&gt;&lt;xref rid=&quot;B110-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;110&lt;/xref&gt;&lt;xref rid=&quot;B111-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;111&lt;/xref&gt;&lt;xref rid=&quot;B112-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;112&lt;/xref&gt;&lt;xref rid=&quot;B126-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;126&lt;/xref&gt;&lt;xref rid=&quot;B127-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;127&lt;/xref&gt;&lt;xref rid=&quot;B128-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;128&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NF-kappaB1&lt;list list-type=&quot;bullet&quot;&gt;&lt;list-item&gt;&lt;p&gt;Higher expression of p50 in tumour tissue compared to normal tissue&lt;/p&gt;&lt;/list-item&gt;&lt;list-item&gt;&lt;p&gt;Enhanced degradation of IkappaBalpha leads to increased activation of NF-kappaB1 subunit&lt;/p&gt;&lt;/list-item&gt;&lt;/list&gt;&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Breast tumours, Melanoma cells, Lung cancer, HCC, ALT, ABC-DLBCL&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;xref rid=&quot;B104-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;104&lt;/xref&gt;&lt;xref rid=&quot;B105-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;105&lt;/xref&gt;&lt;xref rid=&quot;B110-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;110&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NF-kappaB2&lt;list list-type=&quot;bullet&quot;&gt;&lt;list-item&gt;&lt;p&gt;Selective activation in some cancer types&lt;/p&gt;&lt;/list-item&gt;&lt;list-item&gt;&lt;p&gt;Overexpression of NIK underlies constitutive activation of non canonical NF-kappaB pathway&lt;/p&gt;&lt;/list-item&gt;&lt;/list&gt;&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Colon carcinoma cell line, MM, Breast cancer, Lung cancer&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;xref rid=&quot;B106-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;106&lt;/xref&gt;&lt;xref rid=&quot;B107-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;107&lt;/xref&gt;&lt;xref rid=&quot;B110-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;110&lt;/xref&gt;&lt;xref rid=&quot;B119-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;119&lt;/xref&gt;&lt;xref rid=&quot;B124-cells-12-00788&quot; ref-type=&quot;bibr&quot;&gt;124&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>78563</offset><text>Factors of NF-kappaB Pathway and Alterations	Cancer Type	References	 	RelA (p65)Higher expression and activation of p65 in tumour tissue compared to normal tissue	HCC, FLHCC, Breast cancer cell lines		 	RelBFrequent activation of RelB leading to non-canonical NF-kappaB pathway activation	GBM, MM, DLBCL		 	c-RelGain of chromosomal material (9p) leading enhanced expression of c-RelGain of 2p leading to nuclear accumulation of c-Rel	Breast tumours, Hodgkin lymphoma, DLBCL, GC-DLBCL, PMBL		 	NF-kappaB-inducing kinase (NIK)Enhanced activation/overexpression of NIK in cancer cells/tumour compared to normal	GBM, MM, Hodgkin lymphoma		 	IkappaBalphaEnhanced degradation of IkappaBalpha causing endogenous activation of NF-kappaB pathwayHigh expression of IkappaBalpha transcript in certain cancer typeDirect transactivation via interaction with kappaB motifs in the DNA inside the nucleus	Ovarian Carcinoma cell line, HCC, Melanoma		 	IKKHigher expression of endogenous IKK in tumour tissue compared to normal tissueConstitutive IKK activity causing enhanced activation of NF-kappaB pathway	Lung carcinoma, Melanoma, Hodgkin lymphoma, ABC-DLBCL, PEL, ALT, HCC		 	NF-kappaB1Higher expression of p50 in tumour tissue compared to normal tissueEnhanced degradation of IkappaBalpha leads to increased activation of NF-kappaB1 subunit	Breast tumours, Melanoma cells, Lung cancer, HCC, ALT, ABC-DLBCL		 	NF-kappaB2Selective activation in some cancer typesOverexpression of NIK underlies constitutive activation of non canonical NF-kappaB pathway	Colon carcinoma cell line, MM, Breast cancer, Lung cancer		 	</text></passage></document>
</collection>